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1.1. Introduction 
 
The chemistry of coumarins 
Benzo-2-pyrones, commonly known as coumarins, are a fascinating group of compounds 
occurring widely in nature, both in free and combined states. Benzo-2-pyrones and 
benzo-4-pyrones are known as coumarins and chromones respectively. They occur in 
plants of the families Orchideceae, Leguminaceae, Rutaceae, Umbellifereae and 
Labiateae. Most red and blue flower petals contain anthocyanine derivatives of the 
benzo-2-pyrones and benzo-4-pyrones are widely distributed. Coumarins form a distinct 
class of oxygen containing heterocycles that are widely distributed in nature.  
 
Coumarin, the parent substance of the benzo--pyrone group, was first isolated from 
Tonka beans in 1820.1 A number of naturally occurring and synthetic monomeric 
coumarin derivatives are used in drugs and dyes.2  
 
The fusion of a pyrone ring with a benzene nucleus gives rise to heterocyclic compounds 
known as benzopyrones, of which two distinct types are recognized as benzo--pyrones, 
commonly called coumarins, and benzo--pyrones, called chromones, the latter differing 
from the former only in the position of the carbonyl group in the heterocyclic ring.3 
(Figure-1). 
 
O O O
O
Benzo-α-pyrone Benzo-γ-pyrone
Figure-1
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Figure-2: Few Naturally occurring coumarins 
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The coumarins have diverse biological properties and various effects on the different 
cellular systems. Coumarins have important effects in plant biochemistry and physiology, 
acting as antioxidants, enzyme inhibitors and precursors of toxic substances. In addition, 
these compounds are involved in the actions of plant growth hormones and growth 
regulators, the control of respiration, photosynthesis, as well as defense against infection.  
 
The coumarins have long been recognized to possess anti-inflammatory, antioxidant, 
antiallergic, hepatoprotective, antithrombotic, antiviral and anticarcinogenic activities. 
The coumarins are extremely variable in structure, due to the various types of 
substitutions in their basic structure, which can influence in their biological activity.4 
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A number of natural and synthetic coumarin (2-oxo-2H-chromene) derivatives have been 
reported for their notably antimicrobial,5,6  antifungal7,8 and tuberculostatic9 activity.  
 
The -benzopyran-2-one moiety the structural core of coumarins, is often found in more 
complex natural products2 and is frequently associated with biological activity, such as 
anti-cancer,10 antifungal11,12 anti-HIV,13 and anti-clotting.14 For example, carbochromen 
is a potent specific coronary vasodilator used for many years in the treatment of angina 
pectoris.15  
 
1.2. Pharmacology 
Coumarins as cytotoxic agents 
Coumarins have attracted intense interest in recent years because of their diverse 
pharmacological properties. The cytotoxic coumarins represent an exploitable source of 
new anticancer agents, which might help addressing cytotoxicity and resistance 
phenomena. These natural compounds have served as valuable leads for further design 
and synthesis of more active analogues. Promising data have been reported for a series of 
different coumarins used as cytotoxic agents.16 
 
A large number of structurally novel coumarin derivatives have ultimately been reported 
to show substantial cytotoxic and anti-HIV activity in vitro and in vivo.17 Coumarins have 
shown cytotoxicity with derivatives containing o-dihydroxy substituents as reported by 
Kolodziej et. al.14. The chemical structure and biological activity study of the coumarins 
showed that the addition of a catecholic group to the basic structure induced increased 
cytotoxic activity in tumor cell lines.18 
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Figure-3: Structures of cytotoxic coumarins14 
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The aminocoumarin antibiotics novobiocin, clorobiocin and coumermycin A1 are known 
as potent inhibitors of gyrase.19 Their equilibrium dissociation constants are in the range 
of 10 nM,20 i.e., their affinity for gyrase is considerably higher than that of modern 
fluoroquinolones. Novobiocin is licensed as an antibiotic for clinical use (Albamycin; 
Pharmacia-Upjohn) and is used for the treatment of infections with multi resistant gram-
positive bacteria, e.g. Staphylococcus aureus21 (Figure-4). 
 
O
O
N C
O
CH3
O
OHO
CH3
CH3OH
CH3
O
C O
NH2
OH
Figure-4: Novobiocin
H
OCH3
CH3
 
 
Novobiocin is produced by Streptomyces spheroides (syn. S. caeruleus)22 NCIMB 11891, 
Clorobiocin (Figure-5) is produced by S. roseochromogenes var. oscitans DS12.976 and 
coumermycin A1 (Figure-6) is produced by S. rishiriensis DSM 40489.23 Obviously, 
these organisms must protect their gyrases from the inhibitory effect of aminocoumarin 
during antibiotic formation. 
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Thiara and Cundliffe24-26 reported that the principal resistance mechanism of the 
novobiocin producer S. sphaeroides is the de novo synthesis of a coumarin-resistant 
gyrase B subunit, which replaces the sensitive GyrB subunit in the active 
(GyrA)2(GyrB)2 heterotetramer. Thus, this novobiocin producer contains two gyrB 
genes, a constitutively expressed gyrBS, encoding the coumarin-sensitive protein and the 
gyrBR gene, encoding the resistant protein and expressed in the presence of novobiocin. 
The promoter of gyrBR appears to be regulated by changes in the superhelical density of 
DNA.24 Mitchell et. al.21 supplied evidence that additional genes may contribute to 
novobiocin resistance. They used the novobiocin producer S. niveus, which has recently 
been identified as a subjective synonym for S. spheroids.19 
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Coumarins as potent anti-HIV compounds 
Natural coumarins and their derivatives can display anti-HIV activity through different 
mechanisms, including blockade of viral entry, inhibition of reverse transcriptase and 
interference with viral integration.27,28 Some phenylcoumarins and chalcones, as well as 
tannins and lignins, have been proposed as suppressors of LTR-dependent transcription, 
but the mechanism of action has not been fully characterised.29 
 
(+)-Calanolide A,  a natural dipyranocoumarin, currently undergoing anti-AIDS clinical 
trials,30 has also proven to be an effective antimycobacterial against drug-sensible and 
drug-resistant Mycobacterium tuberculosis strains (Figure-7). 
 
O
O
CH3H3C
OO
OHH3C
CH3
CH3
Figure-7: (+)-Calanolide A
 
 
It has been reported that mesuol and isomesuol, (Figure-8) two 4-phenyl coumarins, 
isolated from the tree Marila pluricostata, suppress HIV-1 replication in Jurkat T cells.31 
These coumarins do not affect the reverse transcription and intregration steps of the viral 
cycle and their antiviral effect is additive with that of azidothymidine (AZT). In addition, 
mesuol inhibits TNF-induced HIV-1-LTR transcriptional activity by targeting the 
nuclear factor-B (NF-B) pathway. While mesuol does not prevent either the binding of 
NF-B to DNA or the phosphorylation and degradation of NF-B inhibitory protein, 
IB, it inhibits the phosphorylation and the transcriptional activity of the NF-B p65 
subunit in TNF-stimulated cells. These results highlight the potential of the NF-B 
transcription factor as a target for anti-HIV-1 compounds such as 4-phenyl coumarins, 
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which could serve as lead compounds for the development of additional therapeutic 
approaches against AIDS.  
 
O
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CH3
CH3
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CH3
H3C
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Figure-8: Chemical structures of the 4-phenylcoumarins Isomesuol and Mesuol.
 
 
 Table-1: A review of EC50 values and TIs (defined as LD50/IC50) for some coumarins 
 
Sr. 
No. 
Compound EC50 TI Ref. 
1 Suksdorfin 1.3 µM > 40 32 
2 3’, 4’ Di-o-(-)-camphanoyl-(+)- 
cis-khellacetone 
4×10-4 µM* 136.719 33 
3 4-Methyl-DCK lactum 0.00024 µM 119.333 34 
4 5-Methoxy-4-methyl DCK 7.21×10-6 µM > 2.08 × 107 35 
5 3-Hydroxymethyl-4-methyl-DCK 0.004 µM in H9 cells 
0.024 µM in PBMC** 
 36 
6 
3-Methyl-, 4-methyl-, and 5-methyl- 
3’,4’-di-o-(S)-camphanoyl- 
(3’R, 4’R)-(+)-cis-khellactone 
5.25 × 10-5 µM 2.15 × 106 37 
7 3-Hydroxymethyl DCK 1.87 × 10-4 µM 1.89 × 105 38 
8 4-Methyl-3’,4’-di-o-( - )- 
camphanoyl-(+)-cis-khelthiolactone 
0.00718 µM > 21000 32 
9 3-Bromomethyl-4-methyl-DCK 0.00011 µM 189600 36 
* Here IC50 but not EC50 is reported 
** Peripheral Blood Mononuclear Cells 
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A. Protease inhibitors 
Warfarin is believed to inhibit the vitamin K dependent conversion of prothrombin and 
serine protease activity of thrombin. A 100 µM dose of warfarin is inhibitory toward HIV 
aspartyl protease. In view of the four remarkable properties of warfarin, i.e., inhibition of 
serine protease, aspartyl protease, reverse transcriptase and integrase, all of which are 
essential for HIV replication, this drug deserves clinical testing in a larger population of 
HIV-positive individuals (Figure-9). 
 
Two large pharmaceutical companies, Parke-Davis, a division of Warner Lambert and 
Pharmacia & Upjohn confirmed that warfarin and related coumarin compounds were 
HIV protease inhibitors.39 Warfarin, the first non-peptide derived protease inhibitor, was 
proclaimed to be a modest PI (IC50 of 18 or 30 µM) and coumarin derivatives with better 
specificity were provided. Inhibitors of HIV-1 protease, the pyran-2-one group, 4 
hydroxyl group, and substitution at the 3-position are all necessary for activity.40  
PD099560 is also identified as a non-peptide competitive HIV-1 protease inhibitor41 
(Figure-9). 
 
O
CH3
O
O
OH O
OH
O
O
Warfarin PD099560
Figure-9
 
 
B. Integrase inhibitors 
In addition to HIV RT and protease, HIV integrase is also a major chemotherapeutic 
target;42 integrase inhibitors mainly includes biscatechols and coumarins. Because 
catechols are cytotoxic, partly due to in situ oxidation to quinone species, coumarins have 
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clinical advantages. A natural tetrameric coumarin showed high anti-integrase activity 
(IC50 ¼ 0.8 µM for integration and 1.5 µM for 30-processing)43 (Figure-10). 
 
Increasing the number of aryl rings on the central linker enhanced potency; the rigid 
stilbene analog44 is the most potent (integration 3.7 µM, 30-processing 5.5 µM) among 
the compounds synthesized (Figure-11). 7-Hydroxylation was beneficial in a wide range 
of dimeric 4,7-hydroxycoumarins and led to a simplified coumarin integrase inhibitor 
without greatly sacrificing the potency of the tetrameric compound.  
 
O O
O O
O
O O
O
OH OH
OH OH
Figure-10: A Natural tetrameric coumarin
O O
O O
OH OH
HO OH
Figure-11: Stilbene analog
 
C. Reverse trancriptase inhibitors 
HIV-1 RT interacts with complementary oligodeoxynucleotide (ODN) primers at the 50-
end of the tRNA binding site as well as at the 30-end of the primer. ODN derivatives can 
form specific, more stable complexes with complementary nucleic acids. When several 
chromone and coumarin structures were conjugated to the 50-end of ODNs affinity 
toward HIV-1 RT is increased, suggesting that these compounds may be functioning as 
primers. This action was confirmed when protection of RT by tRNA lys3 decreased the 
complex formation between the enzyme and the conjugated ODN. The same ODNs 
conjugated to chromone or coumarin did change the polymerization rate: either inhibition 
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or slight activation followed by inhibition depending on the concentration. When ‘‘chain 
terminator’’ 30ddT was added, the ligand-ODN complex was easily converted to a strong 
inhibitor45 (Figure-12). 
 
O O
C2H5
O(CH2)3NH ODN
OO O(CH2)nNH ODN
n=5 or 3
Figure-12
 
 
D. Coumarins as photodynamic therapeutics (PDT) agents 
Furanocoumarins, such as the psoralene and angelicin, are common constituents of many 
members of the Rutaceae and Apriaceae plant families. They are commonly UV 
phototoxic toward cells, bacteria, fungi, and viruses. Photomodified viral genomes can 
not be transcribed into RNA/DNA,46 thus, the furanocoumarins inhibit viral replication. 
Coriandrin, a furanoisocoumarin from coriander, is much more photoreactive than 
psoralen but does not cross-link with DNA nor photosensitize human skin.47(a)  
 
Most of the dialkylaminoalkyl coumarin-4-acetates showed a local anesthetic activity47(b) 
by infiltration approaching that of procaine. In contrast to procaine, they were also found 
to be topically active. For example, 3-(2-methylpiperidyl-1)-propyl 7-methylcoumarin-4-
acetate hydrochloride was equal in activity to procaine by infiltration (external canthus of 
the rabbit's eye) and about one-half as active as cocaine topically. Its toxicity was about 
onehalf that of cocaine. In general, the coumarin-4-acetic acid derivatives were much less 
toxic than the corresponding coumarin-3-carboxylic acid derivatives.  
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Figure-13: Some natural furo- and pyranocoumarins  
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Known drugs with alkanoic (acetic acid) as a core fragment 
NSAIDs used as starting points for the design of selective CRTH2 antagonists. 
Several non-steroidal anti-inflammatory drugs (NSAIDs) (Figure-14) showed moderate 
binding affinity for CRTH2 (chemoattractant receptor-homologous molecule expressed 
on TH2 cells), such as fenclofenac and sulindac sulphide (4,953 nM and 3,450 nM 
respectively), but were also active on DP1. Indomethacin, however, demonstrated 
selective binding for CRTH2 (binding values vary between 25 nM and 8.000 nM 
depending on assay conditions) and was shown to be a potent agonist of the receptor (15-
50 nM) in functional assays. Zomepirac was subsequently shown to have antagonistic 
activity in vitro.48 
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Cl Cl
CH2COOH
Diclofenac
sodium
Figure-14: NSAIDs used as starting points for the design of selective CRTH2 antagonists
  
 
Important leads containing acetic acid chain 
1. Ramatroban analogues with CRTH2 antagonist activity.  
Moving the amide nitrogen present in ramatroban into the core ring structure led to 
compound 1, which demonstrated potent (3 nM) antagonistic activity in vitro. By 
transposing fused benzene and cyclohexyl rings, a series of compounds were identified 
with moderate binding activity and selectivity. CRTH2 (chemo attractant receptor-
homologous molecule expressed on TH2 cells. Further modification of compound 2, by 
shortening the propionic acid group to an acetic acid group gave compound 3, a more 
potent and selective analogue. Acetic-acid group is a strongly preferred group as 
compared to propionic-acid group in potent CRTH2 antagonists. By simple N 
methylation the sulphonamide NH (TM30642) or by truncating the propionic-acid group 
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to an acetic-acid group (TM30643) or a combination of both modifications (TM30089), 
three potent CRTH2 binding compounds with high selectivity over TP binding were 
modified with improved selectivity over ramatroban48 (Figure-15). 
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Figure-15: Ramatroban analogues with CRTH2 antagonist activity. 
 
 2. Physicogenetically identified CRTH2 antagonists.  
A physicogenetically based method that classifies seven transmembrane receptors with 
respect to the physicochemical properties of the key amino-acid residues located in a 
common core ligand-binding site to CRTH2 (chemo attractant receptor-homologous 
molecule expressed oil TH2 cells) identified angiotensin II receptor type 1 (AGTR1) and 
AGTR2  receptors as likely to share similar binding properties to CRTH2. Screening of a 
focused compound library led to the identification of TM27632 and TM3170 as CRTH2 
ligands with low micromolar affinity, whereas selected screening of AGTR1 and AGTR2 
ligands identified Candesaetan as the most potent (2.100 nM) ligand for CRTH248 
(Figure-16). 
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Figure-16: Physicogenetically identified CRTH2 antagonists.
 
Aryl acetic acid CRTH2 antagonists 
The biaryl thioether, 1, was first identified as CRTH2 (chemoattractant receptor-
homologus molecule expressed on TH2 cells) antagonists within this structural class with 
40 fold functional selectivity for CRTH2 over DP1. Biaryl-acetic acid derivatives such as 
compound, 2, with a CRTH2 binding pIC50 of 8.2 and biaryl-ether-acetic-acid derivatives 
such as compound, 3, with a CRTH2 binding pIC50 of 9.0 have been patented49-52 (Figure-
17). 
 
1 2 3
SCl
COOH
Cl
S
O
H
N
O
O
COOH
F3C
O
O
COOH
F
Cl
SO2C2H5
CH3
Figure-17: Aryl acetic acid CRTH2 antagonists
 
Prostaglandin D2 (PD2) is an important mediator of allergic responses. The high 
contraction produced in response to an allergic stimulation combined with its highly 
potent activity result in PGD2, having a dominant role in mediating mast-cell dependent 
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activation of TH2 lymphocytes, all effect mediated by CRTH2. Therefore, PGD2, 
produced by mast cells might provide all essential link between the early phase and late-
phase allergic responses. Such antagonism of PGD2, provides an attractive target for 
therapeutic intervention. There are a number of potent and selective CRTH2 antagonist 
series identified with drug -like properties and results of ongoing clinical trials in asthma 
and allergic rhinitis are awaited.  
 
Coumarin-3-and coumarin-4-acetates are written in hypothetical non-cyclic forms (I, II), 
it is apparent that they are, respectively, a substituted Phenylvinylacetic ester and a 
substituted pheny1 propionic ester53 (Figure-18). 
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The literature contains no references to basic derivatives of coumarin-3-or -4-acetic acids, 
other than a single benzene derivative, viz. 7-dimethylaminocoumarin-4-acetic acid. No 
pharmacological investigations appear to have been made in these series.54  
 
1.3. Synthetic aspects 
Coumarin-3-carboxylic acids can be synthesized by the conventional Knoevenagel 
method,55 from a substituted salicylaldehyde and malonic ester. The ethyl esters were 
saponified by refluxing with an excess of dilute sodium hydroxide solution for several 
hours, followed by acidification with hydrochloric acid. Therapeutic assay of the 
coumarin-3-carboxylic acid derivatives for local anesthetic activity has been carried out 
by Becker and Luduena56 (Scheme-1). 
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Werder et. al.57 have synthesized more than 100 derivatives of coumarin-3-carboxylic 
acid, which were found to be sedative in low doses and hypnotic in large doses. Among 
the derivatives of these acids, the diethyl amide proved to be a good drug in general 
nervous disease and in various neuro anaesthetic and hysterical ailments. It has also been 
found that some oxygenated coumarins possessing the power of absorbing UV rays 
which were extensively used as medicines in skin desieses.58  
 
1.4. Present Work 
The present work aims at preparation of coumarin-4-acetic acids of different 
substitutions, to find out optimum reaction conditions and also to study their anticancer 
properties as a core scaffold.  
 
The coumarin-4-acetic acids were prepared by the von Pechmann reaction59  from a m-
substituted phenol and acetone dicarboxylic acid (prepared in situ from citric acid). 
Biginelli6 condensed quinol with ethyloxalacetate in presence of sulfuric acid to obtain 6-
hydroxy-coumarin-4-acetic acid. Pechmann and Kraft60 extended this reaction to other 
phenols. Gokhle and Ghosh,61 Chakravarti62 and Banerjee63 have studied the formation of 
coumarin-4-acetic acid from substituted phenol and acetone dicarboxylic acid using 
sulfuric acid as condensing agent. Limaye64 found that phenol when condenced with 
citric acid, gave coumarin-4-acetic acid. Dey,65 Dixit,66 Fries67 have studied the reaction 
of phenol with acetonedicarboxilic acid and also using citric acid. Burton and Muller68, 69a 
have found that condensation of resorcinol with diethylacetone dicarboxylate afforded 7-
hydroxy coumarin-4-acetic acid. Ghia and co-workers69b also studied these compounds 
for bromination of styryl derivatives (Scheme-2). 
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In general, these syntheses offered no difficulty, although in certain cases the yields were 
poor. However, the von Pechmann reaction failed with m-thiocresol, m- 
trifluoromethylphenol and p-hydroxydiphenyl and the synthesis of pharmacologically 
interesting 7-methylthiocoumarin and 7-trifluoromethylcoumarin-4-acetic acids was 
failed.  
 
Drawback of reaction conditions 
The complication in this reaction arises from the extreme case of decarboxylation 
observed in the coumarin-4-acetic acid series.53 A similar phenomenon was observed in 
the related esterification reaction between a coumarin-4-acetic acid and a basic alcohol. 
In both reactions the chief product was the 4-methylcoumarin. Dey70 attempted to prepare 
coumarin-4-acetyl chlorides from the acids and phosphorus pentachloride, which failed, 
instead, only deeply colored decomposition products were obtained. Acyl chlorides were 
successfully isolated from the reaction between coumarin-4-acetic acids and thionyl 
chloride, but the acyl chlorides, contained a second chlorine atom (Figure-19). 
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Gardner et. al.71 prepared basic esters and amides of coumarin-4-acetic acids, via -
haloalkyl coumarin-4-acetates, which were readily obtained by esteritication of the acids 
with an -haloalkanol. Replacement of the -halogen group by reaction with a secondary 
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amine gave excellent results if the condensations were carried out in an appropriate 
solvent (toluene with bromo esters and xylene with chloro esters). The coumarin-4-
acetamides were easily prepared by amination of the corresponding ethyl coumarin-4-
acetates with a primary amine in boiling xylene.  
 
Woods and co-workers72 have reported a new one-step method of preparing substituted 
coumarins in which phenols were condensed with various β-keto esters under the 
influence of trifluoroacetic acid. The ethyl esters of coumarin-4-acetic acids can be 
prepared if diethyl acetone dicarboxylate is the β-ketonic ester component. The fact that 
coumarin-4-acetic acids are subject to easy dehydration to an internal ester, makes the 
ester a more satisfactory compound for consistent syntheses. Further, since the free acid 
is a malonic acid vinylog, methods of isolation and purification often cause considerable 
decarboxylation (Scheme-3). 
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Applications 
Ultrafast transient absorption spectroscopy has been employed by Ramakrishna and co-
workers73 to understand the effect of molecular structure on interfacial electron transfer 
(ET) dynamics of 7-N, N-dimethyl amino coumarin 4-acetic acid (DMACA) and 7-
hydroxy coumarin 4-acetic acid (HCA) sensitized TiO2 and ZrO2 nanoparticles. Electron 
injection is confirmed by observing the cation radical of the dye molecules as well as the 
conduction band electron in the visible and near-IR regions. Electron injection efficiency 
has been found to be higher for the HCA/TiO2 system as compared to the DMACA/TiO2 
system. Both dyes are structurally similar except that HCA has a hydroxyl group at the 7-
position while DMACA has a dimethyl amino group at the 7-position (Figure-20). 
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Figure-20: Molecular Structure of 7-N,N-Dimethyl Coumarin-4-acetic Acid (DMACA) 
and 7-Hydroxy Coumarin-4-acetic Acid (HCA)
 
 
The steady-state and time-resolved fluorescence measurements confirmed that, in highly 
polar solvent, the excited state of DMACA dye exists both in twisted intramolecular 
charge transfer (TICT) and intramolecular charge transfer (ICT) states, whereas excited 
HCA exists only in the ICT state (figure-21). 
 
 
 
Sarges et. al.74 synthesized some coumarin-4-acetic acids contain the preapations of 
substituted and unsubstitutred coumarin-4-carboxylic or acetic acid derivatives which has 
been proved as aldose reducatase inhibitors and as therapeautic agents for the treatment 
of chronic diabetic complications. Sarges et. al.74 synthesized certain novel carboxylic 
acid derivatives which are useful in the treatment of certain chronic complications arising 
from diabetis mellitus, such as diabetic cataracts and neuropathy. Aldose reduatase 
inhibitors such as 1,3-dioxo-1H-benz[-d,e]-isoquinoline-2(3H)-acetic acid and its 
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derivatives are useful in this regard. Such compounds inhibit the enzymatic reduction of 
aldoses, such as glucose and galactose, to the corresponding polyols, such as sorbitol and 
galactol, thus preventing or reducing the harmful and unwanted accumulations of polyols 
in the diseased organs of the body (Figure-22). 
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The derivatives are easily prepared by condensing an acetonedicarboxilic acid or 
ketosuccinic acid with the approproiate phenol compound. The ability of these active 
ingredients of the derivatives, to control chronic diabetic complications and enzymatic 
reduction of aldoses has been determined by a number of standared biological or 
pharmacological tests. 
These tests include:  
1. Measuring the ability to inhibit the enzyme activity or isolated aldose reductase. 
2. Measuring the ability to reduse or inhibit sorbitol accumulation in th sciatic nerve 
or acutely diabetic rats. 
3. Measuring the ability to reverse already-elevated sorbitol levels in the sciatic 
nerve and lens of chronic streptozocin-induced diabetic rats. 
4. Measuring the ability to prevent or inhibit glactitol formation in the lens of 
acutely glactosemic rats. 
5. Measuring the ability to delay cataract formation and reduse the severity of lens 
opacities in chronic galctosemic rats. 
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The derivatives were tested for their ability to reduce or inhibit aldose reductase enzyme 
activity, based on the procedure of Hayman et. al.75 The drugs were tested at a level of 
10-4 M to determine the degree of inhibition of enzyme activity relative to untreated 
controls. 
 
The compound useful for prophylactic or remedial treatment of diabetic cataracts, 
retinopathy, nephropathy or neuropathy in a diabetic patient should comprise of a 
pharmaceutical carrier and a therapeutic amount of a coumarin carboxylic acid derivative 
selected from the group consisting of the above structures: Where, R1, R2, R3 and R4 must 
be H, CH3 and X must be either F or Cl, n can be either 0 or 1 (Figure-22). 
 
Clinton et. al.76 synthesized basic esters and amides derived from 7-substituted coumarin-
4-acetic acids, which were found effective as local anesthetics. Basic esters and amides 
were prepared by the general method of Pechman and Duisberg.  
 
Profit et. al.77 demonstrated that 7-hydroxy-coumarin-4-acetic acid linked to the N-
terminus of pTyr-Glu-Glu-Ile-amide significantly enhances the affinity of this peptide for 
the SH2 domain of Lck (lymphoid T cell kinase).78 Although this effect appears to be 
quite specific for Lck, we do observe a modest enhancement for the SH2 domain of Fyn 
(Fgr and Yes-related kinase) as well.  
 
Brubaker et. al.79 synthesized a number of 4,7-disubstituted benzopyran-2-ones and 
evaluated them for crude rat lens aldose reductase inhibitory activity. The 3-oxo-3H-
naphtho[2,1-b]pyran-l-acetic acid, 2-oxo-2H-naphtho[l,2-b]pyran-4-acetic acid, and 1-
naphthylacetic acids. The structure-activity relationships reveal that optimal enzyme 
inhibitory activity is displayed by those compounds possessing the acetic acid moiety. 
The most potent derivative, 3-oxo-3H-naphtho-[2,1-b]pyran-l-acetic acid  with an IC50 of  
0.020 pM, is as potent as sorbinil (IC50 = 0.017 pM) in the crude rat lens aldose reductase 
assay. 
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DeRuiter and co-workers80 described the aldose reductase inhibitory activity of some 
quinazolinones containing acetic acid moiety. The most potent aldose reductase inhibitor 
of the series, 6,7-dimethoxy-2- [(4-carboxyphenyl)amino]-4(3H)-quinazolinone, 
suggested that the presence of an acidic moiety on the quinazolinone nucleus contributed 
significantly to the inhibitory potency of the quinazolinones.81  The potent inhibitory 
activity demonstrated for an extensive series of 2-oxo--benzopyran-4-acetic acids in 
which the electronic nature of the substituent on the aromatic ring is varied, suggested 
that these compounds could serve as excellent probes to investigate the steric and 
electronic requirements of the common inhibitor binding site82 present on aldose 
reductase (Scheme-4). 
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The compounds listed in the table-2 below were screened for their ability to inhibit crude 
aldose reductase obtained from rat lens83 as described previous1y. The IC50 values were 
determined for those compounds displaying greater than 50% inhibition at 100 µM by 
least-squares analysis of log dose-response curves. These data suggest two basic SAR 
points.84  
a) An ionizable carboxyl moiety is necessary for optimal aldose reductase inhibitory 
activity. 
b) The number of atoms between the carboxyl group and benzopyran-2-one ring is a 
critical determinant of potency.  
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Table: Aldose reductase inhibitory activity of 2H-1-benzopyran-2-ones80 
O
R1
O
R2
 
R1 R2 Inhibition typea Inhibition
b
  
% (SEM) 
IC50c 
µM 
H CH3  19 (4.12)  
6-OH CH3  22 (2.00)  
7-OH CH3 noncomp  62 
7-OCH3 CH3  21 (3.25)  
7-OAC CH3  13 (0.75)  
7-CH2CH3 CH3  16 (0.0)  
7-Cl CH3  10 (2.10)  
5,7-(OH)2 CH3 noncomp  17 
7,8-(OH)2 CH3 noncomp  10 
H CH2COOH noncomp  0.60 
7-OH CH2COOH noncomp  0.15 
  noncomp  (NADPH)   
7-OH CH2COOCH3 noncomp  38 
7-OH CH2CONH2 noncomp  10 
7-OAc CH2COOH noncomp  61 
7-OCH3 CH2COOH noncomp  0.37 
7-OCH3 COOH noncomp  11 
7-OCH3 CH=CHCOOH noncomp  4.4 
7-OCH3 CH2CH2COOH noncomp  2.1 
7-Cl CH2COOH noncomp  0.56 
7-CH2CH3 CH2COOH noncomp  0.24 
5,7-(OH)2 CH2COOH noncomp  0.26 
5,6-(CH)4 CH2COOH noncomp  0.020 
  noncomp (NADPH)   
7,8-(CH)4 CH2COOH noncomp  0.41 
1-Napthylacetic  acid  noncomp  32 
Sorbinil  noncomp  0.017 
(a) Double-reciprocal plots were linear, and the significance level for the least-squares was       
< 0.01 unless indicated otherwise. (b) Present inhibition produced at 10-4 M followed by the 
standard error of the mean (SEM). (c) IC50 values represent the concentration required to 
produce 50% inhibition.  
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1.5. Chemistry and synthesis of coumarin-3- and -4-acetic acids 
Coumarin-3- and 4-acetic acids comprise within their molecules a double bond between 
carbon atoms 3 and 4 in the pyrone ring and a reactive methylene group attached to either 
of these atoms. Dey and Row85 and Dey and Seshadri86 have shown that coumarin-4-
acetic acids resemble malonic acid in decomposing smoothly and quantitatively into 4-
methylcoumarins and carbon dioxide. Further, coumarin-4-acetic acids and their esters 
readily condense with aromatic aldehydes both by Perkin's and by Knoevenagel's 
methods, giving rise to 4-coumarylphenylethylene and 4,3-dicoumaryl derivatives. 
Coumarin-3-acetic acids, on the other hand, are more stable and do not decompose even 
on heating at high temperatures; they are less reactive, as they do not undergo the 
Knoevenagel reaction (Scheme-5). 
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Dey and Radhabai87 have studied the action of halogens on the above acids. They found 
that halogen does not attack the double bond in the pyrone ring, but substitutes one of the 
methylene hydrogen atoms, a considerable amount of decarboxylation taking place. 
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Dey88  condensed various phenols with acetonedicarboxylic acid ester and observed that 
the methylene group in the side chain in the 4-position was attacked and that 4-halogeno 
coumarin acetic acids were obtained. Addition of the halogen to the double bond of the 
pyrone ring was observed in the case of l,2-naphthopyrone-4-acetic acid only. 
Bartosova et. al.89 studied some new coumarin derivatives i.e.  3-(2-oxo-2H-chromen-4-
yl)-2-oxo-2H, 5H-pyrano-[3,2-c]chromen-5-yl esters of ethanoic acid and their reaction 
with nucleophiles and rearrangement in acetic acid. 3-Formylchromones were prepared 
by Vilsmeier-Haack reaction.90 They are attractive intermediates for preparation of new 
heterocycles.91,92 Microwave irradiation was used for the preparation of coumarins such 
as compounds a, b, c.93 (Figure-23) . 
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3-Formylchromones were reacted with 3-coumarin- or 4-coumarin- acetic acids in acetic 
anhydride at reflux temperature and gave 3-(2-oxo-2H-chromen-4-yl)-2-oxo-2H,5H-
pyrano[3,2-c]chromen-5-yl acetate and  3-(2-oxo-2H-chromen-3-yl)-2-oxo-2H,5H-
pyrano[3,2-c]chromen-5-yl acetate. The reaction were carried out in acetic anhydride in 
the presence of potasium acetate as a catalyst under microwave irradiation conditions. 
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Above products were obtained after ten minutes irradiation in a microwave oven at 
400W. The subsequent nucleophile reaction (alcoholysis) of above compounds producted 
ethers, i.e. alkyloxy-3-(-2-oxo-2H-chromen-4-yl)-5H-pyrano[3,2-c] chromen-2-ones) and  
alkyloxy-3-(2-oxo-2H-chromén-3-yl)-5H-pyrano[3,2-c]chromen-2-ones), in the presence 
of catalytic amount of p-toluenesolfonic acid in various alcohols at 60-100ºC.  It was 
found that the synthesized compounds shown in scheme-6 underwent a rearrengment by 
treatment with acetic acid at 60-80ºC without another part of reaction medium and 
yielded compounds  3-(2-oxo-2H-chromen-4-yl)-3,10a-dihydro-pyrano[2,3-b] chromene-
2,5-diones and   3-(2-oxo-2H-chromen-3-yl)-3,10a-dihydro-pyrano[2,3-b] chromene-2,5-
diones.94 
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Vida and co-workers95 did the selective reduction of 3,4-dihydrocoumarin-4-acetic acid 
which leads to 2-o-hydroxyphenyl-4-hydroxybutane-I-carboxylic acid lactone. 
Lactonization of the intermediate 4-hydroxycarboxylic acid to form the above & 
carboxylic acid lactone is preferred over the formation of the phenolic lactone 3,4-
dihydro-4-(-hydroxyethyl)coumarin. Electrophilic reagents convert -hydroxyphenyl-4-
hydroxybutane-l-carboxylic acid lactone into 4-substituted 3,4-dihydrocoumarins. The 
phenolic lactone 3,4-dihydro-4-(p-bromoethyl)coumarin, reacts with primary or 
secondary amine to form 4-substituted chroman derivatives. 
 
3, 4-Dihydrocoumarin-4-acetic acid, upon treatment with diazomethane, was converted 
into the methyl ester which was brominated and dehydrobrominated to yield 4-
carbomethoxymethylcoumarin.96 Coumarin-4-acetic acids are vinyl analogs of malonic 
acid; when the methyl ester was hydrolyzed in boiling aqueous dioxane with hydrochloric 
acid, 4-methyl coumarin was obtained. Similarly, the latter compound was obtained from 
bromination, followed by dehydrobromination of coumarin-4-acetic acid. 
 
Cleavage of the carboxylic acid lactone ring and the subsequent ring closure to form the 
dihydrocoumarin ring system can be affected with electrophilic reagents, e.g., 
trifluoroacetic anhydride, thionylchloride in benzene,97 and gaseous hydrobromic acid in 
chloroform98 (Figure-24). 
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Figure-24:  Reactions of coumarin-4-acetic acid
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Zhu et. al.99 synthesized various coumarin-4-acetic acids and their its basic esters as well 
as amides. The following compounds were synthesized and were used in the solution-
based microplate assays (Figure-25). 
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Ahmed Mustafa and co-workers100 synthesized some new styryl derivatives by 
condensing 4-coumarin acetic acid derivatives with the appropriate aldehyde in the 
presence of pyridine and a few drops of piperidine101.  
 
Elderfield et. al.102 reported the synthesis of nitrogen mustards derived from 7-
hydroxycoumarins from 7-hydroxycoumarin-4-acetic acid (Scheme-7). 
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Synthesis of coumarin-4-acetic acid
OH
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CH2COOH
CHO COOH
CH2COOH
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R1
O
OH
O
Conc. H2SO4
Where, R1, R2, R3, R4= OH, CH3, H, C6H5, NH2.
1.6. REACTION  SCHEME
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1.7. Experimental 
 
General method of preparation of coumarin-4-acetic acid 
A mixture of citric acid monohydrate (0.1 M) and 28 ml of concentrated sulphuric acid 
was stirred at room temperature for sixty minutes, and then slowly heated to 70oC. After 
half an hour at this temperature, with stirring throughout, the evolution of carbon 
monoxide had slackened and the clear yellow coloured solution was rapidly cooled to 
0oC. To this stirred solution, was added phenol (0.08 M) and 11.2 ml of concentrated 
sulphuric acid, each in three equal portions, at a rate that the temperature does not exceed 
10oC. The resulting was stored at 0oC for sixteen hours, poured into ice and the resulting 
crystalline precipitates were filtered off and washed thoroughly with water. It was then 
treated with 10% sodium bicarbonate solution and then filtered. The filterate, on 
acidification gave coumarin-4-acetic acids. The bicarbonate insoluble portion is 4-methyl 
coumarin. The purity of the compound is checked by TLC. (Acetone: Benzene :: 5:5). 
 
Several substituted coumarin 4-acetic acids were similarly prepared by using different 
phenols.49 
The physical data and Rf value of various coumarin 4-acetic acids were recorded in the 
Table No. 3. 
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1.8. Table 3:  Physical data of coumarin-4-acetic acids 
 
O
R4
R3
R2
R1
O
OH
O
 
 
Substitution 
Codes 
R1 R2 R3 R4 
Moleular 
formula 
Molecular 
weight 
Melting point 
(oC) Rf value Colour 
% 
Yield 
JCT-10 H H OH H C11H8O5 220.18 202-204a 0.43 White 68 
JCT-11 H H -Benzo- C15H10O4 254.24 210-212 0.46 Brown 59 
JCT-12 -Benzo- H H C15H10O4 254.24 208-210 0.55 Yellow 61 
JCT-13 H H H CH3 C12H10O4 218.21 202-204 0.41 White 54 
JCT-14 H H CH3 H C12H10O4 218.21 204-206 0.51 Off white 58 
TLC solvent system: Acetone: Benzene = 5:5 
Ref.: (a= Reported m. p.: 204-206oC) (1) Laskowski, S. C.;  Clinton, R. O.  Coumarins. II. Derivatives of Coumarin-3- and -4-Acetic 
Acids, J. Am. Chem. Soc. 1950, 72, 3987-3991. (2) Dey, B. B.  J. Organic Chem. 1915, 107, 1606-1651. 
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1.8. Table 3 (contd.):  Physical data of coumarin-4-acetic acids 
 
 
 
 
 
 
Substitution 
Codes 
R1 R2 R3 R4 
Moleular 
formula 
Molecular 
weight 
Melting point  
(oC) Rf value Colour 
% 
Yield 
JCT-15 H CH3 H H C12H10O4 218.21 184-185 0.49 Pale white 63 
JCT-16 H H CH3 CH3 C13H12O4 232.23 205-206 0.50 White 69 
JCT-17 H CH3 H CH3 C13H12O4 232.23 206-208 0.47 Off white 58 
JCT-18 H CH3 CH3 H C13H12O4 232.23 168-170 0.53 Pale yellow 53 
JCT-19 CH3 H CH3 H C13H12O4 232.23 202-206 0.54 White 52 
JCT-20 H C6H5 H H C17H12O4 280.27 184-185 0.48 Off white 36 
JCT-21 OH H OH H C11H8O6 236.18 166-168 0.52 Brown 67 
JCT-22 H H NH2 H C11H9NO4 219.19 172-176 0.55 Brown 46 
JCT-23 H H H naphtyl C21H14O4 330.09 156-158 0.47 Off white 22 
 
 
Synthesis and Characterization of Some (2-Oxo-2H-chromen……. 36 
1.9. Spectral study 
Infra Red spectra 
Infra Red spectra of 2-(2-oxo-2H-chromen-4-yl)acetic acids were taken on SHIMADZU 
8400 FT-IR-435 Spectrometer using KBr Pellet method. The characteristic carbonyl 
group in coumarin moiety is observed at 1710-1680 cm-1. The carboxylic acid group in 2-
(2-oxo-2H-chromen-4-yl) acetic acids was observed between the values 1794-1844 cm-1. 
The coumarin moiety showed the ring skeleton vibrations at 1600-1645, 1550-1590, 
1550-1520, 1470-1495 cm-1. The methylene group was observed between the values 
1396-1458 cm-1.  The ether (C-O-C) was observed at  1275-1235 cm-1 and 1085-1025 
cm-1. Mono, ortho as well as meta substitution at C6, C7 as well as C8 of coumarin ring 
showed the absorbance frequency between 830-890 cm-1, 760-780 cm-1, 720-760 cm-1. 
 
1H NMR spectra 
1H NMR spectra of 2-(2-oxo-2H-chromen-4-yl)acetic acids were recorded on  Bruker AC 
400 MHz FT-NMR Spectrometer using TMS (Tetramethyl Silane) as an internal standard 
and DMSO-d6 as a solvent. In the NMR spectra of  2-(2-oxo-2H-chromen-4-yl)acetic 
acid, various proton values like methylene (-CH2), methyl (-CH3), aromatic protons (Ar-
H) were observed. The values for methyl (-CH3) protons are seen between 2.3-2.6  ppm 
and for methylene (-CH2) protons between 3.5-4  ppm. The aromatic protons (Ar-H) 
shows doublets or multiplets between 6.4-7.8  ppm. The carboxylic proton (-COOH)  in 
coumarin 4-acetic acid in one of the spectra (JCT-24) was observed very broad at 10  
ppm but the broad peak in all other compounds was not observed in the 1H NMR spectra.  
 
13C NMR spectra 
13C NMR spectra were recorded on Bruker AC 400 MHz instrument using DMSO as the 
solvent with TMS (Tetramethyl Silane) as respective internal standard.  As the carboxylic 
acid group in most of substituted coumarin-4-acetic acid is not observed in 1H NMR 
spectra, 13C NMR spectra of the coumarin-4-acetic acids clearly shows the presence of 
carboxylic acid group from 170-170 ppm. 
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Mass spectra 
The mass spectrum of compounds was recorded by GCMS-QP2010 spectrometer (EI 
method). The mass spectrum of compounds were obtained by positive chemical 
ionization mass spectrometry. The molecular ion peak and the base peak in all 
compounds were clearly obtained in mass spectram study. The molecular ion peak (M+) 
values are in good agreement with molecular formula of all the compounds synthesized. .  
 
C, H, N analysis  
Elemental analysis of the compounds was carried out on Elemental Vario EL III Carlo 
Erba 1108 model at CDRI, Lucknow and the results are in agreement with the structures 
assigned. 
 
1.10. Spectral characterization 
 
2-(7-Hydroxy-2-oxo-2H-chromen-4-yl) acetic acid (JCT-10) 
IR (KBr) cm-1: 3335 (-OH), 2960  (C-H str.), 1812 (-COOH), 1732 (-C-O-O, ester), 
1712 (>C=O), 1612, 1548, 1507, 1436 (ring skeleton), 1449 (CH2), 1273, 1057 (C-O-C), 
887 (mono substd.). 
1H NMR 400 MHz (DMSO-d6,  ppm): 3.69 (s, 2H, -CH2), 6.17 (s, 1H, OH), 6.7-7.4 
(m, 4H, Ar-H), 9.95 (s, br, 1H, OH). 
13C NMR 400 MHz (DMSO-d6,  ppm): 38.9 (CH2), 102-125 (Ar), 160 (C=O), 170 
(COOH). 
Mass [m/e (%)], M. Wt.: 220, 202, 192, 176, 148, 131, 120, 91, 74, 65, 44. 
C, H, N analysis, Calculated: C, 60.00; H, 3.66. Found: C, 60.23; H, 3.54.  
 
2-(2-Oxo-2H-benzo[h]chromen-4-yl)acetic acid (JCT-11) 
IR (KBr) cm-1: 3362 (-OH), 2960 (C-H str.), 1834 (-COOH), 1746 (-C-O-O, ester), 1685 
(>C=O), 1591, 1545, 1508, 1473 (ring skeleton), 1473 (CH2), 1268, 1089 (C-O-C). 
1H NMR 400 MHz (DMSO-d6,  ppm): 3.86 (s, 2H, -CH2), 8.52 (s, 1H, OH), 6.46 (s, 
1H, CH), 6.49-7.8 (m, 7H, Ar-H). 
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13C NMR 400 MHz (DMSO-d6,  ppm): 38.03 (CH2), 114-135 (Ar), 159 (C=O), 170 
(COOH). 
Mass [m/e (%)], M. Wt.: 254, 210, 181, 152, 139, 115, 91, 76, 63, 44. 
C, H, N analysis, Calculated: C, 70.86; H, 3.96. Found: C, 70.57; H, 3.89.  
 
2-(3-Oxo-3H-benzo[f]chromen-1-yl)acetic acid (JCT-12) 
IR (KBr) cm-1: 3113 (-OH), 2935  (C-H str.), 1907 (-COOH), 1746 (-C-O-O, ester), 
1701 (>C=O), 1624, 1537, 1477, 1452 (ring skeleton), 1477 (CH2), 1278, 1145 (C-O-C). 
Mass [m/e (%)], M. Wt.: 254, 210, 181, 152, 139, 115, 91, 76, 63, 44. 
C, H, N analysis, Calculated: C, 70.86; H, 3.96. Found: C, 70.57; H, 3.58.  
 
2-(8-Methyl-2-oxo-2H-chromen-4-yl)acetic acid (JCT-13) 
IR (KBr) cm-1: 3335 (-OH), 2956  (C-H str.), 1824 (-COOH), 1737 (-C-O-O, ester), 
1745 (>C=O), 1615, 1517, 1476, 1438 (ring skeleton), 1413 (CH2), 1369 (CH3), 1255, 
1016 (C-O-C), 883 (mono substd.).        
Mass [m/e (%)], M. Wt.: 218, 200, 190, 174, 162, 145, 131, 115, 103, 91, 77, 65, 44. 
C, H, N analysis, Calculated: C, 60.05; H, 4.62. Found: C, 65.98; H, 4.32.  
 
2-(7-Methyl-2-oxo-2H-chromen-4-yl) acetic acid (JCT-14) 
IR (KBr) cm-1: 3394 (-OH), 3043 (C-H str.), 1832(-COOH), 1745 (-C-O-O, ester), 1680 
(>C=O), 1618, 1558, 1500, 1413 (ring skeleton), 1424 (CH2), 1332 (CH3), 1255, 1059 
(C-O-C), 815 (mono substd.). 
1H NMR 400 MHz (DMSO-d6,  ppm): 2.45 (s, 3H, CH3), 3.74 (s, 2H, CH2), 6.33 (s, 
1H, 0H), 7.1-7.5 (m, 3H, Ar-H). 
400 MHz 13C NMR (DMSO-d6,  ppm): 37.56 (CH2), 115-125 (Ar), 142 (C=O), 170 
(COOH). 
Mass [m/e (%)], M. Wt.: 218, 174, 145, 131, 115, 103, 91, 77, 63, 44. 
C, H, N analysis, Calculated: C, 60.05; H, 4.62. Found: C, 65.78; H, 4.57.  
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2-(6-Methyl-2-oxo-2H-chromen-4-yl) acetic acid (JCT-15) 
IR (KBr) cm-1: 3514 (-OH), 2951 (C-H str.), 1811 (-COOH), 1720 (-C-O-O, ester), 1672 
(>C=O), 1587, 1546, 1516, 1440 (ring skeleton), 1440 (CH2), 1323 (CH3), 1276, 1014 
(C-O-C), 858 (mono substd.). 
1H NMR 400 MHz (DMSO-d6,  ppm): 2.41 (s, 3H, CH3), 3.74 (s, 2H, -CH2), 6.38 (s, 
1H, CH), 6.7-7.4 (m, 3H, Ar-H). 
13C NMR 400 MHz (DMSO-d6,  ppm): 37.54 (CH2), 116-151 (Ar), 160 (C=O), 170 
(COOH).   
Mass: [m/e (%)], M. Wt.: 218, 200, 190, 174, 162, 145, 131, 115, 103, 77, 65, 44. 
C, H, N analysis, Calculated: C, 66.05; H, 4.62. Found: C, 65.76; H, 4.13.  
 
2-(7,8-Dimethyl-2-oxo-2H-chromen-4-yl)acetic acid (JCT-16) 
IR (KBr) cm-1: 3477 (-OH), 2939 (C-H str.), 1865 (-COOH), 1726 (-C-O-O, ester), 1687 
(>C=O), 1604, 1558, 1510, 1431 (ring skeleton), 1431 (CH2), 1342 (CH3), 1249, 1093 
(C-O-C), 764 (ortho substd.). 
1H NMR 400 MHz (DMSO-d6,  ppm): 2.36 (s, 3H, CH3), 2.39 (s, 3H, CH3), 3.74 (s, 
2H, -CH2), 6.32 (s, 1H, CH), 7.11 (d, 1H, Ar-H, J=8.12), 7.38 (d, 1H, Ar-H, J=8.16). 
13C NMR 400 MHz (DMSO-d6,  ppm): 37.7 (CH2), 114-125 (Ar), 160 (C=O), 170 
(COOH).   
Mass: [m/e (%)], M. Wt.: 232, 204, 188, 173, 145, 128, 115, 103, 91, 77, 65, 44, 41. 
C, H, N analysis, Calculated: C, 67.23; H, 5.21. Found: C, 67.07; H, 4.79.  
 
2-(6,8-Dimethyl-2-oxo-2H-chromen-4-yl)acetic acid (JCT-17) 
IR (KBr) cm-1: 3500 (-OH), 2879 (C-H str.), 1834 (-COOH), 1718 (-C-O-O, ester), 1668 
(>C=O), 1608, 1566, 1419 (ring skeleton), 1419 (CH2), 1419 (CH3), 1203, 1051 (C-O-C), 
744 (meta substd.). 
1H NMR 400 MHz (DMSO-d6,  ppm): 2.37 (s, 3H, CH3), 2.41 (s, 3H, CH3), 3.74 (s, 
2H, -CH2), 6.37 (s, 1H, CH), 7.23 (d, 2H, Ar-H, J=10.52). 
13C NMR 400 MHz (DMSO-d6,  ppm): 37.65 (CH2), 115-133 (Ar), 160 (C=O), 170 
(COOH).   
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Mass: [m/e (%)], M. Wt.: 232, 214, 204, 188, 176, 159, 145, 128, 115, 103, 91, 77, 65, 
44, 41. 
C, H, N analysis, Calculated: C, 67.23; H, 5.21. Found: C, 67.14; H, 4.69.  
 
2-(6,7-Dimethyl-2-oxo-2H-chromen-4-yl)acetic acid (JCT-18) 
IR (KBr) cm-1: 3564 (-OH), 2934 (C-H str.), 1821 (-COOH), 1735 (-C-O-O, ester), 1723 
(>C=O), 1612, 1586, 1557, 1459 (ring skeleton), 1454 (CH2), 1265, 1042 (C-O-C), 754 
(ortho substd.). 
Mass: [m/e (%)], M. Wt.: 232, 214, 204, 188, 176, 159, 145, 128, 115, 103, 91, 77, 65, 
44, 41. 
C, H, N analysis, Calculated: C, 67.23; H, 5.21. Found: C, 67.08; H, 5.03.  
 
2-(5,7-Dimethyl-2-oxo-2H-chromen-4-yl)acetic acid (JCT-19) 
IR (KBr) cm-1: 3492 (-OH), 2945 (C-H str.), 1834 (-COOH), 1767 (-C-O-O, ester), 1723 
(>C=O), 1601, 1561, 1503, 1452 (ring skeleton), 1457 (CH2), 1379 (CH3), 1268, 1046 
(C-O-C), 734 (meta substd.). 
Mass: [m/e (%)], M. Wt.: 232, 214, 204, 188, 176, 159, 145, 128, 115, 103, 91, 77, 65, 
44, 41. 
C, H, N analysis, Calculated: C, 67.23; H, 5.21. Found: C, 66.96; H, 5.16.  
 
2-(2-Oxo-6-phenyl-2H-chromen-4-yl) acetic acid (JCT-20) 
IR (KBr) cm-1: 3534 (-OH), 2934 (C-H str.), 1814 (-COOH), 1756 (-C-O-O, ester), 1715 
(>C=O), 1606, 1587, 1502, 1458 (ring skeleton), 1451 (CH2), 1269, 1048 (C-O-C). 
Mass: [m/e (%)], M. Wt.: 280, 256, 232, 214, 204, 188, 176, 159, 145, 128, 115, 103, 
91, 72. 
C, H, N analysis, Calculated: C, 72.85; H, 4.32. Found: C, 71.95; H, 3.97.  
 
2-(5,7-Dihydroxy-2-oxo-2H-chromen-4-yl)acetic acid (JCT-21) 
IR (KBr) cm-1: 3519 (-OH), 2964 (C-H str.), 1811 (-COOH), 1722 (-C-O-O, ester), 1666 
(>C=O), 1598, 1583, 1521, 1457 (ring skeleton), 1411 (CH2), 1253, 1128 (C-O-C), 862 
(meta substd.). 
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1H NMR 400 MHz (DMSO-d6,  ppm): 2.94 (s, 2H, -CH2), 5.19(s, 1H, 0H), 5.36 (s, 1H, 
0H), 6.27 (d, 2H, Ar-H, J= 2.48), 9.8 (br. s, 2H, 2 x OH). 
13C NMR 400 MHz (DMSO-d6,  ppm): 38.9 (CH2), 102-125 (Ar), 160 (C=O), 170 
(COOH).   
Mass: [m/e (%)], M. Wt.: 284, 258, 230, 218, 202, 190, 162, 147, 134, 120, 105, 95, 77, 
69, 44. 
C, H, N analysis, Calculated: C, 55.94; H, 3.41. Found: C, 55.37; H, 3.13.  
 
2-(7-Amino-2-oxo-2H-chromen-4-yl) acetic acid (JCT-22) 
IR (KBr) cm-1: 3535 (-OH), 3419 (N-H str.), 2954 (C-H str.), 1825 (-COOH), 1734 (-C-
O-O, ester), 1715 (>C=O), 1613, 1584, 1524, 1448 (ring skeleton), 1437 (CH2), 1267, 
1058 (C-O-C), 789 (mono substd.). 
Mass: [m/e (%)], M. Wt.: 219, 190, 162, 134, 120, 109, 80, 69, 44. 
C, H, N analysis, Calculated: C, 60.27; H, 4.14; N, 6.39. Found: C, 60.04; H, 3.69; O, 
28.99; N, 6.43. 
 
2-(8-(Naphthalene-1-yl)-2-oxo-2H-chromen-4-yl)acetic acid (JCT-23) 
IR (KBr) cm-1: 3523 (-OH), 2942 (C-H str.), 1835 (-COOH), 1731 (-C-O-O, ester), 1724 
(>C=O), 1596, 1557, 1508, 1468 (ring skeleton), 1433 (CH2), 1275, 1064 (C-O-C), 753 
(mono substd.). 
Mass: [m/e (%)], M. Wt.: 330, 306, 280, 256, 232, 214, 204, 188, 176, 159, 145, 128, 
115, 103, 91, 77, 65, 44, 41. 
C, H, N analysis, Calculated: C, 76.35; H, 4.27. Found: C, 76.26; H, 3.77.  
 
2-(2-Oxo-2H-chromen-4-yl) acetic acid (JCT-24) 
IR (KBr) cm-1: 2836 (C-H str.), 1823 (-COOH), 1726 (-C-O-O, ester), 1738 (>C=O), 
1623, 1582, 1502, 1493 (ring skeleton), 1458 (CH2), 1236 (C-O-C). 
1H NMR 400 MHz (DMSO-d6,  ppm): 3.97 (s, 2H, -CH2), 6.47 (s, 1H, -CH), 6.80-7.66 
(m, 4H, Ar-H), 10.01 (br. s, 1H, COOH). 
13C NMR 400 MHz (DMSO-d6,  ppm): 39.50 (CH2), 115.25-130.70 (Ar), 165.40 
(C=O), 171.90 (COOH). 
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C, H, N analysis, Calculated: C, 64.71; H, 3.95. Found: C, 64.43; H, 3.56. 
 
1.11. Conclusion 
 
Total 15, 2-(2-oxo-2H-chromen-4-yl) acetic acids were synthesized in this chapter and in 
few cases process development was also undertaken to improve the yield, compared to 
the earlier reported methods. The compounds were characterized by IR, NMR, Mass 
spectral data and elemental analysis. All the synthesized compounds have been sent for 
anti-cancer activity and the results are awaited. 
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1.12. Spectra of (2-oxo-2H-chromen-4-yl)acetic acid derivatives 
Infra Red spectrum of 2-(7-hydroxy-2-oxo-2H-chromen-4-yl) acetic acid (JCT-10) 
 
 
Infra Red spectrum of 2-(7-methyl-2-oxo-2H-chromen-4-yl)acetic acid (JCT-14) 
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Infra Red spectrum of 2-(6-methyl-2-oxo-2H-chromen-4-yl)acetic acid (JCT-15) 
 
 
Infra Red spectrum of 2-(7,8-dimethyl-2-oxo-2H-chromen-4-yl)acetic acid (JCT-16) 
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Infra Red spectrum of 2-(6,8-dimethyl-2-oxo-2H-chromen-4-yl) acetic acid (JCT-17) 
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Mass spectrum of 2-(7-hydroxy-2-oxo-2H-chromen-4-yl) acetic acid (JCT-10) 
 
 
Mass spectrum of 2-(2-oxo-2H-benzo[h]chromen-4-yl) acetic acid (JCT-11) 
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Mol. For.: C15H10O4
Mol. Wt.: 254.24
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Mass spectrum of 2-(8-methyl-2-oxo-2H-chromen-4-yl) acetic acid (JCT-13) 
 
 
Mass spectrum of 2-(7-methyl-2-oxo-2H-chromen-4-yl) acetic acid (JCT-14) 
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Mass spectrum of 2-(6-methyl-2-oxo-2H-chromen-4-yl) acetic acid 
 
 
Mass spectrum of 2-(6-methyl-2-oxo-2H-chromen-4-yl) acetic acid (JCT-16) 
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Mass spectrum of 2-(6,8-dimethyl-2-oxo-2H-chromen-4-yl) acetic acid (JCT-17) 
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1H NMR spectrum of 2-(7-hydroxy-2-oxo-2H-chromen-4-yl) acetic acid (JCT-10) 
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1H NMR spectrum of   2-(2-oxo-2H-benzo[h]chromen-4-yl)acetic acid (JCT-11) 
 
 
 
 
O
OH
O
O
Synthesis and Characterization of Some (2-Oxo-2H-chromen……. 52 
1H NMR spectrum of  2-(6-methyl-2-oxo-2H-chromen-4-yl) acetic acid (JCT-15) 
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1H NMR spectrum of  2-(7,8-dimethyl-2-oxo-2H-chromen-4-yl) acetic acid (JCT-16) 
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1H NMR spectrum of 2-(6,8-dimethyl-2-oxo-2H-chromen-4-yl) acetic acid (JCT-17) 
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1H NMR spectrum of 2-(5,7-dihydroxy-2-oxo-2H-chromen-4-yl) acetic acid (JCT-21) 
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1H NMR spectrum of 2-(2-oxo-2H-chromen-4-yl) acetic acid (JCT-24) 
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 13C NMR spectrum of 2-(7-hydroxy-2-oxo-2H-chromen-4-yl) acetic acid (JCT-10) 
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13C NMR spectrum of 2-(2-oxo-2H-benzo[h]chromen-4-yl) acetic acid (JCT-11) 
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13C NMR spectrum of 2-(7-methyl-2-oxo-2H-chromen-4-yl) acetic acid (JCT-14) 
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13C NMR spectrum of 2-(6-methyl-2-oxo-2H-chromen-4-yl) acetic acid (JCT-15) 
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13C NMR spectrum of 2-(7,8-dimethyl-2-oxo-2H-chromen-4-yl) acetic acid (JCT-16) 
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13C NMR spectrum of 2-(6,8-dimethyl-2-oxo-2H-chromen-4-yl)acetic acid (JCT-17) 
 
 
13C NMR spectrum of 2-(6,7-dimethyl-2-oxo-2H-chromen-4-yl)acetic acid (JCT-18) 
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13C NMR spectrum of 2-(2-oxo-2H-chromen-4-yl)acetic acid (JCT-24) 
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2.1. Introduction 
Coumarin,1(a) the parent substance of the benzo--pyrone group, was first isolated 
from Tonka beans in 1820. Their derivatives have been found to be widely distributed 
in plant kingdom.1(b-e)  The three classical methods were adopted for the preparation 
of coumarin derivatives. 
i. Perkin2 synthesized coumarins from salisaldehyde with acetic anhydride and 
anhydrous sodium acetate. 
ii. Pechmann3 prepared coumarins from phenol and malic acid when heated in 
concentrated sulfuric acid. 
iii. Knoevenagel4 developed coumarin from 2-hydroxyaldehyde with diethyl 
malonate in presence of piperidine. 
 
Pechmann reaction has been studied by many researchers, using various substituted 
phenols and different β-ketonic esters. Biginelli5 condensed quinol with 
ethyloxalacetate in presence of sulfuric acid and obtained 6-hydroxy-coumarin-4-
acetic acid. Pechmann, Kraft,6 and Graeger7 extended this reaction to other phenols 
(Scheme-1). 
 
R
OH
H2C
CH2
H2C
COOC2H5
COOC2H5
O
R
CH2COOH
O
R=H, OH,CH3 etc.
Scheme-1
  
 
 Limaye8 found that phenol when condensed with citric acid, gave coumarin-4-acetic 
acid. Dey9, Dixit10, Fries11 and Radhabai12 had studied the reaction of phenol with 
acetone dicarboxylic acid and citric acid. Gokhle, Ghosh,13 Chakravarti14 and 
Banerjee15 have studied the formation of coumarin-4-acetic acid from substituted 
phenol and acetone dicarboxyllic acid using sulfuric acid as condensing agent. Burton 
and Muller16,17 have found that condensation of resorcinol with diethylacetone 
dicarboxylate afforded 7-hydroxy coumarin-4-acetic acid. Ghiya and co-workers18a 
also studied these compounds for bromination of styryl derivatives. 
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Werder18b have synthesized more than 100 derivatives of coumarin-3-carboxylic acid, 
which were found to be sedative in small doses and hypnotic in large doses. Among 
the derivatives of these acids, the diethyl amide proved to be a good drug in general 
nervous disease and in various neuro anaesthetic and hysterical ailments. It has been 
further found that some oxygenated coumarins possessing the power of absorbing UV 
rays were extensively used as medicines in skin desieses18c.  
 
A number of natural and synthetic coumarin (2-oxo-2H-chromene) derivatives have 
been reported to exert notably antimicrobial19,20 as well as antifungal21,22 and 
tuberculostatic23 activity. Moreover, the antibiotic novobiocin belongs to the hydroxy 
coumarin series (Figure-1). 
 
O
OH
ORO
H
N
O
CH3
CH3
OH
Figure-1
 
 
Aryl alkanoic acids 
A phenyl ring or aryl ring attached with acetic or propionic acid gave phenyl acetic 
acid derivatives. It was found that when a heterocyclic system was introduced in place 
of aromatic ring, the resulting alkanoic acid derivatives showed therapeutic 
importance such as analgesics, anti-inflammatory and antiarthritic. Many aryl 
alkanoic acids are classified as non-steroidal antiinflamatory drugs (NSAIDS). 
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Figure-2: Some of the aryl alkanoic acids and their biological activity profile 
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Benzothiazole containing analogues 
Benzothiazoles are heterocyclic compounds with multiple applications and, have been 
known from long ago as biologically active.32-34 Their varied biological features are 
still of much scientific interest.  2-Aminobenzothiazoles are oxygen sensitive and 
therefore used as acid salts, alkaline salts, zinc salts and di-sulphides which generate 
free 2-aminobenzothiazoles under reducing conditions. 2-Aminobenzothiazoles are 
appreciably reactive and react with a number of compounds to produce 
benzothiazoles (Figure-3). 
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Benzothiazole
S
N
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Figure-3
 
 
They show very potent antitumor activity, especially the phenyl-substituted 
benzothiazoles,35-37 while condensed pyrimido[2,1-b]benzothiazoles and 
benzothiazolo[2,3-b]-quinazolines exert antiviral activity.38  
 
Recently, Racane et. al.39 have described the synthesis of bis-substituted 
amidinobenzothiazoles as potential anti-HIV agents. Substituted benzamido- and 
phenylacetamido-substituted 2-phenylbenzothiazoles,40-42 2-substituted 6-nitro- and 6-
aminobenzothiazoles,43 fluorobenzothiazoles44  and Schiff bases derived from 
benzothiazoles45 had also shown anti-microbial activity (Figure-4). 
 
Benzothiazole derivatives show other biological activities, too. 2-Amino-substituted 
benzothiazoles are reported as inhibitors of Src family kinases .46, 47 
 
X
X
HN
S
N
CN
R
HN
S
N
CN
N
N
N
HN
Figure-4
 
 
During last 50 years, number of 2-benzothiazolamines was intensively studied as 
central muscle relaxants.48 Biologist’s attention was drawn to this series when the 
pharmacological profile of riluzole was discovered. Riluzole, 6-(trifluoromethoxy)-2-
benzothiazolamine, was found to interfere with glutamate neurotransmission in 
biochemical, electrophysiological and behavioral experiments. Riluzole is the most 
active compounds displaying in vivo “antiglutamate” activity (Figure-5). 
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Two series of analogues of riluzole, i.e. mono-substituted 2-benzothiazolamines and 
3-substituted derivatives, have been synthesized by Jimonet and co-workers.49 Of all 
the compounds synthesized, only 2-benzothiazolamines bearing alkyl, 
polyfluoroalkyl, or polyfluoroalkoxy substituents in the 6-position showed potent 
anticonvulsant activity against administration of glutamic acid in rats. 
 
Synthetic aspects and biological profiles of benzothiazoles 
6-Substituted-2-benzothiazolamines bearing various substituents in the 6-position 
(scheme-2) shows the classical synthetic route50 used for the preparation of various 
derivatives 6-substituted-2-benzothiazolamines. One-pot reaction of the appropriate 
aniline with thiocyanogen generated from bromine and alkaline thiocyanate in acetic 
acid medium led to formation of the desired products in good to moderate yields. 
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Another classical way51 previously used for the preparation of 2-aminobenzothiazoles 
is cyclization of phenylthioureas with bromine in chloroform (Scheme-3).  
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Hofmann52 obtained benzothiazoles by the action of acids, acid chlorides and acid 
anhydrides upon o-aminothiophenol. Upon condensing certain aldehydes with o-
aminothiophenol, also obtained were benzothiazoles53 (Scheme-4). 
 
SH
NH2
2CH2CHO
N
S
CH3 C2H5OH H2O
Scheme-4
 
 
Green and Perkin54 also obtained a benzobisthiazole by condensing benzaldehyde 
with p-phenylenediamine-2,5-di-(thiosulfonic acid). Claasz55 condensed a number of 
aldehydes with o-aminothiophenol hydrochloride and obtained benzothiazolines 
(Scheme-5). 
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Investigations for the preparation of 2-aminobenzothiazoles can be traced to the early 
1900s with the work of Hugerschoff,56 who found that an arylthiourea can be cyclized 
with bromine solution in chloroform to form an 2-aminobenzothiazoles.57 This 
reaction usually proceeds efficiently at room temperature. Hugerschoff reaction is a 
well known reaction for the production of 2-aminobenzothiazoles by the reaction of 
molecular bromine (Br2) with arylthioureas (Scheme-6). 
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Cecchetti and co-workers58 synthesized substituted 2-aminobenzothiazoles and 
carried out successive cyclocondensation with 1-bromo-2-chloroethane. Few of the 
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pyridobenzothiazine acids showed potent antibacterial activities against Gram-
positive and Gram-negative pathogens (Scheme-7). 
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However, Jordan et. al.59 synthesized 2-aminobenzothiazoles by using 
benzyltrimethylammonium tribromide (PhCH2NMe3Br3), a stable, crystalline organic 
ammonium tribromide (OATB), which can be readily utilized as an alternative 
electrophilic bromine source. It is easier to control the stoichiometry of addition with 
an OATB, which minimizes aromatic bromination caused by excess reagent. They 
developed a direct procedure from isothiocyanates and amines using 
tetrabutylammonium thiocyanate and benzyltrimethylammonium tribromide to afford 
functionalized 2-aminobenzothiazoles (Scheme-8). 
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Benzothiazoles of biological interest 
A new series of 2-(4-aminophenyl) benzothiazoles substituted in the phenyl ring and 
benzothiazole moiety has been synthesized by Shi and co-workers60 by simple, high-
yielding routes. The parent molecule 4-(benzo[d]thiazol-2-yl)benzenamine (figure-6) 
shows potent inhibitory activity in vitro in the nanomolar range against a panel of 
human breast cancer cell lines, activity against the sensitive breast lines MCF-7 and 
MDA 468 is characterized by a biphasic dose-response relationship. 
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Racane et. al.61 synthesized 6-nitro-2-(substituted-phenyl)benzothiazoles by 
condensation reactions of substituted benzaldehydes with 2-amino-5-nitrothiophenol. 
Few compounds were found to exert cytostatic activities against malignant human cell 
lines such as cervical (HeLa), breast (MCF-7), colon (CaCo-2), laryngeal carcinoma 
(Hep-2) and normal human fibroblast cell lines (WI-38). An efficient synthesis of 2-
phenylbenzothiazole derivatives was carried out by the reactions outlined in scheme-
9. 
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Mackie et. al.62 reported the paralysant and lethal action of some benzothiazole 
compounds toward Ascaris lumbricoides and Fasciola hepatica. In view of the 
important physiological properties63 (a-c) possessed by the 2-amino-6-substituted 
benzothiazoles, it appeared of interest to prepare the condensation products of these 
compounds with chloral,64 incorporating a lipid-solubilizing group (trichloromethyl) 
which might assist the penetration of the compounds through the cuticle of Ascaris 
lumbricoides and thereby have a deleterious effect on the neuromuscular system of 
the intestinal nematodes and on other trematodes. Condensation products of aromatic 
and heterocyclic amines with chloral had previously been reported by Sumerford et. 
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al.65 and Nelson et. al.66 (figure-7) but no work in this respect seems to have been 
done with the 2-amino-6-substituted benzothiazoles. 
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On the other hand, bis-benzothiazoles and substituted bis-benzothiazoles are 
frequently fluorescent compounds and therefore convenient for fluorimetric 
measurements, which could serve as a potential method for detection of binding the 
biologically active compounds on DNA.67  (Scheme-10) However, there is little data 
describing compounds containing two benzothiazole rings attached via a heterocyclic 
system.68 
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Several lines of evidence support the hypothesis that c-Jun N-terminal kinase (JNKs) 
plays a critical role in a wide range of diseases including cell death (apoptosis)-related 
disorders (neurodegenerative diseases, brain, heart, and renal ischemia, epilepsy) and 
inflammatory disorders (multiple sclerosis, rheumatoid arthritis, inflammatory bowel 
diseases). The c-Jun N-terminal kinases (JNKs) (also known as “stress-activated 
protein kinases”) are members of the mitogen-activated protein kinase (MAPK) 
family along with p38 mitogen-activated protein kinases (p38 kinases) and 
extracellular signal-regulated kinases (ERKs). 
 
Recently,69 the identification of (benzoylaminomethyl) thiophene sulfonamide 
inhibitors such as AS600292  (figure-8) as the first potent and selective JNK inhibitor 
of this class that demonstrates a protective action against neuronal cell death induced 
by growth factor and serum deprivation.70  
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Figure-9: Amide linkage containing analogues: A collection of commercial 
analogues based on -aminoamide structure:71 
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A number of drugs and drug like compounds have amide linkages. Coumarin 
carboxamide72 has been prepared from the corresponding coumarin carboxylic acid 
and 2-amino-4-phenylthiazole73 and tested for anti-fungal and antibacterial activity.74 
(Figure-10). 
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Mayaux and Soler et. al. have reported that RPR 103611, the most promising 
betulinic acid derivative in their studies, interfered with virus replication specifically 
at syncytium formation.75,76 RPR 103611, a triterpene derivative, has been identified 
as a fusion inhibitor (Figure-11). 
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Aromatic polyamide dendrons HOOC-G1, were synthesized by Ishida et. al.77 by an 
orthogonal approach, which utilizes the direct condensation reaction and palladium 
catalyzed carbon monoxide insertion reaction in an alternating fashion to form amide 
linkages (Scheme-11). 
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Nevirapine,78 consisting of amide linkage, is used for inhibition of RT enzyme  
(Figure-12). 
N
HN
N N
H3C
O
Figure-12: Nevirapine
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2.2. Pharmacology 
Biologically active heterocycles containing amide linkage 
Guanidinothiazolecarboxamides are a novel class of antitumor agents found to be 
systemically active against experimental pulmonary metastates of 3LL Lewis lung 
carcinoma (Figure-13). 
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Schnur and co-workers79 found that a series of substituted benzothiazole GTCs 
enhances the survival in this model by using 8 days of intraperitoneal dosing, initiated 
2 days after intravenous tumor challenge. Quantitative structure-activity relationships 
have been studied in the GTC series with survival enhancement correlated to 
substituent parameters. 
 
A large number of hydrazides have been reported to be of biological interest80,81 while 
oxadiazole derivatives and thiosemicarbazides have been reported to possess 
antibacterial,82,83 antifungal84,85 and other biological activities. Furthermore, a number 
of substituted thiazolines and thiazolidinones were found to exhibit appreciable 
antimicrobial and antifungal activities86-90 (Scheme-12). 
 
It was therefore thought worthwhile to incorporate the hydrazide, thiosemicarbazide 
and oxadiazole moieties into the coumarin nucleus91 (Scheme-13). 
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Synthesis of amide derivatives 
There are number of approaches for carrying out amide bond formation from a 
carboxylic acid and an amine. 
i. Use of an acid and an amine with direct heating to eliminate water.  
ii. Use of acid chloride and an amine with the use of catalytic acid scavenger.  
iii. Use of Dicyclohexyl Carbodiimide (DCC) at room temperature. 
 
Following are the few examples: 
Hassner and co-workers92 synthesized amide linkage coupling 2,3-
diphenylcyclopropane-1-carbobxylic acid with the corresponding chiral amine using 
DCC/DMAP (Scheme-14). 
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Khunnawutmanotham et. al.93 developed an efficient synthetic route to prepare 2-
chloro-5,11-dihydro-11-ethyl-8- (phenylthio)methyl-6H-dipyrido[3,2-b:2’,3’-
e][1,4]diazepin-6-one (T1) and 2-chloro-5,11-dihydro-11- ethyl-8-(3-methoxy-
phenylthio)methyl-6H-dipyrido[3,2-b:2’,3’-e][1,4]diazepin-6-one (T2) and to 
evaluate their anti-HIV-1 activity.  
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The use of 7-amino-4-methyl coumarin (AMC) peptide substrates for the assay of 
protease activity is a well established.94 Upon conjugation of its aromatic amino group 
to the C-terminal carboxyl group of a peptide, however, the fluorescence of the 
molecule is essentially quenched, thereby rendering the resulting peptide–AMC 
conjugate practically non-fluorescent. Incubation of an AMC-containing peptide 
substrate with a protease leads to specific cleavage of the anilide bond between AMC 
and the conjugated peptide, which liberates the fluorogenic AMC leaving group, 
allowing for the simple determination of cleavage rates for individual substrates. 
Libraries of fluorogenic AMC peptide substrates have also been synthesized to 
investigate the substrate specificity of proteases.95,96 This was accomplished by the 
use of a bifunctional fluorophore, 7-amino-4-carbamoylmethyl coumarin (ACC), to 
replace the original AMC in the library synthesis.97  
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The bifunctional fluorophore, ACC without any protection groups, was 
regioselectively attached to different solid supports functionalized with a primary 
amino group. The resulting resins were used to synthesize fluorogenic protease 
substrates with high yields and purity98 (Figure-15). 
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Planarity of the CONH linkage 
The XC(CO)NHY linkage, under the assumption Y=H called the amide linkage, or 
referred to as the peptide linkage, is generally assumed to have a planar structure99  
(Figure-15). 
 
 
 
It is shown that formamide, considered prototype for the amide linkage, is not typical 
as it has a planar equilibrium amide linkage corresponding to a single-minimum 
inversion potential around N. In contrast, several molecules containing the CONH 
linkage seem to have pyramidal nitrogen at equilibrium and a double-minimum 
inversion potential with a very small inversion barrier allowing for an effective planar 
ground-state structure.100  
 
Many of the molecules containing the XC(CO)NHY linkage are not planar at 
equilibrium. The simple molecules containing the C(CO)NH linkage can be divided 
into three groups:  
(i) All of the atoms of the molecule lie in a plane, i.e., the point-group 
symmetry of the molecule is Cs.  
(ii) All of the atoms of the molecule lie in a plane except pairs of hydrogen 
atoms which are situated symmetrically about the plane of symmetry, i.e., 
the point-group symmetry of the molecule is Cs. 
(iii) Molecules which do not have a plane of symmetry. 
 
Coumarin ring linked through -CH2-NH group with benzothiazoles were also studied 
and gave very good antimicrobial activity. Bhawsar et. al.101 have proved that the 
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Mannich bases of 4-methyl-7-hydroxy coumarins with various aliphatic amines102 and 
those derived from benzoxazoles have been found to possess antimicrobial and also 
CNS stimulating activity.  
 
Antifungal activity of 4-methyl-7-hydroxy/acetoxy coumarins and substituted amino 
benzothiazoles have been reported.103,104  (Figure-16). 
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Adityavardhan et. al.105,106  synthesized 3-(2-aminothiazolyl) derivatives of coumarins 
with open chain functionalities and heterocyclic systems possessing thiazole at 2-
position and 3-(2-amino-4-thiazolyl) coumarin from 3-acetyl coumarin and thiourea 
(Figure-17) . 
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Various pharmacological properties have been observed in different heterocyclic 
moieties having -CH2COOH group or -CH2-CO-NH linker. They can be categorized 
as under: 
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A. Aldose reductase inhibitors 
Aldose reductase has become a prime target for the development of compounds for 
preventing or treating chronic complications of diabetes mellitus. Experimental results 
generated during last few years suggest that diabetic pathology may be partly 
controlled through inhibition of the enzyme aldose reductase.107 
 
Specific structural and electronic similarities of apparently diverse aldose reductase 
inhibitors have been observed through basic studies and the presence of an acidic 
proton appears to be of prime importance in inhibiting the enzyme. 
 
The search for aldose reductase inhibitors, which has been underway for more than 25 
years, culminated in 1989 with the launch of the first aldose reductase inhibitor 
Tolrestat,108  for the treatment of diabetic neuropathy, retinopathy and nephropathy. 
 
The second aldose reductase inhibitor to reach the market was Epalrestat in 1992. 
Alrestatin,109 a carboxylic acid type aldose reductase inhibitor was discovered, had an 
IC50 values between 10-5 to 10-6 against bovine lense aldose reductase. While 5, 6-
benzocoumarin-4-acetic acid, being the most potent representative110 had IC50 of 20 
mM against bovine ladose reductase.111 Repaglinide, oral hypoglycemic agent have a 
–CH2-NH-CO-CH2- linkage between two benzene ring showing antidiabetic 
property112  (Figure-18). 
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Figure-18: Aldose reductase inhibitors under clinical trials113 
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B. Antioxidant activity 
Oxidants such as hydrogen peroxide and oxygen derived free radicals may play an 
important role in the physiopathology of tissue damage. Studies have shown that 
diabetes causes a thrombotic tendency in patients with increased oxidative stress.114 
Recently, it appeared that new threpeautic approaches for the prevention of diabetic 
complications may be found in free radical scavengers in order to limit the damage 
caused by oxidant stress.115,116 Antioxidant compounds often possess an acidic proton 
in their chemical structures. The structures of the synthetic antioxidant derivatives, 
oxypurinol and nifedipine contain an acidic or related function.117, 118. 
 
2.3. Synthetic aspects 
Coumarin-4-acetic acids were synthesized by many researchers using different 
methods. Limaye8 synthesized coumarin-4-acetic acid from phenol and citric acid 
using conc. sulfuric acid. Dixit and Gokhle10 condenced phenols with acetone 
dicarboxilic acids in presence of concentrated sulfuric acid to afford coumarin-4-
acetic acids. Dixit and Padukone119,120 prepared 6-hydroxy coumarin-4-acetic acid 
from citric acid and hydroquinone. 7-Hydroxy coumarin-4-acetic acid was prepared 
from resorcinol and acetone-dicarboxylic acid in presence of different Lewis catalysts 
like alluminium chloride, phosphporous oxychloride, phosphorous pentoxide or 
thionyl chloride under different reaction time and temperature conditions. 
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2.4. Present work 
Several coumarin-4-acetic acids were prepared by Pechmann condensation of 
appropriate phenols and citric acid using sulfuric acid as a condensing agent (Figure-
19). 
 
O O
O
OH
R
Figure-19
 
 
In the present work, mono-methyl as well as di-methyl coumarin-4-acetic acids were 
synthesized. Moreover, 7-hydroxylation in coumarin systems found to possess 
excellent pharmacodynamic properties.121 While 5,6-benzocoumarin-4-acetic acid and 
7,8-benzocoumarin-4-acetic acid were synthesized particularly to correlate with the 
pharmacological study. It is interesting to note the pronounced anti-diabetic nature of 
the later compound in light of former’s activity results. 
 
In well known Hantzsch synthesis,122 a reaction of 2-haloketone with thiourea and 
alcohol gave thiazole. 4-(Substituted phenyl)-2-amino thiazoles were also prepared by 
using acetophenone, thiourea and Iodine. Straley and Adams123 used β-ketoesters for 
the preparation of thiazoles. The 5th position of aminothiazole is highly reactive 
towards electophilic substitution reaction.  
 
Taking into account, pharmacological active pharmacophores like coumarin and 
benzothiazole, few heterocycles of the type below were prepared by direct fusion of 
coumarin-4-acetic acid with 2-amino benzothiazoles at high temperature (Figure-20).  
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Modifications 
Method-1:  N-1, 3-benzo[d]thiazol-2-yl-2-(2-oxo-2H-chromen-4-yl) acetamides were 
synthesized in three steps. 
1. The formation of coumarin-4-acetic acids. 
2. The formation of coumarin-4-acetic acids into acid chlorides by using excess 
thionyl chloride. It was taken without further purification in next step. 
3. The condensation of coumarin-4-acetic acid chlorides and 2-
aminobenzothiazoles in presence of pyridine using benzene as a solvent. 
 
Method 2: An alternate method is a single step method, where a mixture of coumarin-
4-acetic acid and 2-amino benzothiazole were heated at high temperature on sand 
bath. In both the methods, the purity of compounds were monitered by TLC 
(Acetone:Benzene:: 1:1). The purity as well as the yields were found better in the later 
method and thus, this has been found to be very quick and efficient method for the 
condensation reactions between 2-amino thiazoles and coumarin-4-acetic acids. 
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Where, R1, R2, R3, R4= OH, CH3, H, C6H5, NH2.
2.5. REACTION  SCHEME-I
Synthesis of  coumarin-4-acetic acid
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Synthesis of 2-amino benzothiazole
REACTION  SCHEME-II
N
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00C
Where R5, R6= NO2, Cl, F.
 
Preparation of N-1, 3-Benzo[d]thiazol...... 98 
 
REACTION  SCHEME-III
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Where, R1, R2, R3, R4= CH3, OH, C6H5, NH2.
and R5, R6= NO2, Cl, F.
Condensation of coumarin-4-acetic and 2-amino benzothiazole
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2.6. Experimental 
 
General method for preparation of coumarin-4-acetic acid 
A mixture of citric acid monohydrate (0.1 M) and 28 ml of conc. sulphuric acid was 
stirred at room temperature for sixty minutes and then slowly heated to 70oC. After 
half an hour at this temperature, with stirring throughout, the evolution of carbon 
monoxide had slackened and the clear yellow coloured solution was rapidly cooled to 
0oC. To this stirred solution, phenol (0.08 M) was added and 11.2 ml of conc. 
sulphuric acid, each in three equal portions, at a rate that the temperature does not 
exceed 10oC. The resulting solution was stored at 0oC for sixteen hours, poured into 
ice, and the resulting crystalline precipitate was filtered off and washed thoroughly 
with water. It was then treated with 10% sodium bicarbonate solution and then 
filtered. The filterate, on acidification gave coumarin-4-acetic acids. The bicarbonate 
insoluble portion is 4-methyl coumarin. The purity of the compound is checked by 
TLC. (Acetone: Benzene :: 1:1). The coumarin 4-acetic acid derivatives were 
similarly prepared by using different phenols. The physical data and Rf value of 
various coumarin 4-acetic acids are recorded in the Table No. 1. 
 
General method for preparation of coumarin-4-acetic acid chloride 
A mixture of coumarin-4-acetic acid (0.1 M) and thionyl chloride (0.5 M) was 
refluxed for 6-8 hours in water bath. Excess of thionyl chloride was distilled off and 
crude coumarin-4-acetic acid chloride obtained, was used immediately for further 
reaction without purification. 
 
General method for preparation of 2-amino benzothiazole 
Aniline (0.2 M), potassium thiocyanate (0.4 M) and 500 ml of glacial glacial acetic 
acid were taken in a flask and stirred continuously with mechanical stirring. Bromine 
(0.3 M) in 500 ml of glacial glacial acetic acid was added dropwise to this mixture, 
the temperature being kept below 30-35oC. Stirring was continued for an additional 1 
hr after the bromine addition. The solution was filtered and the filterate was then 
basified with NH4OH and the precipitated solid was collected and washed with water, 
to give the desired 2-amino benzothiazole. It was finally recrystallized with methanol. 
The purity of the compounds was checked by TLC. (Acetone: Benzene :: 1:1). 
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The physical data and Rf value of various  2-amino benzothialole were recorded in the 
Table No. 2. 
 
Preparation of  2-(6,8-dimethyl-2-oxo-2H-chromen-4-yl)-N-(6-nitrobenzo 
[d]thiazole-2-yl)-2-(2-oxo-2H-benzo[h]chromen-4-yl)acetamide (JT-17)  
 
Method-1: The reaction of coumarin-4-acetic acid chloride and 2-aminothiazole 
Method-2: The fusion of coumarin-4-acetic acid and 2-aminothiazole. 
 
Method-1 
6-Nitro-2-aminobenzothiazole (0.1 M) was taken in pyridine (10-12 ml) and was 
stirred at 00C. 6,8-dimethyl coumarin-4-acetic acid chloride (0.1 M) was added 
dropwise to the above solution within 30 minutes. The colour of the solution changes 
and becomes dark, which was further stirred for two hours. The resultant mass was 
poured into crushed ice to get crude 2-(6,8-dimethyl-2-oxo-2H-chromen-4-yl)-N-(6-
netribenzo[d]thiazole-2-yl)-2-(2-oxo-2H-benzo[h]chromen-4-yl)acetamide,which was 
washed with diethyl ether, filtered and dried. It was finally recrystallized from 
ethanol. M.p. 112-114oC, Yield 56 %. Elemental analysis: [Calcd: C, 58.67; H, 3.69; 
N, 10.26. Found C, 58.63; H, 3.66; N, 10.21]. 
Similarly, the other compounds were also prepared by using different coumarin-4-
acetic acids and 2-aminobenzothiazoles. 
 
Method-2 
The 6, 8-dimethyl coumarin-4-acetic acid (0.005 M) and 6-nitro-2-amino 
benzothiazole (0.005 M) were thoroughly mixed together and fused at 180-200oC for 
one hour on a sand bath. The reaction mass was cooled, some water (25-30 ml) was 
added to the reaction mass and further heated for one hour in a boiling water bath. 
The crude mass separated, filtered, dried and purified by first washing with 5% 
sodium bicarbonate solution to remove unreacted coumarin-4-acetic acid and then by 
distilled water. It was further washed with 5% hydrochloric acid and again with 
distilled water. It was filtered, dried and recrystallized from ethanol. m.p. 112-114oC, 
Yield 56 %.  
 
Similarly, the other compounds have also been prepared using various 2-amino 
benzothiazoles. The purity of the compounds was checked by TLC. 
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2.7. Table 1:  Physical data of coumarin-4-acetic acids 
 
O
R4
R3
R2
R1
O
COOH
 
 
Substitution 
Sr. No. 
R1 R2 R3 R4 
Moleular 
formula 
Molecular 
weight 
Melting point  
(oC) Rf value Colour 
% 
Yield 
1 H H OH H C11H8O5 220.18 206-208a 0.58 White 68 
2 H H H CH3 C12H10O4 218.21 202-204 0.56 White 54 
3 H H CH3 H C12H10O4 218.21 204-206 0.53 Off white 58.5 
4 H CH3 H H C12H10O4 218.21 184-185 0.55 Pale white 63.8 
5 H H CH3 CH3 C13H12O4 232.23 205-206 0.52 Pink 69 
6 H CH3 H CH3 C13H12O4 232.23 206-208 0.49 Off white 58 
7 --Benzo-- H H C15H10O4 254.24 208-210 0.48 Dull yellow 61 
8 H H --Benzo-- C15H10O4 254.24 210-212 0.46 Carrot pink 59 
TLC Solvent system: Acetone: Benzene = 1:1 
Ref.: (1) Laskowski, S. C.;  Clinton, R. O.  Coumarins. II. Derivatives of Coumarin-3- and -4-Acetic Acids, J. Am. Chem. Soc. 1950, 72, 3987-
3991. (2) Dey, B. B. J. Chcm. Soc. 1915, 107, 1606. (a= Reported m. p.: 204-206oC) 
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2.7. Table 2: Physical data of 2-amino benzothiazoles 
 
N
S
H2N
R5
R6
 
 
Substitution 
Sr. No. 
R5 R6 
Molecular 
formula Molecular weight 
Melting 
point (oC) Rf value Colour 
% 
Yield 
1 H NO2 C7H5N3O2S 195 174-176 0.52 Orange 42 
2 H Cl C7H5ClN2S 184 186-188 0.54 Pale yellow 64 
3 H F C7H5FN2S 168 168-170 0.48 Greenish white 57 
4 Cl F C7H4ClFN2S 202 194-196b 0.58 Pale white 68 
5 H OCH3 C8H8N2OS 180 152-154 0.46 Brownish black 46 
 
TLC Solvent system: Acetone: Benzene = 5:5 
 
Ref.: Cecchetti, V. et al. J. Med Chem. 1987, 30, 465-473.  
(b= Reported m.p.: 189-192oC)
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2.7. Table 3: N-1, 3-benzo[d]thiazol-2-yl-2-(2-oxo-2H-chromen-4-yl)acetamides 
O
O
H
N
S
N
O
R4
R3
R2
R1
R5
R6
 
Substitution 
Code 
R1 R2 R3 R4 R5 R6 
Molecular formula Molecular 
weight 
Melting 
point (oC) Rf value 
% 
Yield 
JT-1 H H H CH3 H NO2 C19H13N3O5S 395.38 130-132 0.58 54 
JT-2 H H H CH3 H Cl C19H13ClN2O3S 384.83 160-162 0.55 58 
JT-3 H H H CH3 H F C19H13FN2O3S 368.38 106-108 0.54 61 
JT-4 H H H CH3 Cl F C19H12ClFN2O3S 402.82 140-142 0.57 63 
JT-5 H H CH3 H H NO2 C19H13N3O5S 395.38 192-194 0.48 58 
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2.7. Table 3 (contd.): N-1, 3-benzo[d]thiazol-2-yl-2-(2-oxo-2H-chromen-4-yl)acetamides 
 
 
 
 
Substitution 
Code 
R1 R2 R3 R4 R5 R6 
Molecular formula Molecular 
weight 
Melting 
point (oC) Rf value 
% 
Yield 
JT-6 H H CH3 H H Cl C19H13ClN2O3S 384.83 118-120 0.49 56 
JT-7 H H CH3 H H F C19H13FN2O3S 368.38 136-138 0.56 51 
JT-8 H H CH3 H Cl F C19H12ClFN2O3S 402.82 188-190 0.61 48 
JT-9 H CH3 H H H NO2 C19H13N3O5S 395.38 110-112 0.59 43 
JT-10 H CH3 H H H Cl C19H13ClN2O3S 384.83 118-120 0.60 63 
JT-11 H CH3 H H H F C19H13FN2O3S 368.38 98-100 0.46 61 
JT-12 H CH3 H H Cl F C19H12ClFN2O3S 402.82 116-118 0.62 59 
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2.7. Table 3 (contd.): N-1, 3-benzo[d]thiazol-2-yl-2-(2-oxo-2H-chromen-4-yl)acetamides 
 
 
 
 
 
Substitution 
Code 
R1 R2 R3 R4 R5 R6 
Molecular formula Molecular 
weight 
Melting 
point (oC) Rf value 
% 
Yield 
JT-13 H H CH3 CH3 H NO2 C20H15N3O5S 409.41 124-128 0.61 54 
JT-14 H H CH3 CH3 H Cl C20H15ClN2O3S 398.86 152-158 0.55 58 
JT-15 H H CH3 CH3 H F C20H15FN2O3S 382.40 148-154 0.53 60 
JT-16 H H CH3 CH3 Cl F C20H14ClFN2O3S 416.85 142-146 0.58 61 
JT-17 H CH3 H CH3 H NO2 C20H15N3O5S 409.41 112-114 0.62 63 
JT-18 H CH3 H CH3 H Cl C20H15ClN2O3S 398.86 96-98 0.60 56 
JT-19 H CH3 H CH3 H F C20H15FN2O3S 382.40 136-138 0.62 58 
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2.7. Table 3 (contd.): N-1, 3-benzo[d]thiazol-2-yl-2-(2-oxo-2H-chromen-4-yl)acetamides 
 
 
 
 
 
Substitution 
Code 
R1 R2 R3 R4 R5 R6 
Molecular formula Molecular 
weight 
Melting 
point (oC) Rf value 
% 
Yield 
JT-20 H CH3 H CH3 Cl F C20H14ClFN2O3S 416.85 104-106 0.53 49 
JT-21 H H OH H H NO2 C18H11N3O6S 397.36 186-188 0.57 55 
JT-22 H H OH H H Cl C18H11ClN2O4S 386.80 184-186 0.59 52 
JT-23 H H OH H H F C18H11FN2O4S 370.35 188-190 0.52 56 
JT-24 H H OH H Cl F C18H10ClFN2O4S 404.79 208-210 0.49 58 
JT-25 H H --Benzo-- H OCH3 C23H16N2O4S 416.66 122-124 0.52 67 
JT-26 --Benzo-- H H H OCH3 C23H16N2O4S 416.66 136-138 0.57 74 
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2.8. Spectral study 
 
Infra Red spectra 
Infra Red Spectra were taken on SHIMADZU IR-435 Spectrometer using KBr Pellet 
method. The characteristic carbonyl group in coumarin moiety is observed at 1710-
1720 cm-1, while carbonyl value of –CONH- peaks are observed in the range 1630-
1690 cm-1. In some of the compounds, the moisture showed a broad peak between 
3000-3200 cm-1. Secondary amine (> NH) observed a broad peak between 3000-3200 
cm-1, -OH appeared at 3440 cm-1 as a broad band. A (>C=N) str. is observed at 1620 
cm-1 while (>C=S) str. Was observed at 1132-1178 cm-1. The ether (C-O-C) and 
thioether (C-S-C) were observed at 1262-1283 str., 1065-1069 str. and 746-773 cm-1, 
repectively. Monosubstitution at C6 as well as C7 of coumarin ring showed the 
frequency between 860-880 cm-1. 
 
1H NMR spectra 
1H NMR Spectra were recorded on a Bruker AC 400 MHz FT-NMR Spectrometer 
using TMS (Tetramethyl Silane) as an internal standard and DMSO-d6 as a solvent. In 
the NMR spectra of N-1, 3-benzo[d]thiazol-2-yl-2-(2-oxo-2H-chromen-4-
yl)acetamides various proton values of methylene (-CH2), methyne (-CH), methoxy (-
OCH3), methyl (-CH3) and aromatic protons (Ar-H) etc. were observed as under. 
 
The values for methylene (-CH2) proton is observed between  4,45-4.55 ppm. In 
some cases, the value of methylene proton differs to  5.20 and 5.43 ppm. The C6 
protons of methoxy group of benzothiazole observed at  3.61 ppm. Aromatic protons 
shows the multiplet between  6.71-8.54  ppm. The signal due to NH proton of 
(>C=O-NH) group was observed at 8.5  ppm value. 
 
Mass spectra 
The mass spectrum of compounds were recorded by GCMS-QP2010 spectrometer (EI 
method). The mass spectrum of compounds was obtained by positive chemical 
ionization mass spectrometry. The molecular ion peak and the base peak in all 
compounds were clearly obtained in mass spectral study. The molecular ion peak 
(M+) values are in good agreement with molecular formula of all the compounds 
synthesized.  
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C, H, N analysis 
Elemental analysis of the compounds was carried out on Elemental Vario EL III Carlo 
Erba 1108 model at CDRI, Lucknow and the results are in agreement with the 
structures assigned. 
 
2.9. Spectral characterization 
2-(8-Methyl-2-oxo-2H-chromen-4-yl)-N-(6-nitrobenzo[d]thiazole-2-yl)acetamide 
(JT-1) 
IR (KBr) cm-1: 3155 (-NH), 1714 (>C=O), 1680 (-CONH), 1666 (C=N), 1450 (CH2), 
1334 (-CH3, str.), 1273, 1067 (C-O-C), 1112 (>C=S), 872 (o.o.p.), 887 (mono 
substd.), 751 (C-S-C). 
1H NMR 400 MHz: (DMSO-d6,  ppm): 2.35 (s, 3H, -CH3), 2.85 (s, 2H, -CH2), 6.04 
(s, 1H, CH), 6.9-8.5(m, 6H, Ar-H). 
Mass: [m/e (%)], M. Wt.: 395.38, 395, 381, 351, 348, 316, 266, 244, 238, 222, 196, 
188, 176, 165, 145, 134, 122, 102, 89, 79, 63, 44. 
C, H, N analysis, Calculated: C, 57.72; H, 3.31; N, 10.63. Found: C, 57.67; H, 3.26; 
N, 10.61. 
 
N-(6-Chlorobenzo[d]thiazole-2-yl)-2-(8-methyl-2-oxo-2H-chromen-4-
yl)acetamide (JT-2) 
IR (KBr) cm-1: 3080 (-NH), 1735 (>C=O), 1709 (-CONH), 1498 (CH2), 1356 (-CH3, 
str.), 1264, 1170 (C-O-C), 1139 (>C=S), 819(o.o.p.), 861 (mono substd.), 670 (C-S-
C). 
1H NMR 400 MHz: (DMSO-d6,  ppm): 2.55 (s, 3H, -CH3), 2.89 (s, 2H, -CH2), 6.04 
(s, 1H, CH), 7.0-8.5 (m, 6H, Ar-H). 
Mass: [m/e (%)], M. Wt.: 385, 340, 266, 256, 250, 226, 222, 201, 184, 169, 160, 
145, 134, 122, 102, 89, 79, 6, 44. 
C, H, N analysis, Calculated: C, 59.30; H, 3.40; N, 7.28. Found: C, 59.26; H, 3.39; 
N, 7.25. 
 
N-(6-Fluorobenzo[d]thiazole-2-yl)-2-(8-methyl-2-oxo-2H-chromen-4-
yl)acetamide (JT-3) 
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IR (KBr) cm-1: 3068 (-NH), 1748 (>C=O), 1690 (-CONH), 1472 (CH2), 1368 (-CH3, 
str.), 1258, 1184 (C-O-C), 1156 (>C=S), 835(o.o.p.), 872 (mono substd.), 676 (C-S-
C). 
C, H, N  analysis, Calculated: C, 61.95; H, 3.56; N, 7.60. Found: C, 61.92; H, 3.54; 
N, 7.59. 
 
N-(5-Chloro-6-fluorobenzo[d]thiazole-2-yl)-2-(8-methyl-2-oxo-2H-chromen-4-
yl)acetamide (JT-4) 
IR (KBr) cm-1: 3067 (-NH), 1717 (>C=O), 1680 (-CONH), 1623 (C=N), 1452 (CH2), 
1385 (-CH3, str.), 1242, 1123 (C-O-C), 1135 (>C=S), 720(o.o.p.), 750 (mono substd.), 
670 (C-S-C). 
1H NMR 400 MHz: (DMSO-d6,  ppm): 2.35 (s, 3H, -CH3), 2.85 (s, 2H, -CH2), 6.5 
(s, 1H, CH), 7.2-8.9 (m, 5H, Ar-H). 
Mass: [m/e (%)], M. Wt.: 403, 351, 293, 212, 210, 184, 174, 157, 145, 127, 122, 
111, 73, 69, 44. 
C, H, N  analysis, Calculated: C, 56.65; H, 3.00; N, 6.95. Found: C, 56.62; H, 2.96; 
N, 6.91. 
 
2-(7-Methyl-2-oxo-2H-chromen-4-yl)-N-(6-nitrobenzo[d]thiazole-2-yl)acetamide 
(JT-5) 
IR (KBr) cm-1: 3438 (-NH), 1728 (>C=O), 1669 (-CONH), 1572 (C=N), 1451 (CH2), 
1335 (-CH3, str.), 1250, (C-O-C), 1044 (>C=S), 750 (o.o.p.), 669 (mono substd.), 825 
(C-S-C). 
1H NMR 400 MHz: (DMSO-d6,  ppm): 2.45 (s, 3H, -CH3), 2.98 (s, 2H, -CH2), 6.94 
(s, 1H, CH), 7.1-8.9 (m, 6H, Ar-H). 
Mass: [m/e (%)], M. Wt.: 395, 381, 351, 348, 316, 266, 244, 238, 222, 196, 188, 
176, 165, 145, 134, 122, 102, 89, 79, 63, 44. 
C, H, N  analysis, Calculated: C, 56.65; H, 3.00; N, 6.95. Found: C, 56.62; H, 2.96; 
N, 6.91. 
 
N-(6-Chlorobenzo[d]thiazole-2-yl)-2-(7-methyl-2-oxo-2H-chromen-4-
yl)acetamide (JT-6) 
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IR (KBr) cm-1: 3424 (-NH), 1736(>C=O), 167469 (-CONH), 1578 (C=N), 1462 
(CH2), 1378 (-CH3, str.), 1258, (C-O-C), 1046 (>C=S), 756 (o.o.p.), 672 (mono 
substd.), 832 (C-S-C). 
C, H, N analysis, Calculated: C, 59.30; H, 3.40; N, 7.28. Found: C, 59.26; H, 3.39; 
N, 7.25. 
N-(6-Fluorobenzo[d]thiazole-2-yl)-2-(7-methyl-2-oxo-2H-chromen-4-
yl)acetamide (JT-7) 
IR (KBr) cm-1: 343255 (-NH), 1742 (>C=O), 1662 (-CONH), 1646 (C=N), 1444 
(CH2), 1385 (-CH3, str.), 1264, 1067 (C-O-C), 1124 (>C=S), 678 (o.o.p.), 891 (mono 
substd.), 755 (C-S-C). 
C, H, N  analysis, Calculated: C, 61.95; H, 3.56; N, 7.60. Found: C, 61.92; H, 3.54; 
N, 7.59. 
 
N-(5-Chloro-6-fluorobenzo[d]thiazole-2-yl)-2-(7-methyl-2-oxo-2H-chromen-4-yl) 
acetamideb (JT-8) 
IR (KBr) cm-1: 3230 (-NH), 1729 (>C=O), 1680 (-CONH), 1695 (C=N), 1452 (CH2), 
1305 (-CH3, str.), 1278, 1083 (C-O-C), 1112 (>C=S), 817 (o.o.p.), 888 (mono 
substd.), 644 (C-S-C). 
1H NMR 400 MHz: (DMSO-d6,  ppm): 2.2 (s, 3H, -CH3), 2.85 (s, 2H, -CH2), 6.9 
(s, 1H, CH), 7.2-8.4 (m, 5H, Ar-H). 
Mass: [m/e (%)], M. Wt.: 402, 387, 373 (100), 357, 343, 327, 297, 281, 280, 254, 
248, 236, 221, 206, 195, 175, 160, 147, 133, 122, 107, 95, 78, 63, 44. 
C, H, N  analysis, Calculated: C, 56.65; H, 3.00; N, 6.95. Found: C, 56.62; H, 2.96; 
N, 6.91. 
 
2-(6-Methyl-2-oxo-2H-chromen-4-yl)-N-(6-nitrobenzo[d]thiazole-2-yl)acetamide 
(JT-9) 
IR (KBr) cm-1: 3332 (-NH), 1731 (>C=O), 1677 (-CONH), 1667 (C=N), 1448 (CH2), 
1333 (-CH3, str.), 1277, 1048 (C-O-C), 1126 (>C=S), 817 (o.o.p.), 849(mono substd.), 
749(C-S-C). 
C, H, N  analysis, Calculated: C, 56.65; H, 3.00; N, 6.95. Found: C, 56.62; H, 2.96; 
N, 6.91. 
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N-(6-Chlorobenzo[d]thiazole-2-yl)-2-(6-methyl-2-oxo-2H-chromen-4-
yl)acetamide (JT-10) 
IR (KBr) cm-1: 3418 (-NH), 1718 (>C=O), 1664 (-CONH), 1665 (C=N), 1448 (CH2), 
1383 (-CH3, str.), 1294, 1082 (C-O-C), 1124 (>C=S), 778 (o.o.p.), 848 (mono 
substd.), 812(C-S-C). 
Mass: [m/e (%)], M. Wt.: 387, 360, 346, 325, 296, 294, 228, 215, 202, 193, 176, 
160, 145, 125, 111, 93, 81, 69, 4, 41. 
C, H, N analysis, Calculated: C, 59.30; H, 3.40; N, 7.28. Found: C, 59.26; H, 3.39; 
N, 7.25. 
 
N-(6-Fluorobenzo[d]thiazole-2-yl)-2-(6-methyl-2-oxo-2H-chromen-4-
yl)acetamide (JT-11) 
IR (KBr) cm-1: 3498 (-NH), 1718 (>C=O), 1671 (-CONH), 1649 (C=N), 1457 (CH2), 
1383 (-CH3, str.), 1252 (C-O-C), 1124 (>C=S), 78 (o.o.p.), 843 (mono substd.), 
818(C-S-C). 
C, H, N  analysis, Calculated: C, 61.95; H, 3.56; N, 7.60. Found: C, 61.92; H, 3.54; 
N, 7.59. 
 
N-(5-Chloro-6-fluorobenzo[d]thiazole-2-yl)-2-(6-methyl-2-oxo-2H-chromen-4-
yl)acetamide (JT-12) 
IR (KBr) cm-1: 3230 (-NH), 1729 (>C=O), 1680 (-CONH), 1695 (C=N), 1452 (CH2), 
1305 (-CH3, str.), 1278, 1083 (C-O-C), 1112 (>C=S), 817 (o.o.p.), 888 (mono 
substd.), 644(C-S-C). 
Mass: [m/e (%)], M. Wt.: 403, 351, 293, 217, 207, 184, 174 (100), 159, 145, 131, 
115, 103, 91, 77, 65, 44. 
C, H, N  analysis, Calculated: C, 56.65; H, 3.00; N, 6.95. Found: C, 56.62; H, 2.96; 
N, 6.91. 
 
2-(7,8-Dimethyl-2-oxo-2H-chromen-4-yl)-N-(6-nitrobenzo[d]thiazole-2-
yl)acetamide (JT-13) 
IR (KBr) cm-1: 3417 (-NH), 1732 (>C=O), 1676 (-CONH), 1674 (C=N), 1459 (CH2), 
1383 (-CH3, str.), 1276, 1088 (C-O-C), 1127 (>C=S), 814 (o.o.p.), 783 (mono 
substd.), 659(C-S-C). 
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1H NMR 400 MHz: (DMSO-d6,  ppm): 2.32 (s, 3H, -CH3), 2.68 (s, 2H, -CH2), 6.25 
(s, 1H, CH), 7.1-8.5 (m, 5H, Ar-H). 
Mass: [m/e (%)], M. Wt.: 411, 383, 368, 353, 326, 311, 298, 285, 257, 239, 236, 
211, 201, 183, 171, 152, 123, 98, 97, 71, 57, 44. 
C, H, N  analysis, Calculated: C, 58.67; H, 3.69; N, 10.26. Found: C, 58.63; H, 
3.66; N, 10.21. 
N-(6-Chlorobenzo[d]thiazole-2-yl)-2-(7,8-dimethyl-2-oxo-2H-chromen-4-yl) 
acetamide (JT-14) 
IR (KBr) cm-1: 3398 (-NH), 1705 (>C=O), 1696 (-CONH), 1670 (C=N), 1471 (CH2), 
1305 (-CH3, str.), 1305, 1023 (C-O-C), 1097 (>C=S), 817 (o.o.p.), 758 (mono 
substd.), 743(C-S-C). 
C, H, N  analysis, Calculated: C, 60.22; H, 3.79; N, 7.02. Found: C, 60.20; H, 3.78; 
N, 7.00. 
 
N-(6-Fluorobenzo[d]thiazole-2-yl)-2-(7,8-dimethyl-2-oxo-2H-chromen-4-yl) 
acetamide (JT-15) 
IR (KBr) cm-1: 3450 (-NH), 2917 (-CH aromatic), 1699 (>C=O), 1679 (-CONH), 
1611 (C=N), 1474 (CH2), 1350 (-CH3, str.), 1220, 1096 (C-O-C), 1024 (>C=S), 819 
(o.o.p.), 920 (mono substd.), 611(C-S-C). 
1H NMR 400 MHz: (DMSO-d6,  ppm): 2.4 (s, 3H, -CH3), 2.6 (s, 2H, -CH2), 6.4 (s, 
1H, CH), 6.9-8.5 (m, 6H, Ar-H). 
C, H, N  analysis, Calculated: C, 62.82; H, 3.95; N, 7.33. Found: C, 62.76; H, 3.86; 
N, 7.32. 
 
N-(5-Chloro-6-fluorobenzo[d]thiazole-2-yl)-2-(7,8-dimethyl-2-oxo-2H-chromen-
4-yl) acetamide (JT-16) 
IR (KBr) cm-1: 3317 (-NH), 1708 (>C=O), 1677 (-CONH), 1678 (C=N), 1436 (CH2), 
1378 (-CH3, str.), 1256, (C-O-C), 1117 (>C=S), 914 (o.o.p.), 764 (mono substd.), 680 
(C-S-C). 
1H NMR 400 MHz: (DMSO-d6,  ppm): 2.4 (s, 3H, -CH3), 2.8 (s, 2H, -CH2), 8.0 (s, 
1H, -NH), 7.1-8.5 (m, 4H, Ar-H). 
Mass: [m/e (%)], M. Wt.: 417, 402, 387, 374, 357, 456, 320, 290, 280, 263, 251, 
228, 202, 187, 175, 148, 129, 115, 111, 95, 79, 6, 44. 
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C, H, N  analysis, Calculated: C, 57.63; H, 3.39; N, 6.72. Found: C, 57.62; H, 3.37; 
N, 6.69. 
 
2-(6,8-Dimethyl-2-oxo-2H-chromen-4-yl)-N-(6-nitrobenzo[d] thiazole-2-
yl)acetamide (JT-17) 
IR (KBr) cm-1: 33OO (-NH), 2948 (-CH aromatic), 1728 (>C=O), 1695 (-CONH), 
1664(C=N), 1452 (CH2), 1333 (-CH3, str.), 1250, (C-O-C), 1O25 (>C=S), 858 
(o.o.p.), 752 (mono substd.), 684 (C-S-C). 
1H NMR 400 MHz: (DMSO-d6,  ppm): 2.4 (s, 3H, -CH3), 2.8 (s, 2H, -CH2), 8.5 (s, 
1H, -NH), 7.3-8.8 (m, 5H, Ar-H). 
Mass: [m/e (%)], M. Wt.: 410, 401, 382, 373, 352, 338, 327, 292, 260, 231, 214, 
195, 165, 149, 138, 122, 105, 95, 78, 63, 44. 
C, H, N  analysis, Calculated: C, 58.67; H, 3.69; N, 10.26. Found: C, 58.63; H, 
3.66; N, 10.21. 
 
N-(6-Chlorobenzo[d]thiazole-2-yl)-2-(6,8-dimethyl-2-oxo-2H-chromen-4-yl) 
acetamide (JT-18) 
IR (KBr) cm-1: 341O (-NH), 2916 (-CH aromatic), 1724 (>C=O), 1681 (-CONH), 
1669(C=N), 1472 (CH2), 1320 (-CH3, str.), 1244, (C-O-C), 1025 (>C=S), 858 (o.o.p.), 
670 (mono substd.), 552 (C-S-C). 
1H NMR 400 MHz: (DMSO-d6,  ppm): 2.9 (s, 3H, -CH3), 2.8 (s, 2H, -CH2), 8.0 (s, 
1H, -NH), 7.0-8.5 (m, 5H, Ar-H). 
Mass: [m/e (%)], M. Wt.: 400, 361, 319, 300, 292, 278, 261, 234, 210, 194, 174, 
168, 145, 131, 115, 108, 91, 77, 69, 44. 
C, H, N  analysis, Calculated: C, 60.22; H, 3.79; N, 7.02. Found: C, 60.20; H, 3.78; 
N, 7.00. 
 
N-(6-Fluorobenzo[d]thiazole-2-yl)-2-(6,8-dimethyl-2-oxo-2H-chromen-4-yl) 
acetamide (JT-19) 
IR (KBr) cm-1: 3076 (-CH aromatic), 1748 (>C=O), 1680 (-CONH), 1648(C=N), 
147O (CH2), 1313 (-CH3, str.), 1245 (C-O-C), 1024 (>C=S), 838 (o.o.p.), 674 (mono 
substd.), 562 (C-S-C). 
C, H, N  analysis, Calculated: C, 62.82; H, 3.95; N, 7.33. Found: C, 62.76; H, 3.86; 
N, 7.32. 
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N-(5-Chloro-6-fluorobenzo[d]thiazole-2-yl)-2-(6,8-dimethyl-2-oxo-2H-chromen-
4-yl)acetamide (JT-20) 
IR (KBr) cm-1: 3372 (-NH), 2917 (-CH aromatic), 1718(>C=O), 1669 (-CONH), 
1653 (C=N), 1457 (CH2), 1369 (-CH3, str.), 1243, (C-O-C), 1O25 (>C=S), 861 
(o.o.p.), 845 (mono substd.), 669 (C-S-C). 
C, H, N  analysis, Calculated: C, 57.63; H, 3.39; N, 6.72. Found: C, 57.62; H, 3.37; 
N, 6.69. 
 
2-(7-Hydroxy-2-oxo-2H-chromen-4-yl)-N-(6-nitrobenzo[d]thiazole-2-
yl)acetamide (JT-21) 
IR (KBr) cm-1: 3690 (free –OH str.), 341O (-NH), 3074 (-CH aromatic), 1714 
(>C=O), 1681 (-CONH), 1629 (C=N), 1453 (CH2), 1360 (-CH3, str.), 1256 (C-O-C), 
1023 (>C=S), 851 (o.o.p.), 751 (mono substd.), 763 (C-S-C). 
1H NMR 400 MHz: (DMSO-d6,  ppm): 2.25 (s, 2H, -CH2), 6.05 (s, 1H, -OH), 8.0 
(s, 1H, -NH), 6.7-8.8 (m, 6H, Ar-H). 
Mass: [m/e (%)], M. Wt.: 397, 379, 369, 351 (100), 350, 324, 310, 295, 289, 276, 
258, 245, 224, 211, 197, 184, 175, 159, 142, 130, 122, 107, 95, 82, 63, 44. 
C, H, N  analysis, Calculated: C, 54.41; H, 2.79; N, 10.57. Found: C, 54.38; H, 
2.76; N, 10.55. 
 
N-(6-Chlorobenzo[d]thiazole-2-yl)-2-(7-hydroxy-2-oxo-2H-chromen-4-
yl)acetamide (JT-22) 
IR (KBr) cm-1: 3742 (free –OH str.), 3083 (-CH aromatic), 1743 (>C=O), 1715 (-
CONH), 1539 (C=N), 1476 (CH2), 1386 (-CH3, str.), 1218 (C-O-C), 1023 (>C=S), 
842 (C-S-C). 
1H NMR 400 MHz: (DMSO-d6,  ppm): 2.25 (s, 2H, -CH2), 6.8 (s, 1H, -CH), 8.6 (s, 
1H, -OH), 8.0 (s, 1H, -NH), 6.9-7.9 (m, 6H, Ar-H). 
Mass: [m/e (%)], M. Wt.: 387 (100), 372, 360, 346, 325, 319, 296, 294, 244, 228, 
213, 202, 193, 175, 160, 148, 126, 113, 108, 93, 81, 69, 44. 
C, H, N  analysis, Calculated: C, 55.89; H, 2.87; N, 7.24. Found: C, 55.87; H, 2.85; 
N, 7.21. 
 
N-(6-Fluorobenzo[d]thiazole-2-yl)-2-(7-hydroxy-2-oxo-2H-chromen-4-
yl)acetamide (JT-23) 
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IR (KBr) cm-1: 3608 (free –OH str.), 3061 (-CH aromatic), 1744 (>C=O), 1699 (-
CONH), 1668 (C=N), 1457(CH2), 1314 (-CH3, str.), 1255(C-O-C), 1157(>C=S), 
845(C-S-C). 
C, H, N  analysis, Calculated: C, 58.37; H, 2.99; N, 7.56. Found: C, 58.36; H, 2.97; 
N, 7.53. 
 
N-(5-Chloro-6-fluorobenzo[d]thiazole-2-yl)-2-(7-hydroxy-2-oxo-2H-chromen-4-
yl)acetamide (JT-24) 
IR (KBr) cm-1: 3643 (free –OH str.), 3030 (-CH aromatic), 1732 (>C=O), 1696 (-
CONH), 1672 (C=N), 1436 (CH2), 1390 (-CH3, str.), 1252 (C-O-C), 1157(>C=S), 
841(C-S-C). 
C, H, N  analysis, Calculated: C, 53.41; H, 2.49; N, 6.92. Found: C, 53.36; H, 2.48; 
N, 6.87. 
 
N-(6-Methoxybenzo[d]thiazole-2-yl)-2-(2-oxo-2H-enzo[h]chromen-4-yl)acetamide 
(JT-25) 
IR (KBr) cm-1: 3430 (-NH str.), 3078 (-CH aromatic), 1714 (>C=O), 1634 (-CONH), 
1678 (C=N), 1602, 1587, 1534, 1486 (ring skeleton), 1423 (CH2), 1378 (-CH3, str.), 
1245 (C-O-C), 1143 (>C=S), 836(C-S-C). 
1H NMR 400 MHz: (DMSO-d6,  ppm): 2.55 (s, 2H, -CH2), 3.88 (s, 3H, -CH3), 6.36 
(s, 1H, -CH), 8.0 (s, 1H, -NH), 7.6-8.5 (m, 9H, Ar-H). 
C, H, N  analysis, Calculated: C, 66.33; H, 3.87; N, 6.73. Found: C, 66.32; H, 3.83; 
N, 6.69. 
 
N-(6-Methoxybenzo[d]thiazole-2-yl)-2-(3-oxo-3H-benzo[f]chromen-1-
yl)acetamide (JT-26) 
IR (KBr) cm-1: 3486 (-NH str.), 3035 (-CH aromatic), 1693 (>C=O), 1624 (-CONH), 
1657 (C=N), 1636, 1596, 1554, 1474 (ring skeleton), 1453 (CH2), 1393 (-CH3, str.), 
1234 (C-O-C), 1165 (>C=S), 822 (C-S-C). 
1H NMR 400 MHz: (DMSO-d6,  ppm): 2.9 (s, 2H, -CH2), 3.85 (s, 3H, -CH3), 6.48 
(s, 1H, -CH), 8.0 (s, 1H, -NH), 7.0-8.6 (m, 9H, Ar-H). 
Mass: [m/e (%)], M. Wt.: 416, 397, 379, 351 (100), 350, 324, 310, 295, 289, 276, 
258, 245, 224, 211, 197, 184, 175, 159, 142, 130, 122, 107, 95, 82, 63, 44. 
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C, H, N  analysis, Calculated: C, 66.33; H, 3.87; N, 6.73. Found: C, 66.29; H, 3.85; 
N, 6.70. 
 
2.10. Conclusion 
Total 26 N-1, 3-benzo[d]thiazol-2-yl-2-(2-oxo-2H-chromen-4-yl)acetamides were 
synthesized in this chapter and in few cases, process development was also 
undertaken to improve the yields. The compounds are characterized by IR, 1H NMR, 
Mass spectral data and elemental analysis. 
All the newly synthesized compounds have been sent for anti-viral activity and the 
results are awaited. 
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2.11. Spectra of some N-1, 3-benzo[d]thiazol-2-yl-2-(2-oxo-2H-chromen-4-yl) 
acetamide derivatives 
 
Infra Red spectrum of 2-(6-methyl-2-oxo-2H-chromen-4-yl)-N-(6-nitrobenzo[d] 
thiazole-2-yl) acetamide (JT-9) 
 
 
 
Infra Red spectrum of N-(6-fluorobenzo[d]thiazole-2-yl)-2-(6-methyl-2-oxo-2H- 
chromen-4-yl)acetamide (JT-11) 
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Infra Red spectrum of N-(6-fluorobenzo[d]thiazole-2-yl)-2-(7,8-dimethyl -2-oxo-
2H- chromen-4-yl)acetamide (JT-15) 
 
 
 
Infra Red spectrum of 2-(6, 8-dimethyl-2-oxo-2H-chromen-4-yl)-N-(6-
nitrobenzo[d] thiazole-2-yl)acetamide (JT-17) 
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Mass spectrum of N-(6-fluorobenzo[d]thiazole-2-yl)-2-(8-methyl-2-oxo-2H- 
chromen-4-yl)acetamide (JT-3) 
 
 
 
Mass spectrum of N-(5-chloro-6-fluorobenzo[d]thiazole-2-yl)-2-(8-methyl-2-oxo-
2H- chromen-4-yl)acetamide (JT-4) 
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Mol. For.: C19H13FN2O3S
Mol. Wt.: 368.38
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Mass spectrum of 2-(6, 8-dimethyl-2-oxo-2H-chromen-4-yl)-N-(6-nitrobenzo[d] 
thiazole-2-yl)acetamide (JT-17) 
 
 
 
Mass spectrum of N-(6-fluorobenzo[d]thiazole-2-yl)-2-(6,8-dimethyl -2-oxo-2H- 
chromen-4-yl)acetamide (JT-19) 
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Mass spectrum of N-(5-chloro-6-fluorobenzo[d]thiazole-2-yl)-2-(6,8-dimethyl-2-
oxo-2H-chromen-4-yl)acetamide (JT-20) 
 
 
 
Mass spectrum of 2-(7-hydroxy-2-oxo-2H-chromen-4-yl)-N-(6-nitrobenzo[d] 
thiazole-2-yl)acetamide (JT-21) 
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1H NMR spectrum of N-(5-chloro-6-fluorobenzo[d]thiazole-2-yl)-2-(7-methyl-2-
oxo-2H- chromen-4-yl)acetamide (JT-8) 
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1H NMR spectrum of 2-(6, 8-dimethyl-2-oxo-2H-chromen-4-yl)-N-(6-
nitrobenzo[d] thiazole-2-yl)acetamide (JT-17) 
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1H NMR spectrum of N-(6-methoxybenzo[d]thiazole-2-yl)-2-(3-oxo-3H-
benzo[f]chromen-1-yl)acetamide (JT-26) 
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3.1. Introduction 
 
The imidazole core is an important unit in heterocyclic chemistry. It occurs in different 
natural products and in a variety of synthetic compounds. Imidazole is a nitrogen 
containing five membered heterocyclic system. It is an aromatic molecule with a pyrrole-
type and pyridine-type annular nitrogen.  The systematic name 1, 3-diazole is seldom 
used, but the IUPAC names of these type of aromatic systems are generally taken as 
follows: imidazole 1, benzimidazole 2, 2H-imidazole 3, imidazolines 4-6, and 
imidazolidine,7 (Figure-1). 
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Figure-1
 
Some examples of imidazole-containing compounds in living organisms are the essential 
amino acids histidine and histamine. A lot of imidazoles show different biological 
activities.1(a-d) Some known imidazole based drugs are ketoconazole, which has 
antifungal properties and losartan, a drug against hypertension. Recently, interest in 
imidazoles is still increasing due to applications as green solvents by means of ionic 
liquids2 and in organometallic chemistry as N-heterocyclic carbenes.3 
Cortes and co-workers4 reported selectively substituted hydantoins 8, 4-hydroxy-2-
imidazolidinones 9, 2-imidazolones 10, 2-imidazolidinones 11, have been prepared and 
evaluated in the maximal electroshock seizure (MES), subcutaneous pentylenetetrazole 
seizure threshold (sc Met) and rotorod (Tox) tests. The medium effective doses (ED50) 
and the medium toxic dose (TD50) for the most active compounds were reported. The 
most pronounced activity was observed for hydantoins (Figure-2).  
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The most active compounds observed were the two 2-imidazolones 4-methyl-l-
(phenylmethyl)-l,3-dihydro-2H-imidazol-2-one and l-phenyl-l,3-dihydro-2H-imidazol-2-
one. Among the most important members of this class of compounds are the hydantoins.5 
The effect of structural modification of the hydantoin ring system on biological activity 
has been a subject of considerable intererest.6  Many hydantoins served as anticonvulsants 
for years which disappeared in use only after advent of new drugs in this therapeautic 
area. 
Many procedures have been developed to generate a broad range of differentl substituted 
imidazoles.7 Several synthetic approaches are reported in literature for single step to 
multistep synthesis of imidazole skeleton. 
Davidson and Baudisch8 have utilized the von Pechmann reaction9 for a novel synthesis 
of uracil by treating malic acid and urea with fuming sulfuric acid. Hilbert and co-
workers 10 synthesized uracil-4-acetic acid from citric acid and urea (Scheme-1). 
 
HO COOH
COOHHO
O
NH2H2N
HN NH
HOOC COOH
O
Scheme-1
 
 
Hilbert11 reported 2-imidazolone-4-carboxilic acid, synthesized by the reaction of tartaric 
acid, with urea in sulfuric acid. The initial product formed in a reaction between tartaric 
and sulfuric acids would be , β-dihydroxyacrylic acid (formylglycolic acid) which upon 
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subsequent reaction with sulfuric acid would yield glyoxal. The condensation of urea 
with the citric acid and  or β-hydroxy groups of would be expected to yield 2-
imidazolone-4-carboxylic acid (Figure-3). 
 
HO COOH
HHO
HN NH
COOH
O
Figure-3
 
 
Duschinsky12 reported that Friedel-Crafts acylations of 4-methyl-2-imidazolone (R = 
CH3), followed by hydrogenation of the obtained ketones, lead to imidazolidone 
compounds, the keto group being first reduced to methylene. It was then reported that 2-
imidazolone (R = H) and 4-ethyl-2-imidazolone (R = C6H6) react in a similar manner. 
The compounds having different properties were described in the literature as 2-
imidazolones.  
 
In 1892, Marckwald13 reported the synthesis of imidazolone from amino acetal via ureido 
acetal, and described it as a substance not melting at the boiling point of sulfuric acid. 
Duschinsky14  then reported the analogue of 2-imidazolone-4,5-dicarboxilic acid 
(Scheme-2). 
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Later, Fenton and Wilks15 prepared the same from dihydroxymaleic acid a substance 
melting at 245oC, which they found to be not identical with Marckwald's preparation and 
therefore called iso-imidazolone. Finally Hilbert16 obtained imidazolone by heating 2-
imidazolone-4-carboxylic acid in vacuo at 230°C (Scheme-3). 
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O
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Scheme-3
 
 
Stoffel  et. al.17 reported a novel ring closure effected by treating a propynyl urea with 
phosphorus pentachloride. A stable imidazolium chloride was obtained which on 
treatment with base was converted to an imidazolone. The propynyl urea with PCl5 in 
refluxing benzene gave the cyclized imidazolium chloride. On reaction with sodium 
hydroxide gave 1-(3,4-dichlorophenyl)-3-isopropyl-5-methyl-1H-imidazol-2(3H)-one 
which on reduction obtained 3-(3,4-dichlorophenyl)-1-isopropyl-4-methylimidazolidin-2-
one (Scheme-4). 
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Stoffel18 then reported the closure affected by treating a suitable propynylurea with 
phosphorus pentachloride. A 2-imidaxolone is obtained via a stable isolable imidazolium 
chloride. Recent reports show19-22 the formation of stable acylic amido chlorides and 
carbamido chlorides from the corresponding amides (Scheme-5). 
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The oxidation of 4,5-diphenyl-2-imidazolone to 4,5-diphenyl-4,5-dihydroxy-2-
imidazolone  was reported by Dunnavant et. al.24  which utilized concentrated nitric acid 
as the oxidant (Scheme-6). The nitric acid was cooled at 0oC before addition to a slurry of 
propynylurea in glacial acetic acid.  This unusual nitric acid hydroxylation method may 
also be applicable to other carbon-carbon double bonds with adjacent amide linkages.  
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3.2. Pharmacology 
Schnettler23 reported a series of 4-aroyl-l,3-dihydro-2H-imidazol-2-ones which were 
synthesized and evaluated for pharmacological activity in the anesthetized dog. Most 
members of this series produced dose-related increases in cardiac contractile force as well 
as relatively minor increases in heart rate and decreases in systemic arterial blood 
Synthesis, Anti-inflammatory and Anti-cancer activity...... 
 
139 
pressure. The 4-methoxy or 4-methylthiobenzoyl substitution afforded compounds of 
greatest inotropic potency. The 1,3-dihydro-4-(4-methoxybenzoyl)-6-methyl-2-imidazol-
2-one was shown to produce a dose-related positive inotropic effect and reverse the 
depressant effect of pentobarbital on cardiac pump function in the dog heart-lung 
preparation. The cardiotonic activity of this series may have important utility in the 
treatment of congestive heart failure. The 1,3-dihydro-4-[4-(methylthio)benzoyl]-5-
methyl-2H-imidazol-2-one was chosen for human studies and is currently undergoing 
clinical trials.  
 
The 2H-imidazol-2-one, an inhibitor of cyclic nucleotide phosphodiesterases,24 was 
reported to produce positive inotropic and chronotropic effects and peripheral 
vasodilation in dogs.25 In isolated tissue preparations at low Ca2+ concentrations, 
substituted 2H-imidazol-2-one increased cardiac contractile force in a manner similar to 
the effect of increasing Ca2+ concentration. Chemical changes that would increase the 
chelation potential might also increase the inotropic effect. Compounds that would appear 
to offer greater metal binding or chelating potential are the 4-aroylimidazol-2-ones 
(Scheme-7). 
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Table-1: Effect of 1,3-dihydro-4-(4-methoxybenzoyl)-5-methyl-2H-imidazole-2-one in 
the Dog Heart-Lung preparationa. 
 
Measurement Dose, µg/kg n Control Changeb    %  Change 
0.3 5  71.8±6.8   62.0±4.4c   88±7 
1.0 8  80.1±1.6   96.7±6.2c 121±7 Cardiac contractile force,g 
3.0 5  74.2±4.7 128.9±7.7c 179±19 
0.3 5   154±7      22±1 c   14±0.3 
1.0 8   154±4      35±3 c   23±1 Heart rate, beats/min 
3.0 5   150±3      41±5 c   28±4 
0.3 5 1088±31      37±7 c     3±1 
1.0 8 1079±34      28±11 c     3±1 Cardiac output, ml/min 
3.0 5 1019±74      46±10 c     4±1 
0.3 5    7.1±0.3   -0.7±0.1c  -10±1 
1.0 8    7.0±0.3   -1.1±0.1 c  -16±2 Stroke control, ml 
3.0 5    6.8±0.5   -1.2±0.2 c  -18±3 
0.3 5    3.1±0.5   -1.6±0.6 c  -49±14 
1.0 8    2.8±1.0   -1.2±0.4 c  -31±10 Left atrial pressure, mmHg 
3.0 5    3.2±0.7   -1.1±0.7  -43±23 
aMeans and standard errors. bMeasurements made 10 min after addition of 6 to the blood reservoir. cA 
significant change from control by paired Student’s t test, p < 0.05. Additionally, there was a 
significant linear dose-response curve for cardiac force and heart rate by regression analysis. 
 
In continuing search for new cardiotonic agents, Knope et. al.26 synthesized imidazole 
and Ro 7-2956 (Figure-4) which were recently reported to increase myocardial 
contractility. It was suggested that imidazole may act upon calcium tissue 1evels.27   2-
Imidazole exerted a positive inotropic effect on spontaneously beating rabbit atria and 
isolated hearts. It was suggested that the 2-imidazole was making more Ca2+ available to 
the contractile mechanism. Pharmacological evaluation showed these compounds have 
strong cardiotonic activity.28-32 
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However, one of the derivative of 2-imidazolone (Figure-5) has been reported to be a 
potent inhibitor of a CAMP phosphodiesterase isozyme.33 
 
HN NH
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Figure-5
 
 
Shaw and co-workers34,35 aimed toward the development of nitrogen acylated prodrugs of 
cardiotonic agents36 (a) and obtained some novel fluorescent compounds which were 
determined to be 3H-pyrrolo[1,2-c]imidazole-3,5(2H)-diones37 (b) (Figure-6) . 
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Several of the pyrrolo[1,2-c]imidazoledione derivatives derived, displayed cardiotonic 
properties similar to the parent [4-(1H-imidazol-l-yl)benzoyl]-imidazolones.38(a,b) 
imidazolone was prepared in an 87% yield by Friedel-Craft reaction of 5-ethyl-2-
oxoimidazole-4-carboxylic acid39  (Scheme-8). 
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Bovy et. al.40 invented the derivatives of 2-imidazolones (figure-7) which inhibited 
platelet aggregation in mammals. Fibrinogen is a glycoprotein present as a normal 
component of blood plasma which participates in platlet aggregation and fibrin formation 
in the blood clotting mechanism. 
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Potent anticonvulsant activity has been demonstrated by Walker et. al.41 for a large 
number of l-(naphthyl)-3-lH-imidazoles containing a variety of functional groups in the 
alkylene bridge. The presence of a small oxygen function in the bridge, in general, 
confers a high therapeutic index between anticonvulsant and depressant activity. Clinical 
expectations are discussed for 1-(2-naphthoylmethyl)imidazole hydrochloride, which is 
undergoing development for testing in humans (Figure-8). 
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The Ca2+ channel blockers such as pimozide demonstrate potent sodium channel binding 
activity and are used for treatment of chronic pain.42 The mechanism of action for all 
these compounds could perhaps be related to their common effects on a particular 
subtype of neuronal Na+ channel (Figure-9). 
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The importance of oxygenated imidazoles in the metabolism of histidine led Beiler43 to 
synthesize 2-imidazolone-propionic acid and the corresponding imidazolidone for 
metabolic studies. The method involved the synthesis of 5-aminolevulinic acid and its 
condensation with potassium cyanate. High pressure reduction of the imidazolone was 
unnecessary; the solubility of the imidazolidone in acetic acid facilitated smooth 
reduction with Adam's catalyst at atmospheric pressure. 
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A series of chalcones and their derivatives have been identified as novel potential 
antimalarials using both molecular modeling and in vitro testing against the intact 
parasite. Some chalcone derivatives have been synthesized by Rongshi and co-workers44 
and were screened in vitro against both chloroquine-sensitive and chloroquine-resistant 
strains of Plasmodium falsiparum and shown to be active at concentrations in the 
nanomolar range. The most active chalcone derivative, l-(2,5-dichlorophenyl)-3-(4-
quinolinyl)-2-propen-l-one, had an IC50 value of 200 nM against both a chloroquine-
resistant strain (W2) and a chloroquine sensitive strain (D6). 
 
A series of chalcones was evaluated as antimitotic agents. One of these, (E)-l-(2,5-
dimethoxyhenyl)-3-[4-(dimethylamino) phenyl]-2-methyl-2-propen-l-one), was found to 
be an effective antimitotic agent at a concentration of 4 nM in an in vitro HeLa cell test 
system, exhibited antitumor activity against L1210 leukemia and BI6 melanoma in 
experimental tumor models in vivo45 (Scheme-9). 
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Chauhan and co-workers46 synthesized a series of 2,4,6-trisubstituted-pyrimidines and 
evaluated for their in vitro antimalarial activity agaist P. falciparum. The 2,4,6-
trisubstituted-pyrimidines were synthesized by reacting 4-acetylpyridine with different 
aldehydes in NaOH and methanol to yield the corresponding chalcones (Scheme-10). The 
chalcones were further cyclized with imidine hydrochlorides in the presence of sodium 
isopropoxide to afford pyrimidines. It has been found that the chloro group in the 
aromatic ring system did not affected the activity of the compounds but the presence of 
methoxy group in the phenyl ring increased the activity. These compounds found out to 
be 5-40 times more potent than pyrimethamine. These identified pyrimidines are new 
lead in antimalarial chemotherapy. 
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Where, 
a= different aldehydes, 10% aq. NaOH, methanol, 0oC, rt, 1 hr
b= Piperidine-1-carboxamide.HCl, sodium isopropoxide, isopropanol, reflux, 8hr.
Scheme-10
  
Laufer et. al.47 reported  a series of polysubstituted pyridin-4-yl imidazole inhibitors of 
p38 MAP (mitogen-activated protein) kinase which was prepared as small molecular 
anticytokine agents and drug candidates for the treatment of chronic inflammatory 
diseases. The contribution of substituents at the pyridinyl and imidazole moiety to 
selective inhibition of p38 without concomitant cytochrome P450 interaction was 
evaluated. Placement of a 1-phenylethyl (p38: IC50 0.38 íM) or acetyl substituent at the 
exocyclic nitrogen of several 2-aminopyridine imidazoles led to the identification of 
potent p38 inhibitors which exceeded the starting lead ML 3375 (p38: IC50 0.63 íM) in 
potency (Figure-10). 
Synthesis, Anti-inflammatory and Anti-cancer activity...... 
 
146 
N
H
N
NH
F
H
S
O
H3C
N
H
O
H2N
N
NH
O
O
O
CH3
OH
O
TMe 
109
His 107
Leu 108
Linker 
region
Phosphate
binding
ribbon
Lys 53
hydrophobic
pocket
hydrophobic area
Thr 106
Figure-10: Schemetic drawing of important interactions between 
the prototypical pyridine-4-yl imidazole inhibitor SB 203580 and 
the ATP binding site of p38.
 
 
A preliminary modeling study related the enhanced bioactivity of 1-phenylethyl 
substituent to a novel interaction between its 1-phenylethylamino side chain and a 
hydrophobic pocket close to the linker region of p38. The most active p38 inhibitors in 
this series maintained their efficacy in functional PBMC (peripheral blood mononuclear 
cells) and whole blood assays (Figure-11). 
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Figure-11: Banzylsulfulfanylimdazoles and Modeling of 7g into the 
ATP cleft of p38 MAP kinase. The arrows denote the hydrophobic 
area in close proximity to the linker region which stretches both 
above and below the pyridine ring.
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Laufer and co-workers48 then prepared novel 1,2,4,5-tetrasubstituted imidazole 
derivatives with high anti-inflammatory activity. Systematic optimization of the 
imidazole N-1 substituent resulted in a compound that potently inhibited the mitogen 
activated protein kinase p38 (p38 IC50 ) 0.218 íM) as well as the release of the 
proinflammatory cytokines interleukin-1 (¹L-1) and tumor necrosis factor R (TNFR) 
from human whole blood after stimulation with LPS. Furthermore, this compound 
exhibited reduced cytochrome P450 interaction in comparison with SB203580. This 
result is particularly important, since cytochrome P450 interaction is observed for some 
p38 inhibitors and in turn can potentially cause drug-drug interaction or lead to other 
hepatic changes such as P450 enzyme induction (Figure-12). 
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Figure-12: Representation of the active site interactions 
between SB203580 and p8-MAPK.
 
 
A new therapeutic drug target for the treatment of inflammatory disorders is the mitogen-
activated protein kinase (MAPK) p38.49-52 P38 is a serine/threonine kinase that is part of 
the stress-activated signal transduction cascade that transduces extracellular signals to 
intracellular response, e.g. cytokine production.53,54 Activated p38 phosphorylates other 
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kinases or transcription factors, leading to mRNA stabilization or expression of certain 
target genes.55-57 
 
Pyridinylimidazoles (i.e. SB203580) are potent and selective inhibitors of p38-
MAPK7,58,59 by competing with ATP for binding to the ATP pocket60-62 This small 
hydrophobic pocket near the ATP-binding site is responsible for the selectivity of 
SB203580 for p38 compared to most other kinases63,64 The pyridin-4-yl moiety is 
essential for the inhibitory potency and generates a pivotal hydrogen bond with the amino 
backbone of Met109 through its pyridinium nitrogen65  (Figure-13). 
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Figure-13: Pyidinylimidazole inhibitors of p-38-MAP kinase.
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Table-2: Inhibition of p-38-MAP kinase by acetylaminopyridines. 
 
N
N
N
F
R1
NHH3C
O
S
CH3
 
 
IC50 ± (µM) Compd              R1 
P38 
1 -(CH2)-OH 0.398±0.037 (n=3) 
2 -(CH2)2-O-CH3 0.218±0.010 (n=3) 
3 -(CH2)3-OH 0.813±0.040 (n=3) 
4 -(CH2)3-O-CH3 0.205±0.027 (n=3) 
5 -(CH2)2O-(CH2)2-OH 8.479±0.384 (n=2) 
6 -(CH2)-CH-(CH3)-OH 8.692±0.188 (n=2) 
7 -(CH2)2-NH-COCH 7.29 (n=1) 
8 -(CH2)2-N(CH3)2 2.409±0.145 (n=3) 
9 -(CH2)2OCH2CH=CH2   1.85±0.753 (n=3) 
10 -(CH2)2OCH2CCH 0.666±0.148 (n=3) 
11 -(CH2)2-S-CH3 0.431±0.1 (n=3) 
12 -(CH2)-CH(OCH3)2 4.099±1.690 (n=2) 
13 
    
O
O
C
H2
CH3
H3C
 
 
3.732±2.116 (n=2) 
14 N O(H2C)2
 
 
2.029±0.686 (n=2) 
16 N(H2C)2
 
 
1.343±0.576 (n=2) 
17 
     
N
O
O C2H5
 
 
> 10 
SB 203580  0.462±0.025 (n=6) 
 Results are given as mean of two independent experiments except stated 
otherwise. 
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3.3. Synthetic approach & present work 
Over the years there have been many attempts to design and develop adenosine receptor 
antagonists and over the past decade the search for ligands that show selectivity toward 
individual receptors has intensified as the role of the receptors in many therapeutic areas 
expands.66 Adenosine A1 receptors are in abundance in the mammalian brain and play 
role in important functions, such as in the modulation of neurotransmitter release, sleep 
regulation and cognition enhancement, has been thoroughly investigated.67-69 For this 
reason, it is essential that a compound targeted at these therapeutic areas is able to cross 
the blood brain barrier (BBB). Research into the BBB and the ability of a compound to 
cross it has become a highly investigated topic in recent years. 
 
In the wider field of adenosine receptor ligands, (dihydro) pyrimidines have been 
developed and explored as A3 receptor antagonists by Jacobson et. al.70-72 and as 
adenosine receptor agonists by Bayer.73 Adenosine receptor antagonists usually possess a 
bi- or tricyclic heteroaromatic structure at their core with varying substitution patterns to 
achieve selectivity and/or greater affinity. 
 
Chang and co-workers74 synthesized two novel series of pyrimidines, A & B, possessing 
good potency at the adenosine A1 receptor and desirable PSA values (Figure-14). LUF 
5735 displayed excellent A1 affinity (Table-3). 
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Al-Hajjar and Sabri75 described a method in which guanidine was reacted with 
benzylideneacetophenone. This 2-aminopyrimidine was then reacted with the respective 
acid chlorides in the presence of triethylamine to give the desired 2-amido compounds. 
With the alkyl amides, significant improvements were made over the phenyl substituents 
at the L1 pocket. In the straight-chained alkyls, from methyl to pentyl (7-10) a distinct 
optimum is apparent for a two-carbon chain at the A1 receptor, with an affinity of 9.5 
nM. This pattern is repeated at the adenosine 2A receptor, with a Ki of 82 nM. At the A3 
receptor, however, the methyl substituted derivative, with an affinity of 7 nM, was the 
better compound. In terms of selectivity, compound 7 was 5-fold more selective for the 
A3 receptor than for the A1 receptor, while, in a slight reversal of this, compound 8 
showed a 2-fold selectivity in favor of the A1 adenosine receptor over the A3 receptor. 
Better selectivity for the A1 adenosine receptor came with the n-propyl derivative with an 
almost 7-fold better affinity over the A2A receptor. 
 
Based on these observations, a new series of 24 compounds have been synthesized by 
taking 2-imidazolone-4-carboxylic acid and various 2-amino-4,6-di-sibstituted 
pyrimidines and making an amide linkage between them.  
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Table-3: Affinities and PSA values of the 4,6-diphenyl-substituted-2-amidopyrimidines 
22-40 in radioligand binding assays at the human adenosine receptors. 
 
N
N
N
H
O
R
 
 
Ki (nM) or % displacement a 
Compd R 
Calcd. 
PSA values 
(aÅ2) hA1
b
 hA2Ac hA2Bd hA3e 
1 Ph 53 309±73 5%  38% 
2 4-Cl-Ph 53 0% 0%  3280±1700 
3 4-MeOPh 64 31% 45%  41% 
4 4-Me-Ph 53 37% 0%  13% 
5 3,4-DiCl-Ph 53 0% 0%  30% 
6 3-Cl-Ph 53 368±66 22%  41% 
7 Me 53 483±90 31%  237±150 
8 Et 53 46.4±2.5 893±160  547±47 
9  (LUF 5735) Pr 53 3.70±1.9 7% 54% 38% 
10 Bu 53 27.6±10 0%  23% 
11 Pent 52 28% 0%  24% 
12 (LUF 5737) I-Pr 51 8.87±4.2 44% 79% 45% 
13 T-Bu 50 224±120 0%  4% 
14 CH2CHMe2 51 25.1±6.6 42%  23% 
15 CHEt2 51 27.1±5.7 11%  27% 
16 C-Prop 52 24.9±4.9 228±95  676±120 
17 C-But 53 107±36 33%  18% 
18 (LUF 5751) C-Pent 51 11.4±2.4 11% 42% 39% 
19 C-Hex 51 119±42 31%  9% 
a Ki ± SEM (n=3), % displacement (n=2). b Displacement of specific [3H]DPCPX binding in CHO 
cell membranes expressing human adenosine A1 receptors or % displacement of specific binding at 
1µM concentrations. cDisplacement of specific [3H]ZM241385 binding in HEK 293 cell 
membranes expressing human adenosine A2A receptors or % displacement of specific binding at 
1µM concentrations. d % Displacement of specific [3H]MRS1754 binding in CHO cell membranes 
stably transfected with the human adenosine A2B receptor at 1 µM concentrations. e Displacement of 
specific [125I]AB-MECA binding in HEK 293 cell membrane expressing human adenosine A3 
receptors or % displacement of specific binding at 1µM concentrations. 
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3.4. REACTION SCHEME-I
2-Imidazolone-4-carboxylic acid
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REACTION SCHEME-II
Synthesis of 2-amino-4,6-disubstituted phenyl pyrimidine
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REACTION SCHEME-III
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Pyridine, 0oC
Synthesis of N-(4, 6-diphenylpyrimidin-2-yl)-2-oxo-2, 3-dihydro-
1H-imidazole-4-carboxamide
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3.5. Experimental 
 
Method for preparation of 2-imidazolone-4-carboxylic acid11 
To a 2 liter three-necked flask fitted with a stirrer, 400 cc of 13% fuming sulfuric acid 
was added. After cooling this to 0oC, 11g of finely powdered anhydrous tartaric acid was 
added at such a rate that the temperature did not rise above 10oC, which required 10 
minutes. The ice-bath was removed and 100g of urea was then added. The temperature 
during this operation rose rapidly and was finally held with the aid of a burner at 80oC for 
30 min. A vigorous reaction ensued with the concomitant evolution of carbon monoxide 
and carbon dioxide the reaction mixture rapidly turned black. After completion of the 
reaction, the contents of the flask were cooled and poured on 1200 g of ice. An 
amorphous chocolate colored precipitate immediately separated. This, having stood in the 
icebox overnight, was filtered, yield of crude dry product 35 g. It was decolorized by 
boiling a water solution with large portions of bone black and finally recrystallizing from 
water from which it was separated as colorless needles, it melted with vigorous 
effervescence at 260oC (Reported m.p. 261oC), 2-imidazolone-4-carboxyllic acid is 
slightly soluble in boiling water and insoluble in organic solvents. 
 
General method for the preparation of chalcones45 
A mixture of methanol (50 ml), acetophenone (0.015 mol), benzaldehyde (0.015 mol) and 
50% aqueous NaOH (1 ml) was stirred for 18 hr at ambient temperature. The resulted 
solid was filtered, dried and recrystalized with methanol to give the product as pure white 
needles. m.p. 96-98oC (Reported m.p. 94-96oC) 
 
General method for preparation of 2-amino-4,6-disubstituted phenyl 
pyrimidines74,76 
 
A mixture of chalcone (1.1 equiv) and guanidine hydrochloride (1 equiv) was refluxed in 
methanol (150 ml). Sodium hydroxide (3.2 equiv) was dissolved in a minimum amount 
of water (40 ml) and added drop wise to the refluxing mixture. The reaction mixture was 
then stirred at reflux for a further 6 h and poured into 250 ml of cold water. The product 
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obtained was filtered, washed with water and crystallized from ethyl acetate to give 
orange coloured needles. Yield, 31%. 
 
General method for preparation of N-(4, 6-diphenylpyrimidin-2-yl)-2-oxo-2, 3-
dihydro-1H-imidazole-4-carboxamide153 
 
Method I  
A mixture of  2-imidazolone-4-carboxylic acid (0.1 M) and 2-amino-4,6-disubstituted 
phenyl pyrimidine (0.1 M) was taken in pyridine (10 ml) and was stirred at 00C. Thionyl 
chloride (10 ml) was added drop wise to the above solution within 30 minutes. After the 
color of the solution changed to dark, it was further stirred for two hours. The resultant 
mass was poured into crushed ice to get crude amide, which was washed, filtered and 
dried. It was thoroughly washed with hot water and ethyl acetate and was finally 
recrystalized with dimethyl formamide to obtain the corresponding amide in crystalline 
form. 
 
Method II 
To a mixture of the amino-diphenylpyrimidine (0.202 mM, 1 equiv) in 1,4-dioxane (5 ml) 
was added triethylamine (0.223 mM, 1.1 equiv) , followed by the appropriate acid 
chloride (0.304 mM, 1.5 equiv). This was stirred at reflux until no starting material was 
identified. The progress of the reaction was monitered by TLC. Upon completion, the 
reaction mixture was washed with ethyl acetate and finally recrystallized with petroleum 
ether-ethyl acetate to yield the corresponding amide in crystalline form. 
The same procedure was followed for the preparation of all the amides listed in Table 4. 
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3.6. Protocol for determination of TNF- mRNA77 
Plasma was collected from ACD blood after the cells were pelleted at 1,000 x g for 10 
min. The cell pellet was resuspended in Dulbecco’s phosphate-buffered saline (PBS) and 
peripheral blood mononuclear cells (PBMC) were prepared by centrifugation through 
Ficoll-Hypaque and resuspended in fresh plasma at approximately 2 × 107 /ml. Plasma 
was distributed in 250-µl aliquots into 4 ml polypropylene tubes and incubated in 5% 
CO2 at 37oC. Lipopolysaccharide (LPS) (2.5 ml of a solution at 100 × final 
concentration) was added at intervals so that all reactions could be terminated together. 
To detect bioactive LPS, 50 µl of the PBMC-plasma suspension was added, and the 
reaction mixtures were incubated an additional 30 min. Cells were harvested, and TNF- 
mRNA expression was analyzed by Reverse Transcriptase-PCR (RT-PCR) by pelleting 
the cells at 1,000 x g for 7 min at 4oC. The supernatant liquid was carefully aspirated, 
with care taken not to disturb the soupy pellet. Total RNA was prepared from the cells by 
using a kit on the basis of the method of Chomczynski and Sacchi, by lysing the pelleted 
cells in 0.5 ml of solution D (4 M guanidine thiocyanate, 20 mM sodium citrate [pH 7.0], 
0.5% Sarkosyl, 0.1 M -mercaptoethanol). Recovery of the RNA precipitates was 
maximized by increasing the centrifugation times to 60 min. All recovered RNA for each 
sample was converted to cDNA in a 50-µl reaction mixture with oligo (dT) and 500 U of 
Moloney murine leukemia virus RT according to recommended conditions. 
Amplifications were done with 1 µl of cDNA in a final 20-µl reaction mixture volume 
(10 mM Tris-Cl [pH 8.8], 50 mM KCl, 1.8 mM MgCl2, 0.1% Triton X-100, 0.2 mM 
deoxynucleoside triphophates, 0.5 µM each primer [with 50,000 to 250,000 cpm of one 
32P-5’-end-labelled primer], 0.4 U of Taq polymerase). Reaction mixtures were 
assembled on ice, transferred to a prewarmed block (> 50oC), and cycled at 94.5oC (20 s), 
60oC (30 s), and 72oC (60 s) for 22 cycles.  Amplification products were separated on 6% 
polyacrylamide gels, and bands of the appropriate sizes were quantified by using a 400E 
PhosphoImager. To allow comparison of mRNA expression patterns from different 
donors, the data for each gene were normalized by the following formula: 
 
Relative amplified product = (P/Pmax) × 100 
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Where, P is the amount of amplified product obtained at each point and Pmax is the 
maximum amount of amplified product obtained in a particular experiment. Results are 
reported as the mean relative amplified product (± standard errors of the means [SEM]), 
unless otherwise noted.  
 
For secreted cytokines, blood was incubated as described for the RT-PCR analysis, but 
the reactions were stopped by the addition of 0.75 ml of ice-cold RPMI 1640. Protein 
levels were measured by enzyme-linked immunosorbent assay (ELISA) with kits for 
TNF- and IL-1, following the manufacturers’ instructions. Each sample was assayed in 
triplicate. Again, to compare expression patterns from different donors, the data for each 
donor were normalized by the following formula:  
 
Relative secreted product = (S/Smax) ×100 
 
Where, S is the concentration of cytokine measured at each point and Smax is the 
maximum concentration of cytokine measured in a particular experiment. Results are 
reported as the mean relative secreted product (6 SEM) for Fig. 5A or the mean relative 
secreted product. 
The result obtained is tabulated in table-5.  
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3.7. Table 4:  Physical data of N-(4, 6-diphenylpyrimidin-2-yl)-2-oxo-2, 3-dihydro-1H-imidazole-4-carboxamides 
 
NHHN
O
O
H
N
N
N
R'
R
 
 
Substitution 
Codes 
R R’ 
Molecular formula Molecular weight Melting point (OC) Rf  value 
% of 
Yield 
JT-51 H H C20H15N5O2 357.36 146-148 0.43 43 
JT-52 4-F 4-F C20H13F2N5O2 393.34 212-214 0.47 54 
JT-53 4-Cl 4-Cl C20H13ClN5O2 426.25 226-228 0.40 46 
JT-54 4-F 4-CH3 C21H16FN5O2 389.38 196-198 0.52 48 
JT-55 4-F 4-OCH3 C21H16FN5O3 409.38 144-148 0.54 52 
TLC Solvent system: Dichloromethane: Methanol :: 6:40.48 
Ref.: Chang, L. C. W.; Spanjersberg, R. F.; Frijtag Drabbe Kunzel, J. K.; Mulder-Krieger, T.; Hout, G.; Beukers, M. W.; Brussee, J.; 
IJzerman, A. P. 2,4,6-Trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists, J. Med. Chem. 2004, 
47, 6529-6540. 
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3.7. Table 4 (contd.):  N-(4, 6-diphenylpyrimidin-2-yl)-2-oxo-2, 3-dihydro-1H-imidazole-4-carboxamides 
 
 
 
 
  
 
Substitution 
Codes 
R R’ 
Molecular formula Molecular 
weight 
Melting point 
(OC) Rf  value 
% of 
Yield 
JT-56 4-Br 4-CH3 C21H16BrN5O2 450.28 246-248 0.61 55 
JT-57 H 4-OCH3 C22H19N5O4 387.39 212-216 0.55 46 
JT-58 4-OCH3 4-OCH3 C21H17N5O3 398.36 166-168 0.57 48 
JT-59 H 3,4,5-tri-OCH3 C23H21N5O5 447.44 136-138 0.47 53 
JT-60 4-F H C20H14FN5O2 375.35 208-212 0.63 54 
JT-61 4-Cl H C20H14ClN5O2 391.81 186-188 0.46 41 
JT-62 4-Br H C20H14BrN5O2 436.26 162-164 0.32 56 
JT-63 4-CH3 H C21H17N5O2 371.39 188-190 0.49 47 
JT-64 4-OCH3 H C21H17N5O3 387.39 234-236 0.44 44 
JT-65 4-OCH3 2-Cl C21H16ClN5O3 421.83 266-268 0.54 53 
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3.7. Table 4 (contd.):  N-(4, 6-diphenylpyrimidin-2-yl)-2-oxo-2, 3-dihydro-1H-imidazole-4-carboxamides 
 
 
 
 
 
 
 
Substitution 
Codes 
R R’ 
Molecular formula Molecular weight Melting point (OC) Rf  value 
% of 
Yield 
JT-66 3-NO2 2-Cl C20H13ClN6O4 36.80 156-158 0.49 45 
JT-67 4-OCH3 4-F C21H16FN5O3 405.38 142-144 0.52 39 
JT-68 4-Cl 2-OH C20H14ClN5O3 407.80 210-212 0.50 46 
JT-69 2-Cl 2,5-di-OCH3 C22H18ClN5O4 451.86 234-236 0.56 53 
JT-70 4-Cl 2,5-di- OCH3 C22H18ClN5O4 452.86 230-234 0.58 57 
JT-71 3-NO2 2,5-di- OCH3 C22H18N6O6 462.41 198-200 0.41 43 
JT-72 4-Br 4-OCH3 C21H16BrN5O3 466.28 256-258 0.63 48 
JT-73 H 4-CN C21H14N6O2 382.37 178-180 0.47 51 
JT-74 4-OCH3 4-CN C22H16N6O3 412.42 172-174 0.53 56 
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3.8. Biological activity results 
 
Table-5 : In-vitro activity for IL-6 and TNF- in monocytes at three concentration (0.3, 3, 30) uM  in human monocytes assay. 
 
 
 
 
 
Sr. No. Sample code 
 
IC50 for IL-6 
Inhibition (µM) 
 
IC50 for TNF- 
Inhibition (µM) 
Toxicity (µM) 
 
1 JT-51 3 ND > 100 
2 JT-52 < 0.3 ND > 100 
3 JT-53 < 0.3 ND > 100 
4 JT-54 3 ND > 100 
5 JT-55 < 0.3 ND > 100 
6 JT-56 3 ND > 100 
7 JT-57 30 ND > 100 
8 JT-58 3 ND > 100 
9 JT-59 30 ND > 100 
10 JT-60 30 ND > 100 
11 JT-61 < 0.3 ND > 100 
12 JT-62 30 ND > 100 
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3.8. Table-5 (contd.) : In-vitro activity for IL-6 and TNF- in monocytes at three concentration (0.3, 3, 30) uM  in human monocytes 
assay. 
 
 
 
 
Sr. No. Sample code 
 
IC50 for IL-6 
Inhibition (µM) 
 
IC50 for TNF- 
Inhibition (µM) 
Toxicity (µM) 
 
13 JT-63 < 0.3 ND > 100 
14 JT-64 30 ND > 100 
15 JT-65 3 ND > 100 
16 JT-66 30 ND > 100 
17 JT-67 30 ND > 100 
18 JT-68 30 ND > 100 
19 JT-69 3 ND > 100 
20 JT-70 30 ND > 100 
21 JT-71 0.3 ND > 100 
22 JT-72 30 ND > 100 
23 JT-73 3 ND > 100 
24 JT-74 30 ND > 100 
 
From the above results, it has been concluded that the synthesized compounds are inactive at the selected dose.
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3.9. Spectral study 
 
Infra Red spectra 
IR Spectra were taken on SHIMADZU IR-435 Spectrometer using KBr Pellet method. 
The N-H stretch in N-(4,6-diphenylpyrimidin-2-yl)-2-oxo-2,3-dihydro-1H-imidazole-4-
carboxamides was observed at 3500-3400 cm-1. In some cases, free hydroxyl group (OH) 
was observed at 3550-3580 cm-1. The characteristic carbonyl group (>C=O) was 
observed between 1660-1735 cm-1. The compounds showed the ring skeleton vibrations 
at 1600-1660, 1550-1590, 1550-1520, 1470-495 cm-1. The methoxy groups were 
observed between 1780-1850 cm-1. The amide groups were observed between 1620-1650 
cm-1. The methyl groups were observed between 1350-1380 cm-1. The holagen groups 
were observed between 720-840 cm-1. 
 
 
1H NMR spectra 
1H NMR Spectra were recorded on a Bruker AC 400 MHz FT-NMR Spectrometer using 
TMS (Tetramethyl Silane) as an internal standard and DMSO-d6 as a solvent. In the 
NMR spectra of 5-benzoyl-6-methyl-4-(substituted)phenyl-3,4-dihydropyrimidin-2(1H)-
ones, various proton values like methyl (-CH3), aromatic protons (Ar-H), N-H protons 
and sometimes, hydroxyl (-OH) were observed and recorded in individual compound 
details. 
 
The values for methyl (-CH3) proton is seen between 1.12-1.96  ppm. as well as 
methoxy proton (-OCH3)was observed between 3.2-3.9  ppm respectively. The aromatic 
protons (Ar-H) showed multiplets between 6.00-8.20  ppm. The N-H protons were 
observed between value 4.0-10.0  ppm.  
 
 13C NMR spectra 
13C NMR spectra were recorded on Bruker AC 400 MHz instrument using DMSO as the 
solvent with TMS (Tetramethyl Silane) as respective internal standard.   
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Mass spectra 
The mass spectrum of compounds was recorded by GCMS-QP2010 spectromeyter (EI 
method). The mass spectrums of compounds were obtained by positive chemical 
ionization mass spectrometry. The molecular ion peak and the base peak in all 
compounds were clearly obtained in spectra. The molecular ion peak (M+) values are in 
good agreement with molecular formula of all the compounds synthesized. The probable 
mass fragmentation of N-(4,6-diphenylpyrimidin-2-yl)-2-oxo-2,3-dihydro-1H-imidazole-
4-carboxamides is shown in the spectra. 
 
C, H, N analysis 
Elemental analysis of the compounds was carried out on Elemental Vario EL III Carlo 
Erba 1108 model at CDRI, Lucknow and the results are in agreement with the structures 
assigned. 
 
3.10. Spectral characterization 
 
N-(4,6-Diphenylpyrimidin-2-yl)-2-oxo-2,3-dihydro-1H-imidazole-4-carboxamide 
(JT-51) 
IR (KBr) cm-1: 3403, 3435 (N-H str.), 2857 (C-H str.), 1678, 1720 (>C=O), 1692 
(CONH), 1589, 1488, 1442, 1417 (ring skeleton). 
1H NMR 400 MHz (DMSO-d6,  ppm): 6.49 (s, 1H, -CH), 7.63 (s, 1H, NH), 7.64 (s, 
1H, NH), 7.20-7.84 (m, 11H, Ar-H), 9.84 (s, 1H, CONH). 
13C NMR 400 MHz (DMSO-d6,  ppm): 21.40, 47.26, 48.04, 50.81, 54.44, 82.48, 
109.54, 119.40, 127.07, 132.95, 136.99, 154.67, 176.84, 198.10. 
Mass: [m/e (%)], M. Wt. :357, 343, 328, 313, 301, 285, 273, 258, 230, 191, 171, 164, 
150, 135, 122, 110, 95, 80, 69, 44. 
C, H, N analysis, Calculated: C, 67.22; H, 4.23; N, 19.60. Found: C, 67.18; H, 4.22; N, 
19.56. 
 
N-[4,6-Bis(4-fluorophenyl)pyrimidin-2-yl]-2-oxo-2,3-dihydro-1H-imidazole-4-
carboxamide (JT-52) 
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IR (KBr) cm-1: 3412, 3443 (N-H str.), 2756 (C-H str.), 1686, 1732 (>C=O), 1678 
(CONH), 723 (C-F). 
C, H, N analysis, Calculated: C, 61.07; H, 3.33; N, 17.80. Found: C, 61.02; H, 3.26; N, 
17.77. 
 
N-[4,6-Bis(4-chlorophenyl)pyrimidin-2-yl]-2-oxo-2,3-dihydro-1H-imidazole-4-
carboxamide(JT-53) 
IR (KBr) cm-1: 3356, 3424 (N-H str.), 2855 (C-H str.), 1655, 1712 (>C=O), 1645 
(CONH), 729 (C-Cl). 
C, H, N  analysis, Calculated: C, 56.35; H, 3.07; N, 16.43. Found: C, 56.31; H, 3.02; 
N, 16.40. 
 
N-[4-(4-Fluorophenyl)-6-(4-methylphenyl)pyrimidin-2-yl]-2-oxo-2,3-dihydro-1H-
imidazole-4-carboxamide (JT-54) 
IR (KBr) cm-1: 3378, 3402 (N-H str.), 2823 (C-H str.), 1658, 1727 (>C=O), 1635 
(CONH),1328 (CH3), 745 (C-Cl). 
C, H, N analysis, Calculated: C, 64.78; H, 4.14; N, 17.99. Found: C, 64.76; H, 4.11; N, 
17.97. 
 
N-[4-(4-Fluorophenyl)-6-(4-methoxyphenyl)pyrimidin-2-yl]-2-oxo-2,3-dihydro-1H-
imidazole-4-carboxamide (JT-55) 
IR (KBr) cm-1: 3424, 3467 (N-H str.), 2824 (C-H str.), 1678, 1724 (>C=O), 1649 
(CONH), 1864 (OCH3), 734 (C-F). 
C, H, N analysis, Calculated: C, 62.22; H, 3.98; N, 17.28. Found: C, 62.24; H, 3.90; N, 
17.24. 
 
N-[4-(4-Bromophenyl)-6-(4-methylphenyl)pyrimidin-2-yl]-2-oxo-2,3-dihydro-1H-
imidazole-4-carboxamide (JT-56) 
IR (KBr) cm-1: 3534, 3487 (N-H str.), 2865 (C-H str.), 1698, 1734 (>C=O), 1658 
(CONH), 1574, 1465, 1437, 1417 (ring skeleton), 1339 (CH3), 787 (C-Br). 
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C, H, N analysis, Calculated: C, 56.01; H, 3.58; N, 15.55. Found: C, 55.97; H, 3.53; N, 
15.51. 
 
N-[4-(4-Methoxyphenyl)-6-phenylpyrimidin-2-yl]-2-oxo-2,3-dihydro-1H-imidazole-
4-carboxamide (JT-57) 
IR (KBr) cm-1: 3512, 3487 (N-H str.), 2838 (C-H str.), 1673, 1727 (>C=O), 1569, 1441, 
1479, 1438 (ring skeleton), 1638 (OCH3). 
C, H, N analysis, Calculated: C, 65.11; H, 4.42; N, 18.08. Found: C, 65.03; H, 4.37; N, 
18.02. 
 
N-(4,6-bis(4-Methoxyphenyl)pyrimidine-2-yl)-2,3-dihydro-2-oxo-1H-imidazole-4-
carboxamide (JT-58) 
IR (KBr) cm-1: 3436, 3449 (N-H str.), 2828 (C-H str.), 1683, 1725 (>C=O), 1635 
(CONH),  1669, 1635 (OCH3). 
C, H, N analysis, Calculated: C, 63.30; H, 4.59; N, 16.78. Found: C, 63.28; H, 4.54; N, 
16.76. 
 
2,3-Dihydro-N-(4-(3,4,5-trimethoxyphenyl)-6-phenylpyrimidine-2-yl)-2-oxo-1H-
imidazole-5-carboxamide (JT-59) 
IR (KBr) cm-1: 3514, 3479 (N-H str.), 2828 (C-H str.), 1682, 1722 (>C=O), 1654 
(CONH), 1568, 1468, 1432, 1401 (ring skeleton), 1657, 1645, 1632 (OCH3). 
1H NMR 400 MHz (DMSO-d6,  ppm): 3.00 (s, 9H, 3×OCH3), 5.48 (s, 1H, -CH), 7.35, 
7.35 (s, 1H, NH), 7.36 (s, 1H, NH),  7.20-7.58 (m, 8H, Ar-H), 9.19 (s, 1H, CONH).  
C, H, N analysis, Calculated: C, 61.74; H, 4.73; N, 15.65. Found: C, 61.72; H, 4.68; N, 
15.62. 
 
N-[4-(4-Fluorophenyl)-6-phenylpyrimidin-2-yl]-2-oxo-2,3-dihydro-1H-imidazole-4-
carboxamide (JT-60) 
IR (KBr) cm-1: 3510, 3486 (N-H str.), 2836 (C-H str.), 1684, 1715 (>C=O), 1638 
(CONH), 1567, 1484, 1446, 1427 (ring skeleton), 748 (C-F). 
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C, H, N analysis, Calculated: C, 61.74; H, 4.73; N, 15.65. Found: C, 61.71; H, 4.70; N, 
15.64. 
  
N-[4-(4-Chlorophenyl)-6-phenylpyrimidin-2-yl]-2-oxo-2,3-dihydro-1H-imidazole-4-
carboxamide (JT-61) 
IR (KBr) cm-1: 3519, 3483 (N-H str.), 2837 (C-H str.), 1683, 1734 (>C=O), 1648 
(CONH), 1569, 1425, 1469, 1403 (ring skeleton), 724 (C-Cl). 
Mass: [m/e (%)], M. Wt. : 391, 362, 341, 286, 256, 218, 192, 160, 128, 115, 79, 64, 44. 
C, H, N analysis, Calculated: C, 61.31; H, 3.60; N, 17.87. Found: C, 61.28; H, 3.59; N, 
17.84. 
 
N-(4-(4-Bromophenyl)-6-phenylpyrimidin-2-yl)-2,3-dihydro-2-oxo-1H-imidazole-4-
carboxamide (JT-62) 
IR (KBr) cm-1: 3509, 3485 (N-H str.), 2848 (C-H str.), 1682, 1717 (>C=O), 1675 
(CONH), 1557, 1489, 1443, 1406 (ring skeleton), 716 (C-Br). 
Mass: [m/e (%)], M. Wt. : 435, 368, 354, 344, 328, 301, 278, 249, 235, 221, 209, 180, 
165, 16, 132, 120, 104, 91, 77, 66, 44. 
C, H, N analysis, Calculated:C, 55.06; H, 3.23; N, 16.05. Found: C, 55.01; H, 3.20; N, 
16.02. 
 
2,3-Dihydro-2-oxo-N-(4-phenyl-6-p-tolylpyrimidin-2-yl)-1H-imidazole-4-
carboxamide (JT-63) 
IR (KBr) cm-1: 3435, 3426 (N-H str.), 2879 (C-H str.), 1657, 1706 (>C=O), 1583, 1485, 
1443, 1456 (ring skeleton), 1346 (CH3). 
C, H, N analysis, Calculated: C, 67.91; H, 4.61; N, 18.86. Found: C, 67.89; H, 4.56; N, 
18.82. 
 
N-[4-(4-Methoxyphenyl)-6-phenylpyrimidin-2-yl]-2-oxo-2,3-dihydro-1H-imidazole-
4-carboxamide (JT-64) 
IR (KBr) cm-1: 3494, 3456 (N-H str.), 2859 (C-H str.), 1659, 1723 (>C=O), 1622 
(CONH), 1569, 1474, 1457, 1427 (ring skeleton), 1857 (OCH3). 
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C, H, N analysis, Calculated: C, 65.11; H, 4.42; N, 18.08. Found: C, 65.03; H, 4.37; N, 
18.03. 
 
N-[4-(2-Chlorophenyl)-6-(4-methoxyphenyl)pyrimidin-2-yl]-2-oxo-2,3-dihydro-1H-
imidazole-4-carboxamide (JT-65) 
IR (KBr) cm-1: 3456, 3424 (N-H str.), 2878 (C-H str.), 1684, 1702 (>C=O), 1658 
(CONH), 1635 (OCH3), 739 (C-Cl). 
Mass: [m/e (%)], M. Wt. :423, 357, 340, 332, 280, 266, 251, 237, 213, 209, 180, 163, 
146, 132, 120, 104, 91, 77, 65, 44. 
C, H, N analysis, Calculated: C, 59.79; H, 3.82; N, 16.60. Found: C, 59.74; H, 3.76; N, 
16.56. 
 
N-[4-(2-Chlorophenyl)-6-(3-nitrophenyl)pyrimidin-2-yl]-2-oxo-2,3-dihydro-1H-
imidazole-4-carboxamide (JT-66) 
IR (KBr) cm-1: 3485, 3450 (N-H str.), 2868 (C-H str.), 1691, 1700 (>C=O), 1673 
(CONH), 768 (C-Cl). 
C, H, N analysis, Calculated: C, 54.99; H, 3.00; N, 19.24. Found: C, 54.93; H, 2.87; N, 
19.16. 
 
N-[4-(4-Fluorophenyl)-6-(4-methoxyphenyl)pyrimidin-2-yl]-2-oxo-2,3-dihydro-1H-
imidazole-4-carboxamide (JT-67) 
IR (KBr) cm-1: 3445, 3426 (N-H str.), 2826 (C-H str.), 1695, 1716 (>C=O), 1758 
(OCH3), 1636 (CONH), 745 (C-Cl). 
C, H, N analysis, Calculated: C, 62.22; H, 3.98; N, 17.28. Found: C, 62.16; H, 3.94; N, 
17.23. 
 
N-[4-(4-Chlorophenyl)-6-(2-hydroxyphenyl)pyrimidin-2-yl]-2-oxo-2,3-dihydro-1H-
imidazole-4-carboxamide (JT-68) 
IR (KBr) cm-1: 3601 (OH), 3429, 3416, 3502 (N-H str.), 2736 (C-H str.), 1697, 1717 
(>C=O), 1644 (CONH), 744 (C-Cl). 
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C, H, N analysis, Calculated: C, 58.90; H, 3.46; N, 17.17. Found: C, 58.87; H, 3.36; N, 
17.14. 
 
N-(4-(2-Chlorophenyl)-6-(2,5-dimethoxyphenyl)pyrimidine-2-yl)-2,3-dihydro-2-oxo-
1H-imidazole-4-carboxamide (JT-69) 
IR (KBr) cm-1: 3424, 3419 (N-H str.), 2825 (C-H str.), 1680, 1716 (>C=O), 1623 
(CONH), 728 (C-Cl). 
C, H, N analysis, Calculated: C, 58.48; H, 4.02; N, 15.50. Found: C, 58.46; H, 4.00; N, 
15.46. 
 
N-(4-(4-Chlorophenyl)-6-(2,5-dimethoxyphenyl)pyrimidine-2-yl)-2,3-dihydro-2-oxo-
1H-imidazole-4-carboxamide (JT-70) 
IR (KBr) cm-1: 3456, 3425 (N-H str.), 2868 (C-H str.), 1635, 1719 (>C=O), 1825, 1797 
(OCH3), 1589 (CONH), 723 (C-Cl). 
1H NMR 400 MHz (DMSO-d6,  ppm): 3.69, 3.72 (d, 6H, 2×OCH3), 4.22 (s, 1H, 
CONH), 6.65 (s, 1H, -CH), 6.67 (s, 1H, NH) , 6.65 (s, 1H, NH), 6.96-7.52 (m, HH, Ar-
H). 
400 MHz 13 C NMR (DMSO-d6,  ppm): 31.92, 38.88-40.13, 42.40, 54.92, 55.16, 
77.01, 77.34, 77.66, 111.80, 114.50, 128.17, 138.49, 150.56, 197.06. 
Mass: [m/e (%)], M. Wt. : 456, 438, 423, 407, 343, 317, 303, 285, 271, 261, 249, 228, 
178, 164, 141, 139, 111, 91, 75, 65, 44. 
C, H, N analysis, Calculated: C, 58.48; H, 4.02; N, 15.50. Found: C, 58.44; H, 3.93; N, 
15.47. 
 
2,3-Dihydro-N-(4-(2,5-dimethoxyphenyl)-6-(3-nitrophenyl)pyrimidine-2-yl)-2-oxo-
1H-imidazole-5-carboxamide (JT-71) 
IR (KBr) cm-1: 3435, 3414 (N-H str.), 2846 (C-H str.), 1657, 1703 (>C=O), 1757, 1742 
(OCH3), 1592 (CONH). 
Mass: [m/e (%)], M. Wt.:463, 450, 448, 432, 415, 402, 387, 374, 357, 346, 320, 290, 
280, 263, 251, 220, 202, 187, 175, 148, 129, 115, 111, 95, 64, 44. 
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C, H, N analysis, Calculated: C, 57.14; H, 3.92; N, 18.17. Found: C, 57.12; H, 3.86; N, 
18.14. 
N-[4-(4-Bromophenyl)-6-(4-methoxyphenyl)pyrimidin-2-yl]-2-oxo-2,3-dihydro-1H-
imidazole-4-carboxamide (JT-72) 
IR (KBr) cm-1: 3436, 3428 (N-H str.), 2934 (C-H str.), 1680, 1712 (>C=O), 1826 
(OCH3), 1613 (CONH), 748(C-Br). 
Mass: [m/e (%)], M. Wt.:466, 451, 322, 256, 224, 197, 180, 165, 152, 137, 120, 105, 
93, 78, 64, 52, 44. 
C, H, N analysis, Calculated: C, 54.09; H, 3.46; N, 15.02. Found: C, 54.02; H, 3.43; N, 
14.98. 
 
N-(4-(4-Cyanophenyl)-6-phenylpyrimidin-2-yl)-2,3-dihydro-2-oxo-1H-imidazole-4-
carboxamide (JT-73) 
IR (KBr) cm-1: 3413, 3443 (N-H str.), 2835 (C-H str.), 2169 (CN), 1668, 1704 (>C=O), 
1639 (CONH), 1557, 1479, 1447 (ring skeleton). 
C, H, N analysis, Calculated: C, 65.96; H, 3.69; N, 21.98. Found: 
C, 65.93; H, 3.66; N, 21.97. 
 
N-(4-(4-Cyanophenyl)-6-(4-methoxyphenyl)pyrimidin-2-yl)-2,3-dihydro-2-oxo-1H-
imidazole-4-carboxamide (JT-74) 
IR (KBr) cm-1: 3443, 3418 (N-H str.), 2813 (C-H str.), 2146 (CN), 1689, 1716 (>C=O), 
1893 (OCH3), 1635 (CONH). 
C, H, N analysis, Calculated: C, 64.07; H, 3.91; N, 20.38. Found: C, 64.06; H, 3.88; N, 
20.34. 
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3.11. Conclusion 
Total 24, of N-(4, 6-diphenyl pyrimidin-2-yl)-2-oxo-2, 3-dihydro-1H-imidazole-4-
carboxamides were synthesized in this chapter. The compounds were characterized by 
IR, NMR, Mass spectral data and elemental analysis. The synthesized compounds were 
screened for anti-inflammatory and anti-cancer activity. Unfortunalely, none of the 
compound was found active. 
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3.12. Spectra of some N-(4, 6-diphenyl pyrimidin-2-yl)-2-oxo-2, 3-dihydro-1H-
imidazole-4-carboxamides 
 
Infra Red spectra of N-[4,6-bis(4-fluorophenyl)pyrimidin-2-yl]-2-oxo-2,3-dihydro-
1H-imidazole-4-carboxamide (JT-52) 
 
 
Infra Red spectra of N-[4-(4-fluorophenyl)-6-(4-methylphenyl)pyrimidin-2-yl]-2-
oxo-2,3-dihydro-1H-imidazole-4-carboxamide  (JT-54)  
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Infra Red spectra of N-(4-(4-chlorophenyl)-6-(2,5-dimethoxyphenyl)pyrimidine-2-
yl)-2,3-dihydro-2-oxo-1H-imidazole-4-carboxamide (JT-70)  
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Mass spectrum of 2-Imidazolone-4-carboxylic acid 
 
 
Mass spectrum of N-(4,6-diphenylpyrimidin-2-yl)-2-oxo-2,3-dihydro-1H-imidazole-
4-carboxamide (JT-51) 
 
 
HN
N
NO
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Mol. For.: C20H15N5O2
Mol. Wt.: 357.37
HN NH
COOH
O
Mol. For.: C8H8N4O6
Mol. Wt.: 128.09
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Mass spectrum of N-[4-(4-chlorophenyl)-6-phenylpyrimidin-2-yl]-2-oxo-2,3-
dihydro-1H-imidazole-4-carboxamide (JT-61) 
 
 
 
Mass spectrum of N-(4-(4-bromophenyl)-6-phenylpyrimidin-2-yl)-2,3-dihydro-2-
oxo-1H-imidazole-4-carboxamide (JT-62) 
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ClMol. For.: C20H14ClN5O2
Mol. Wt.: 390.81
H
N
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BrMol. For.: C20H14BrN5O2
Mol. Wt.: 434.26
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Mass spectrum N-[4-(2-chlorophenyl)-6-(4-methoxyphenyl)pyrimidin-2-yl]-2-oxo-
2,3-dihydro-1H-imidazole-4-carboxamide (JT-65) 
 
 
 
Mass spectrum of N-(4-(4-chlorophenyl)-6-(2,5-dimethoxyphenyl)pyrimidine-2-yl)-
2,3-dihydro-2-oxo-1H-imidazole-4-carboxamide (JT-70) 
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Mol. For.: C21H16ClN5O3
Mol. Wt.: 421.84
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N
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HN NH
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N
N
Cl
OCH3H3CO
Mol. For.: C22H18ClN5O4
Mol. Wt.: 451.86
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Mass spectrum of 2,3-dihydro-N-(4-(2,5-dimethoxyphenyl)-6-(3-nitrophenyl) 
pyrimidine-2-yl)-2-oxo-1H-imidazole-5-carboxamide (JT-71) 
 
 
 
Mass spectrum N-[4-(4-bromophenyl)-6-(4-methoxyphenyl)pyrimidin-2-yl]-2-oxo-
2,3-dihydro-1H-imidazole-4-carboxamide (JT-72) 
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Mol. For.: C22H18N6O6
Mol. Wt.: 462.41
H
N
O
HN NH
O
N
N
OCH3
BrMol. For.: C21H16BrN5O3
Mol. Wt.: 466.29
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1H NMR spectrum N-(4,6-diphenylpyrimidin-2-yl)-2-oxo-2,3-dihydro-1H-imidazole-
4-carboxamide (JT-51) 
 
 
 
H
N
O
HN NH
O
N
N
Synthesis, Anti-inflammatory and Anti-cancer activity...... 
 
181 
1H NMR spectrum of 2,3-dihydro-N-(4-(3,4,5-trimethoxyphenyl)-6-
phenylpyrimidine-2-yl)-2-oxo-1H-imidazole-5-carboxamide (JT-59) 
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1H NMR spectrum of N-(4-(4-chlorophenyl)-6-(2,5-dimethoxyphenyl)pyrimidine-2-
yl)-2,3-dihydro-2-oxo-1H-imidazole-4-carboxamide (JT-70) 
 
 
 
            
H
N
O
HN NH
O
N
N
Cl
OCH3H3CO
Synthesis, Anti-inflammatory and Anti-cancer activity...... 
 
183 
13C NMR spectrum of N-(4-(4-chlorophenyl)-6-(2,5-dimethoxyphenyl)pyrimidine-2-
yl)-2,3-dihydro-2-oxo-1H-imidazole-4-carboxamide (JT-70) 
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4.1. Introduction 
 
The study of dihydropyridines began early in 1882, when Hantzsch disclosed the first 
synthesis of these compounds.1 Afterwards, the research was focused on NADH (reduced 
nicotinamide adenine dinucleotide) mimics and on the synthetic aspects of these 
heterocyclic systems, especially with regard to natural products and bioactive agents. 
 
Dihydropyridine chemistry2 is of interest not only from the point of view of pure research 
on heterocyclic compounds but especially because of expanding practical applications of 
dihydropyridine derivatives as pharmaceuticals,3 plating bath components4 photographic 
materials5-7 and different antioxidants and stabilizers of unstable organic substances.8-13 
Certain dihydropyridine derivatives appear to be effective, such as fertility, milk 
productivity and growth stimulators for cows14 stabilizers of fishmeal for broiler 
chicks,15,16 ingredients in hog, calf and cattle feed17-19 as well as agents for antiradiation 
protection of plants.20  Dihydropyridine compounds are important intermediates in the 
synthesis of benmorphane,21-25 thienomorphane26-28 and cephalosporine 29,30 derivatives, 
biosynthesis of indole alkaloids,31 nicotine32 and in the biotransformations of elastine.33  
Two alkaloids possessing a dihydropyridine skeleton has been identified.34 It is well 
known that the reduced coenzyme forms of NAD(P)H are dihydropyridine derivatives35 
and through these compounds dihydropyridine chemistry in all living organisms enters 
fundamental biochemical processes.  
 
Dihydropyridine derivatives, such as nifedipine, nitrendipine and nimodipine, have been 
found to be commercially useful molecules as Ca2+ channel blockers.36-38 A number of 
dihydropyridine Ca2+ channel (Ca2+) antagonists have been introduced as potential drugs 
for the treatment of congestive heart failure.39,40  
 
Cerebrocrast, a dihydropyridine derivative, has been introduced as a neuroprotective 
agent.41 Together with Ca2+ channel blocker and neuroprotective activity, a number of 
dihydropyridine derivatives have been found as vasodilators, antihypertensive, 
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bronchodilators, antiatherosclerotic, hepatoprotective, antitumour, antimutagenic,  
antidiabetic and antiplatelet aggregation agents.42-46 
 
Hantzsch dihydropyridine syntheses 
The first synthesis of a dihydropyridine is attributed to Arthur Hantzsch for work done a 
century ago47. Interestingly, the product from the condensation of two mols of ethyl 
acetoacetate, one mole of aldehyde and one mole of ammonia was assigned the 
dihydropyridine structure by Hantzsch (Scheme-1). Recent interest in the Hantzsch 
dihydropyridine has focused on substituents in the 2, 4, and 6 positions of the ring and on 
condensations involving compounds other than the β-keto esters. The first report of a 
Hantzsch ester unsubstituted at the 1, 2, and 6 positions involved the reaction of methyl 
propionate with an aromatic aldehyde and ammonium acetate in acetic acid.48 
 
H3C
COOC2H5
CHO
F3C
HN
CH3
H3C
COOC2H5
CH3
COOC2H5
O
NH3
2
β-Ketoester
Scheme-1: Hantzsch Dihydropyridine synthesis
 
 
Jerome and co-workers49 reported the classical Hantzsch synthesis50 of dihydropyridines, 
involving the condensation of an aldehyde, ammonia and acetoacetic ester or other β-
dicarbonyl compound, which was previously modified by Beyer51 and later by 
Knoevenagel52. The symmetrical 1,4-dihydropyridines were hence prepared by 
condensation of formaldehyde, ammonia and ethyl acetoacetate which lead to 2,6-
dimethyl-3,5-dicarbethoxy-l,4- dihydropyridine. The mechanism of the condensation was 
represented by involving preliminary formation of ethyl o-aminocrotonate and 
methyleneacetoacetic ester followed by Michael condensation and cyclization (Scheme-
2).  
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N
H
HH
C2H5OOC COOC2H5
H3C CH3H3C
CH
C2H5OOC
COCH3
H2C
NH2
COOC2H5
Scheme-2
 
 
The 1,4-dihydropyridine53 Ca2+ channel antagonists are clinically significant 
antihypertensive drugs and are immensely valuable as molecular tools with probe 
structural and functional aspects of Ca2+ channel function.1,2  Amlodipine5 consists of o-
substituted phenyl ring because it is one of the most widely used drugs in 1,4-
dihydropyridine family. Aza Diels-Alder reaction approach can be taken to construct 
highly substituted 1,4-dihydropyridine moiety focused on Amlodipine (Scheme-3). 
 
H3C O CH3
O O
H3C
H3COOC
NH2
N
H
H3COOC COOCH2CH3
H3C CH3
Cl
CHO
Cl
N
H
H3COOC COOCH2CH3
H3C CH2OCH2CH2NH2
Cl
Amlodipine
Scheme-3: Hantzsch condensation
 
 
4.2. Pharmacology 
DHP as multi drug resistant reverting agents 
The 1,4-dihydropyridine,54 blockers of L-type Ca2+ channels are used extensively in the 
treatment of cardiovascular disorders as dilators of coronary arteries. In addition to 
binding to Ca2+ channels, 1,4-dihydropyridines tends to bind to three subtypes of 
adenosine receptors, i.e. A1, A2A, and A355,56. For example, nifedipine binds these three 
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adenosine receptors with micromolar affinity, although it is much more potent at L-type 
Ca2+ channels. A newer generation Ca2+ channel blocker, nicardipine,57 within the family 
of adenosine receptors is actually selective for the A3 subtype. The (S)-enantiomer of 
niguldipine, which is the more potent enantiomer at L-type Ca2+ channels, binds to 
human A3 adenosine receptors with a Ki value of 2.8 µM and is totally inactive at A1 and 
A2A receptors. Thus, with respect to adenosine receptors alone it is highly specific for the 
A3 subtype. 
 
Some of the other dihydropyridines, such as amlodipine, felodipine, isradipine, 
lacidipine, nifedipine, nimodipine and nitrendipine have been commercialized and it has 
been proven that their therapeutic success is related to their efficacy to bind to Ca2+  
channels and consequently to decrease the passage of the transmembrane Ca2+ current, 
associated in smooth muscle with a long lasting relaxation and in cardiac muscle with a 
reduction of contractility throughout the heart. 58-60 
 
Jiang and co-workers61 designed and synthesized some dihydropyridines that bind to 
adenosine receptors without binding to L-type Ca2+ channels. 1, 4-Dihydropyridine 
derivatives substituted with -styryl or phenylethanyl groups at the 4-position and aryl 
groups at the 6-position were synthesized and found to be selective for human A3 
receptors. 
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Table-1: Some important 1, 4-dihydropyridines as Ca2+ channel antagonists: 
N
H
H3COOC COOC2H5
H3C
O
NH2
Cl
 
Amlodipine 
N
H
H3COOC COOC2H5
H3C CH3
O2N
 
 
Nifedipine 
N
H
H3COOC COOCH-CH2N
H3C CH3
NO2
CH3
Ph
 
Nicardipine 
 
N
H
(H3C)2HCOOC COOCH2CH2OCH3
H3C CH3
H
O2N
  
Nimodipine 
N
H
(H3C)2CHCOOC COOCH3
H3C CH3
H
NO
N
 
Isradipine 
 
NH3C
H3CH2COOC COOCH2CH3
CH3
H
H
(H3C)3COOC
 
Lacidipine 
N
H
NO2
H3C CH3
H3COOC COOC2H5
 
Nitrendipine 
 
N
H
H3C CH3
H3COOC COOiPr
O2N
 
(R) –Nilvadipine 
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N
H
H3C CH3
H3COOC NO2
CF3
 
 
Bay K-8644 
N
H
H3C
H3CH2COOC COOCH2CH3
 
MRS 1097 
N
H
H3C CH3
NO2
O
O
O
O
NH3C
N
.2HCl
 
 
Manidipine dihydrocholride 
 
 
N
H
H3C CH3
O
O
H3C O
O
N
NO2
.HCl
 
Benidipine hydrocholride 
 
N
H
NO2
H3C CH3
O
O
O
O
Ph
H3CO
  
Clinidipine 
N
H
H3C CH3
NO2
HO
O
O
O
Ph
 
APJ2708 
N
O
N
NH3C
NO2
CH3
H
iPrOOC
 
202-791 
NH3C
H3COOC COOCH2CH3
CH3
H
H
Cl
Cl
 
Felodipine 
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Cilnidipine is a 1,4-dihydropyridine derived L/N-type Ca2+ channel dual antagonist 
possessing neuro protective and analgesic effects which are related to its N-type Ca2+ 
channel inhibitory activity.62, 63 It is currently used for the treatment of essential 
hypertension in Japan.64 Its inhibitory effect for N-type Ca2+ channel can be clinically 
observed in the reduction of white coat effect, cold presser stress-induced platelet 
aggregation, urinary catecholamine excretion, and cardiac sympathetic overactivity in 
hypertensive patients.65 Moreover, N-type Ca2+ channel-blocking profile of cilnidipine 
contributes to its neuroprotective action in the animal focal brain ischemia model and its 
intrathecal analgesic effect in rat formalin-induced pain model.66 
 
In order to find specific N-type Ca2+ channel antagonists with the effects on 
cardiovascular system, Yamamota and co-workers67 performed structure–activity 
relationship study on APJ2708, which is a derivative of cilnidipine, and found a 
promising N-type Ca2+ channel blocker possessing analgesic effect in vivo with a 1600-
fold lower activity against L-type Ca2+ channels than that of cilnidipine. APJ2708, which 
is a carboxylic acid derivative of cilnidipine, has almost the same inhibitory activity 
against N-type Ca2+ channels with far lower activity against L-type channels than that of 
cilnidipine. As a consequence of this L-type activity, APJ2708 showed a weak 
hemodynamic effect and needed more than 100-fold intravenously administered dose for 
decreasing the same amount of blood pressure as cilnidipine in vivo. It is assumed that the 
carboxylic acid moiety of APJ2708 was the key structure for this selectivity and hence 
APJ2708 was optimized with the aim of discovering N-type Ca2+ channel blockers with 
low activity against L-type channels which have lesser influence on the cardiovascular 
systems.  
 
Natale and co-workers68 prepared a series of 4-isoxazolyl-1,4-dihydropyridines bearing 
lipophilic side chains at the C-5 position of the isoxazole ring (Scheme-4). The Ca2+ 
channel antagonistic activity of these compounds has been evaluated.  
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NO
O N
H3C R1
CH3
CH3
NO
O N
R1
CH3
CH3
R2
NO
R1
R2
HO
NO
R1
R2
N
H
H3CH2COOC COOCH2CH3
H3C CH3
1. nBuLi
    THF -780C, 2hr.
2. R2CH2X, -780C, rt.
    X=Cl or Br
1. CF3SO2CH3/CHCl2
2. NaBH4/4:1   
    THF:MeOH 0OC
3. H3O+/ THF rt
2 equi. CH3COCH2CO2CH2CH3
95% CH3CH2OH
NH3(aq.)
100-110oC 35-45psi
Scheme-4: Synthesis of Isoxazolyldihyropyridines bearing Lipophilic aryl substituents
 
 
A hypothetical model for binding of these compounds in the Ca2+ channel is proposed 
and the validity of this model is evaluated based on the SAR of this series of Ca2+  
binding, especially for the two most active derivatives (Figure-1). The solid state 
structure for the most active compound, has also been determined, and its important 
features were reported. 
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Si and co-workers69 used gene expression programming, a novel machine learning 
algorithm, to develop quantitative model as a potential screening mechanism for a series 
of 1,4-dihydropyridine Ca2+ channel antagonists. The heuristic method was used to 
search the descriptor space and select the descriptors responsible for activity. A 
nonlinear, six-descriptor model based on gene expression programming with mean-
square errors 0.19 was set up with a predicted correlation coefficient (R2) 0.92. A new 
and effective method for drug design and screening was hence established (Table-2). 
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Table-2:  Experimental and predicted activities [-log (IC50)] of 1, 4-dihydropyridine 
Ca2+ channel antagonists 
N
X
H3COOC COOCH3
H
CH3H3C
H
 
 
Log (I/IC50) Antagonist 
 
X 
Experimental HM GEP 
1 2’-NO2 8.89 8.22 8.76 
2a 2’-CF3 8.82 8.74 9.25 
3 2’Cl 8.66 8.02 8.10 
4 3’-NO2 8.40 8.20 8.23 
5a 2’-CH=CH2 8.35 8.33 7.96 
6 2’-NO2 8.29 7.95 8.16 
7 2’-CH3 8.22 7.71 7.67 
8 a 2’-CH2CH3 8.19 8.05 8.63 
9 2’-Br 8. 12 7.45 7.68 
10 2-CN 7.80 8.37 8.64 
11 a 3’-Cl 7.80 7.54 8.31 
12 3’-F 7.68 7.78 7.81 
13 H 7.68 7.95 7.66 
14 a 3’-CN 7.46 7.78 7.75 
15 3’-I 7.38 7.21 7.09 
16 2’-F 7.37 7.59 7.63 
17 a 2’-I 7.33 7.19 7.31 
18 2’-OCH3 7.24 6.63 7.14 
19 3’-CF3 7.13 7.37 7.64 
20 a 3’-CH3 6.96 6.70 6.43 
21 2’-OCH2CH3 6.96 7.19 7.53 
22 3’-OCH3 6.72 6.59 6.76 
23 a 3’-N(CH3)2 6.05 5.98 6.06 
24 3’-OH 6.00 6.15 6.06 
25 3’-NH2 5.70 5.05 5.60 
26 a 3’-OAc 5.22 5.46 5.49 
27 3’-OCOPh 5.20 4.57 5.64 
28 2’-NH2 4.40 5.43 4.86 
29 a 4’-F 6.89 6.62 6.53 
30 4’-Br 5.40 5.69 5.74 
31 4’-I 4.64 4.53 5.05 
32 a 4’-NO2 5.50 5.00 5.34 
33 4’-NMe2 4.00 3.97 4.25 
34 4’-CN 5.46 5.99 5.85 
aTest Set 
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Budriesi and co-workers70 synthesized novel, substituted 1,4-dihydropyridines with a 3-
methoxy-flavone moiety. Structural modifications of the substituents in the 
dihydropyridine ring of nifedipine were carried out in order to find tissue specific 
compounds. The negative inotropic, chronotropic and vasorelaxant effects were 
investigated on guinea-pig left, right atria and aortic strips, respectively. The introduction 
of an heteroaromatic ring in 4-position of the 1,4-dihydropyridine nucleus led to 
compounds selective for cardiac tissues. Moreover, different residues in the 1,4-
dihydropyridine ring could modulate the chronotropic versus inotropic activity (Figure-
2). 
 
O
O
OCH3
CHO
O
O
OCH3
N
H
COOCH2CH=CH2H3COOC
CH3H3C
O
O
OCH3
N
H
CNR1
CH3H3C
R1=CN
R1=COOCH2CHCH2
O
O
OCH3
N
H
COCH3H3COC
CH3H3C
O
O
OCH3
N
H
PH3COOC
CH3H3C
O
OO
CH3
CH3
O
O
OCH3
N
H
PH3COOC
CH3H3C
O
CH3
CH3
OO
O
O
OCH3
N
H
H3COOC
H3C
O
O
O
O
OCH3
N
H
COOCH2CH3R1OOC
CH3H3C
R1= CH2CH=CH2
R1= CH2CH3
O
O
OCH3
N
H
COOCH2CH3H2C=H2COOC
CH2OCH2CH2NH2H3C
O
O
OCH3
N
H
COOR2R1OOC
CH3H3C
R1=R2=CH3
R1=R2=CH2CH3
R1=R2=CH2CH=CH2
Figure-2
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Several derivatives of 4-aryl-1,4-dihydropyridines are widely used as therapeutic agents 
for the treatment of hypertension, angina,71 and other cardiovascular diseases. The DHPs 
have also proven to be powerful probes of the molecular basis of antagonism and the site 
of action in the Ca2+ channel.72 The bioisosteric replacement of the 4-aryl moiety with a 
4-isoxazolyl group yields analogous 4-isoxazolyl-1,4-dihydropyridines which retain 
potent Ca2+ antagonist activity.73 Some dihydropyridines were prepared with 
pharmacological activity equal to or greater than that of currently used therapeutic agents, 
such as nifedipine. Ideally, new drug development arise from the detailed study of drug-
receptor complexes both in the solid state (X-ray diffractometry) and in the solution 
phase (NMR spectroscopy). In the absence of such detailed information, drug 
development must proceed based on lead compounds and information on the nature of 
drug receptor or interactions gathered from the best-available methodology. 
 
Alker and co-workers74 reported the synthesis of a series of 1,4-dihydropyridines which 
had N-linked heterocycles at the terminus of an ethoxymethyl chain at the 2-position. The 
Ca2+ antagonist activity on rat aorta of this class of DHPs was compared with their 
negative inotropic activity as determined by using a Langendorff-perfused guinea pig 
heart model. The compounds examined showed a wide range of selectivity for vascular 
over cardiac tissue, with those analogues which possess an amide group at the terminus 
of the 2-substituent proved to be the most selective. From the in vitro data obtained for a 
series of 1, 2, 3-triazoles, it was concluded that the SARs for binding to the Ca2+ channels 
in vascular and cardiac tissue are different. One of the compounds, 2-amino-1-[2-[ [4-
(2,3-dichlorophenyl)-3-(ethoxycarbonyl)-5-(methoxycarbonyl)-6-methyl-4-dihydropyrid-
2-y1]methoxy]ethyl]-4(3H)-imidazolone was identified as a potent (ICw = 8 X 104 M) 
Ca2+ antagonist which is 40-fold selective for vascular over cardiac tissue and which has 
a significantly longer duration of action (>3 h) than nifedipine in the anesthetized dog on 
intravenous administration (Scheme-5). 
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Other pharmacollogical properties of 1,4-dihydrpyridines 
Dihydropyridine drugs such as nifedipine, nicardipine, amlodipine and others are 
effective cardiovascular agents for the treatment of hypertension.75 The 4-aryl-1,4-
dihydropyridines have been explored for their Ca2+ channel activity and the heterocyclic 
rings are found in a variety of bioactive compounds such as vasodilator, bronchodilator, 
antiatherosclerotic, antitumour, antidiabetic, geroprotective and heptaprotective agents.76  
Moreover, studies have discovered that these compounds exhibit diverse medical 
functions such as neuroprotectants, compounds with platelet antiaggregators, cerebral 
anti-ischaemic agents and chemosensitizers.77  
 
Li et. al.78 reported some novel 1,4-dihydropyridines which were tested for their affinity 
in radioligand binding assays at adenosine receptors. The Hantzsch condensation, which 
involved condensing three components, a 3-amino-2-propenoate ester, an aldehyde, and a 
β-ketoester, was used for synthesizing 1,4-dihydropyridine derivatives. 
 
R5O
R6
O
NH2
R4
O H
R2
R3
O
O N
O O
OR5R3
R2 R6
H
R4
EtOH, 80oC
24 h
β-Enaminoester aldehyde β-ketoester
Scheme-6: Synthesis of substituted 1,4-dihydropyridines using the Hantzsch reaction
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Shafiee et. al. 79 carried out anticonvulsant activity of alkyl, cycloalkyl and arylalkyl ester 
analogues of nifedipine in which the o-nitro phenyl group at position 4 was replaced by 
1-methyl-4-nitro-5-imidazolyl substituent, were determined against pentylenetetrazole-
induced seizures in mice. The anticonvulsant effects of the compounds were evaluated by 
the measurement of seizure potency and duration. Significant differences were observed 
between treated animals with control group and nifedipine in seizure duration. The results 
had shown that most of the compounds had similar activity to the reference drug 
nifedipine. In addition, some of the compounds were more active than the reference drug 
nifedipine (Scheme-7). 
 
N
N
O2N
OHC
CH3
N
N
N
Rn(H2C)OOC COO(CH2)nR
H3C CH3
H
O2N CH3
CH3COCH2COO(CH2)nR
NH4+CH3COO-
Scheme-7
 
 
4.3. Synthetic approaches 
Multiple synthesis of 1, 4-dihydropyridines 
It has been reported that there are many methods to synthesize 1,4-dihydropyridine 
derivatives, in view of the biological importance associated with these compounds. The 
classical method involves the mixing of aldehyde with ethyl acetoacetate and ammonia in 
acetic acid or in refluxing alcohol.80 Starting from Hantzsch,81 more than a century ago, 
there are several efficient methods developed for the synthesis of 1,4-dihydropyridines, 
which comprise the use of microwave,82 ionic liquids,83 at high temperature in refluxing 
solvent, TMSCl–NaI and metal triflates.84 The development of a simple, efficient and 
versatile method for the preparation of 1,4-dihydropyridine derivatives is an active area 
of research and there is a scope for further improvement towards milder reaction 
conditions and higher product yields. 
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The 4-aryl-1, 4-dihydropyridines are used in the treatment of cardiovascular disease, one 
of the world s leading causes of death. Its synthesis is typical of those in organic 
chemistry that usually involve more than one step, reagents and solvents and overall low 
atom efficiencies. The 4-aryl-1, 4-dihydropyridines are efficiently synthesized by Correa 
and co-workers85 under solvent-free conditions in high yield. The use of volatile solvents 
was restricted to recrystallisation of the product, which, due to the high degree of 
conversion, kept to a minimum. Optimization of reaction conditions by careful 
consideration of the reaction rate and extent of conversion was demonstrated. This is yet 
another example of how readily solvent-free reactions may be implemented in the highly 
reproducible and efficient preparation of pure therapeutic agents with minimal production 
of waste and optimised use of energy.  
Sastry and co-workers86 carried out a simple, inexpensive and efficient one-pot synthesis 
of 1,4-dihydropyridine derivatives at room temperature using catalytic amount of iodine 
with excellent product yields. Various substituted 1,4-dihydropyridine derivatives were 
synthesized using commercially available iodine as a catalyst. A novel synthesis of 1,4-
DHPs using catalytic amount of iodine under ambient conditions with excellent yields 
was carried out by stirring benzaldehyde, 1,3-cyclohexanedione, ethyl acetoacetate and 
ammonium acetate  at room temperature in a few drops of ethanol (Scheme-8). 
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O O
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Khadilkar et. al.87 described the scaling up of clinically important dihydropyridine by 
using a continuous microwave reactor (CMR). The use of aqueous hydrotrope solution as 
a cheap, safe and green alternative to organic solvent was was carry out for homogeneous 
reactions under microwave heating. Different aqueous hydrotrope solutions were studied 
for the reaction in batch as well as continuous-flow process. 
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The Hantzsch ester synthesis was performed using the hydrotrope solution by taking the 
mixture of benzaldehyde, methyl 3-aminocrotonate, and ethyl/methyl acetoacetate. The 
contents were solublized in the aqueous hydrotrope solution of sodium p-toluene 
sulphonate and circulated through the microwave oven cavity to obtain dihydropyridines 
in high yield and of excellent quality. A continuous microwave reactor (CMR) was 
prepared to carry out DHP synthesis reaction at a larger scale. 50% NaPTSA hydrotrope 
solution was used to carry out reaction under CMR (Scheme-9). 
 
O
COOR1
COCH3
R NH3
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Microwave
N
R1OOC
H3C
COOR1
CH3
H
R
R= H, 4-Cl, 3,4-di Cl, 4-Br, 2-NO2, 3-NO2, 4-NO2
Scheme-9
 
 
Chhillar and co-workers88 synthesized 4-aryl-1,4-dihydropyridine and some 4-aryl-
1,2,3,4-tetrahydropyrimidin-2-one derivatives and examined for their activity against 
pathogenic strains of Aspergillus fumigatus and Candida albicans. Two of the 
compounds of the dihydropyridine series, that is, diethyl 4-(4-methoxyphenyl)-2,6-
dimethyl-1,4-dihydropyridin-3,5-dicarboxylate and dimethyl 4-(4-methoxyphenyl)- 2,6-
dimethyl-1,4-dihydropyridin-3,5-dicarboxylate, exhibited significant activity against A. 
fumigatus in disc diffusion, microbroth dilution and percent spore germination inhibition 
assays. The diethyl dicarboxylate derivative of dihydropyridine also exhibited 
appreciable activity against C. albicans. The in vitro toxicity of the most active diethyl 
dihydropyridine derivative was evaluated using haemolytic assay, in which the 
compound was found to be non-toxic to human erythrocytes even at a concentration of 
625 µg/ml. The standard drug amphotericin B exhibited 100% lysis of erythrocytes at a 
concentration almost 16 times less than the safer concentration of the most active 
dihydropyridine derivative (Scheme-10).  
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X-Ray crystallographic study of 1,4-dihydrpyridines 
X-ray crystallographic studies of molecules of dihydropyridine have established the fact 
that majority of 1,4-dihydropyridine rings have a boat type conformation with varying 
degree of puckering at C4 position. To synthesize the analogs of known drugs like 
flordipine, felodipine, darodipine, modifications to the C4 part of 1,4 dihydropyridine 
moiety have been carried out. Some DHP molecules were synthesized with different 
electron donating groups (EDG) such as methoxy group at C4 position89. The title 
compound was prepared by Hantzsch (dihydro) pyridine synthesis (Scheme-11). 
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An N-substituted 1,4-dihydropyridine derivative has been synthesized by reacting ethyl 
acetoacetate, 3-nitro benzaldehyde and aniline in methanol and the X-ray structure was 
proved90 (Scheme-12). The OPTEP drawing of the molecule at 50% probability with the 
ring numbering is also shown (Scheme-12). 
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A 1, 4-dihydropyridine has been synthesized by varing the substituents at the phenyl ring 
without disturbing the novel carbamoyl group at C3 and C5 positions of 1,4-
dihydropyrimidine ring. The crystallographic characterization of the title compound was 
carried out. This compound is obtained by the substitution of cyanide  group at C3 and 
acetyl group at C5 position of 1,4-dihydropyridine91 (Figure-3). 
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A series of potent unsymmetrical DHPs92 were synthesized in our laboratory. Among the 
synthesized compounds, the compound DRC-6001,  in which carbamoyl functionality 
and the esteric part in the C3 and C5 positions was introduced, respectively. This type of 
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hybrid structure was confirmed by X-ray diffraction cryastallography method (Scheme-
13). 
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A potent93 N-substituted 1,4-dihydropyridine, AKS-751, dimethyl-2,6-dimethyl-4-(2-
nitrophenyl)–N-(2-methoxyphenyl)-1,4-dihydropyridine-3,5-dicarboxylate,was synthesiz 
-ed and the crystal structure was proved by X-ray crysatallographic study. The compound 
was synthesized by heating methyl acetoacetate, 2-anisidine and 2-nitro benzaldehyde in 
glacial acetic acid (Scheme-14). 
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Goldmann et. al.94 synthesized 4,4-disubstituted 1,4-dihydropyridines which show a loss 
of Ca2+ antagonistic potency of 103 times both in vitro on aortic rings and in vivo on 
anaesthetized dogs as compared to examples that are mono-substituted at the 4-position 
of the DHP ring. The X-ray structure shows, the 4-aryl substituent is present not in the 
accustomed axial conformation, but in an equatorial one. This dramatic change in 
conformation could be the reason for the major loss of activity and would indicate the 
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need for axial conformation of the aryl residue in pharmacologically active 1,4-
dihydropyridines (Figure-4). 
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Work carried out at our laboratory:  
The development of multidurg resestance (MDR)-tumor cell populations is a major 
problem in the chemotherapy of human cancer95. When tumor cells become resistant to 
anticancer agents such as vinca alkaloids or anthracyclines, they often show resistance to 
other antitumor agents with different structures and mechanisms of actions. One of the 
MDR types was proved to involve a membrane-bound protein, P-glycoprotein (Pgp) in 
MDR cancer cells,  protozoa and baceteria. This protein acts as an efflux pump for the 
anticancer drugs96. Recently, various compounds have been shown to inhibit Pgp-
mediated drug efflux97. These compounds include ion cannel blockers such as verapamil, 
dihydropyridines,98 propafenone,99 etc. Among them, DHPs, Ca2+ antagonists, have been 
studied extensively for the analogy to verapamil. It is very important finding that those 
DHPs which do not have any Ca2+ channel antagonistic, activity possess MDR reversal 
activity100.  
 
Shah et al.101. investigated the cytotoxic and the MDR-reversal activites of 3,5-diacetyl-
2,6-dimethyl-1,4-dihydropyridine derivatives against mouse lymphoma cells transfected 
with MDR1 gene. Among the synthesized compounds, G7 showed highest cytotoxic 
activity against human promyelocytic leukemia HL-60 and human squamous cell 
carcinoma HSC-2 cells (Figure-5).  
Synthesis and Characterization of Some (5-Carboxymethyl……. 211 
N
H
Cl
H3C CH3
H3C CH3
OO
Figure-5: G-7
 
 
On these basis of these102(a) observations, some 4-substituted phenyl-2,6-dimethyl-3,5-
bis-N-(substituted phenyl)carbamoyl-1,4-dihydropyridines were synthesized and tested 
against M. tuberculosis H37Rv.102(b)  
 
Three-dimensional quantitative structure-activity relationship (3D QSAR) methods, 
comparative molecular field analysis (CoMFA) and comparative molecular similarity 
indices analysis (CoMSIA), were applied on a series of 1,4-dihydropyridines possessing 
antitubercular activity.103 
 
The 3, 5-dibenzoyl-1,4-dihydropyridines104 (nifedipine analogues) were synthesized and 
the compounds were tested on three different E. coli. strains. Among all the synthesized 
compounds, GB12 was the most active in enhancing the activity of erythromycin, and 
was selected for plasmid elimination studies (Figure-6). 
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Few of the DHPs of above series105 showed synergistic interactions with ampicillin and 
erythromycin on E. coli. K12LE140/F’lac. With a sensitive clinical isolate of E. coli. Gy-
1/Apsens Erres, compound G1 antagonized the antibacterial effect of Ap and a synergistic 
effect was found in the combination of Er with other compounds (Figure-7). 
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Three different series of 1,4-diphenyl-1,4-dihydropyridine derivatives were 
synthesized106 and were tested to inhibit the transport activity of P-gp and were studied 
by flow cytometry in a MDR human colon cancer cell line (COLO320) and in human 
MDR 1 gene-transfected mouse lymphoma cells (L 5178 Y). The cytoxicities of these 
compounds were also examined against human normal and cancer cell lines. The 
majority of the tested compounds  were proved to be effective inhinbitors of rhodamine 
123 outward transport. Some dihydropyridines derivatives displayed cytotoxic activity 
against four human oral tumor cell lines and against three normal human oral cell lines 
(Figure-8). 
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DP7, a novel dibenzoyl-1,4-dihydropyridine compound107, synthesized in our laboratory  
has been shown to be a powerful P-gp inhibitor, almost devoid of cardiovascular effects, 
but capable of inhibiting liver CYP3A. DP7 is considered a lead compound for the 
development of novel dihydropyridines which do not effect CYP enzyme but still 
remains active towards ABC-efflux transporters ( Figure-9). 
 
N
H
OO
H3C CH3
O
Figure-9: DP7
 
 
The compound, DP7, has also found out as a new multidrug resistance reveting agent 
devoid on vascular smooth muscle contractility. DP7 inhibited L-type Ca2+ ion current 
recorded in artery myocytes  in a concentration dependant manner, with IC50 values 
ranging between 1.12×10-6 and 2.23×10-5.  In L5187 MDR cell line, DP7 exhibited an 
MDR-reversing activity, with IC50 values ranging between 3.02×10-7 and 4.27×10-5, 
being the most potent. The  K+  channel opener cromakalim inhibited the  Ca2+ ion 
induced contraction in K30 but not that evoked in K60. But DP7, on the contrary was 
ineffective in both experimental conditions108. 
 
A series of 4-substituted phenyl-2,6-dimethyl-3,5-bis-N-(substituted phenyl) carbamoyl-
1,4-dihydropyridines were synthesized and the compounds were emerged as potential 
antitubercular agents109. These compounds may act as precursors and after penetration 
into the cell wall may lead to the 3,5-carboxylate anions by enzymatic hydrolysis. All the 
derivatives were screened for their anti-tubercular activity against M. Tuberculosis H37 
Rv (ATCC 27294; American type culture collection, Rockville, MD). Among them, 
some of the derivatives showed > 90% inhibition comparable to rifampicin.  
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A few compounds synthesized in out laboratory having 1,4-dihydropyridine as a 
core structure 
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4.4. Present work 
A large number of heterocyclic alkanoic acids and related compounds have been reported 
for their anti-inflammatory activity.110-113  Some new work is also reported so far on the 
anti-inflammatory activity of 1,4-dihydropyridines possessing analgesic,114 
hypotensive,,115 anti-tumor,116 and coronary dialating activities117. These results promted 
us to synthesize the title compounds. The synthesized compounds belongs to heteroaryl 
alkanoic acids, which are well known as NSAIDs. A series of 26, 1,4-dihydropyridines 
have been synthesized by treating different aromatic aldehydes with β–aroylpropanoic 
acid and ammonia in ethanol (Scheme-24). 
 
Bahekar and Shinde118 synthesized a series of [5-carboxymethyl-2,6-bis-(4-substituted-
phenyl)-4-aryl 1,4-dihydropyridine-3-yl]–acetic acids by reacting different  aromatic 
aldehydes with β–aroylpropanoic acid and ammonia in ethanol. 
 
The compounds were subjected to preliminary testing for their anti-inflammatory 
activity. The percentage of reduction in inflammation 3 hr after administration of 
carrageenin was recorded. Compared to the reference standard, diclofenac sodium, all the 
compounds showed a tendency to reduce the edema. The (5-carboxymethyl-4-phenyl-(2, 
6-(di-4-chlorophenyl))-1, 4-dihydropyridine-3-yl)-acetic acid showed the enhanced 
activity among all the other synthesized compounds. 
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4.5. REACTION  SCHEME-I
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REACTION  SCHEME-II
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4.6. Experimental 
 
General method for preparation of β-benzoyl propionic acid100 
Succinic anhydride (6 g, 0.06 mole), is added to a 500 ml three necked round bottom 
flask equipped with a mechanical stirrer and a reflux condenser. Pure dry benzene (35 
ml) was added and the mixture was stirred. Powdered anhydrous aluminium chloride 
(17.6 g, 0.13 mole) is added in one lot. Hydrogen chloride gas is evolved and the mixture 
becomes hot. It is stirred and heated in a boiling water bath for 30 min. The reaction 
mixture is cooled to room temperature and water (25 ml) was added. Concentrated 
hydrochloric acid (8.3 ml) is added and benzene was removed by steam distillation. The 
mixture is cooled and the separated oil solidified. It was then filtered, washed with dilute 
hydrochloric acid (25 ml, 1:3) and cold water (50 ml). The solid was purified by 
dissolving in sodium bicarbonate solution and acidifying the clear filterate. The 
precipitates were filtered and dried. Yield 10.0 g (94%). m.p.115oC (Reported 
m.p.117oC).100 
Similarly, other substituted β-aroyl propionic acids were prepared. 
  
General method for preparation of (5-carboxymethyl-2, 4, 6-triphenyl-1, 4-
dihydropyridine-3-yl)-acetic acid118 
To a solution of β-benzoyl propionic acid (0.02 mol) in dry ethanol, benzaldehyde (0.01 
mol) and liquid ammonia (0.01 mol) were added. The mixture was refluxed for 6 h.  The 
reaction mixture was allowed to cool to room temperature. The solid obtained was 
filtered off, washed with cold ethanol and upon recrystallization with ethanol afforded the 
pure (5-carboxymethyl-2, 4, 6-triphenyl-1, 4-dihydropyridine-3-yl)-acetic acids. 
 
The physical data and Rf value of various (5-carboxymethyl-2, 4, 6-triphenyl-1, 4-
dihydropyridine-3-yl)-acetic acids were recorded in the Table 1. 
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4.7. Table 3: (5-Carboxymethyl-2, 4, 6-triphenyl-1, 4-dihydropyridine-3-yl)-acetic acids 
 
R
N
H
O
OH
O
OH
R' R'
 
 
Substitution 
Codes 
R R’ 
Moleular 
formula 
Molecular 
weight 
Melting point  
(oC) Rf value 
% 
Yield 
JT-101 4-NO2 phenyl Cl C27H20Cl2N2O6 539.36 158-160 0.363 61 
JT-102 4-OH phenyl Cl C27H21Cl2NO5 510.37 136-138 0.333 46 
JT-103 4-CN phenyl Cl C28H20Cl2N2O4 519.38 168-170 0.38 48 
JT-104 4-OCH3 phenyl Cl C28H23Cl2NO5 524.39 162-164 0.378 72 
Solvent system: Ethyl acetate: Hexane :: 6:4 
Ref: (a)Bahekar S, and Shinde, Synthesis and anti-inflammatory activity of 1,4-dihydropyridines, Acta Pharm., 52, 281-287, 2002. (b) 
Kentoro H.; Hirohito S.; Synthesis of 2-substituted-amino-4-aryl-5-ylalkanoic acids, Chem. Pharm Bull. 1977, 25, 2292-2299. 
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4.7. Table 3 (contd.): (5-Carboxymethyl-2, 4, 6-triphenyl-1, 4-dihydropyridine-3-yl)-acetic acids 
 
 
 
 
 
Substitution 
Codes 
R R’ 
Moleular 
formula 
Molecular 
weight 
Melting point  
(oC) Rf value 
% 
Yield 
JT-105 2,5-(OCH3)2 phenyl Cl C29H25Cl2NO6 554.42 182-184 0.469 51 
JT-106 3,4-(OCH3)2 phenyl Cl C29H25Cl2NO6 554.42 156-158 0.48 58 
JT-107 3,4,5-(OCH3)3 phenyl Cl C30H27Cl2NO7 584.44 140-142 0.41 70 
JT-108 Cinnamyl Cl C29H23Cl2NO4 520.40 126-128 0.40 74 
JT-109 4-N(CH3)2 phenyl Cl C29H26Cl2N2O4 537.43 118-120 0.47 72 
JT-110 2-Pyridyl Cl C26H20Cl2N2O4 595.35 88-90 0.51 68 
JT-111 3-Indolyl Cl C29H22Cl2N2O4 533.40 122-124 0.54 62 
JT-112 1-Naphthayl Cl C31H23Cl2NO4 544.42 136-138 0.47 57 
JT-113 4-NO2 phenyl CH3 C29H26N2O6 498.53 120-122 0.43 73 
JT-114 4-OH phenyl CH3 C30H26N2O4 469.53 158-160 0.47 49 
JT-115 4-CN phenyl CH3 C30H26N2O4 478.54 126-128 0.38 56 
JT-116 4- OCH3 phenyl CH3 C30H29NO5 483.55 162-168 0.51 77 
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4.7. Table 3 (contd.): (5-Carboxymethyl-2, 4, 6-triphenyl-1, 4-dihydropyridine-3-yl)-acetic acids 
 
 
 
 
 
 
 
Substitution 
Codes 
R R’ 
Moleular 
formula 
Molecular 
weight 
Melting point  
(oC) Rf value 
% 
Yield 
JT-117 2,5-(OCH3)2 phenyl CH3 C31H31NO6 513.58 156-158 0.43 58 
JT-118 3,4-(OCH3)2 phenyl CH3 C31H31NO6 513.58 158-160 0.51 53 
JT-119 3,4,5--(OCH3)3 phenyl CH3 C32H33NO7 543.61 124-126 0.56 71 
JT-120 Cinnamyl CH3 C31H29NO 479.57 98-100 0.42 58 
JT-121 4- N(CH3)2 phenyl CH3 C31H32N2O4 496.60 116-118 0.49 68 
JT-122 2-Pyridyl CH3 C28H26N2O4 454.52 82-84 0.48 64 
JT-123 3-Indolyl CH3 C31H28N2O4 492.57 102-104 0.46 62 
JT-124 1-Naphthayl CH3 C23H29NO4 503.59 116-118 0.47 55 
JT-125 4-NO2 phenyl H C27H22N2O6 470.47 128-130 0.46 74 
JT-126 4- OCH3 phenyl H C28H25NO5 455.5 142-144 0.58 63 
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4.8. Spectral study 
 
Infra Red spectra 
IR spectra were taken on SHIMADZU 8400 FT-IR-435 Spectrometer using KBr Pellet 
method. The free hydroxyl group (-OH) is observed between the value 3605-3560 cm-1. 
The NH stretching was observed between 3430-3460 cm-1. The –CH stretching frequency 
was observed between the values 2846-2963 cm-1. The characteristic acid group (COOH 
of carboxylic acid) in dihydropyridine moiety is observed at 1790-1830 cm-1, The 
dihydropyridine moiety showed the ring skeleton vibrations at 1600-1630, 1550-1590, 
1550-1520, 1470-1495 cm-1. The frequency of the methyl as well as methylene group in 
the compounds showed the value between 1436-1468 cm-1, as well as 1358-1394 cm-1  
respectively. The value of C-Cl frequency in some compounds was observed between 
712-756 cm-1. 
. 
1H NMR spectra 
1H NMR spectra were recorded on  Bruker AC 400 MHz FT-NMR Spectrometer using 
TMS (Tetramethyl Silane) as an internal standard and DMSO-d6 as a solvent. In the 1H 
NMR spectra of (5-carboxymethyl-2, 4, 6-triphenyl-1, 4-dihydropyridine-3-yl)-acetic 
acids, various proton values like methylene (-CH2), methyl (-CH3), aromatic protons (Ar-
H) and hydroxyl protons (of carboxylic acid) of carboxylic acid were observed as under. 
The values for methyl (-CH3) proton is observed between 2.3-2.6  ppm and for 
methylene (-CH2) proton, between 3.5-4.0  ppm. The aromatic protons (Ar-H) shows 
doublets or multiplets between 6.4-7.8  ppm. The value for hydroxyl proton (-OH)  in 
carboxylic acid group was observed after 8.0  ppm. 
Individual 1H NMR data of synthesized compounds are mentioned in spectral data 
analysis. 
 
Mass spectra 
The mass spectrum of compounds was recorded by GCMS-QP2010 spectromeyter (EI 
method). The molecular ion peak (M+) and the base peak in all compounds were clearly 
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obtained in mass spectral study. The molecular ion peak (M+) values are in good 
agreement with molecular weight of all the compounds synthesized. 
C, H, N analysis  
Elemental analysis of the compounds was carried out on Elemental Vario EL III Carlo 
Erba 1108 model at CDRI, Lucknow and the results are in agreement with the structures 
assigned. 
 
4.9. Spectral characterization 
 
(5-Carboxymethyl-4-(4-nitrophenyl)-(2,6-di-(4-chlorophenyl))-1,4-dihydropyridine-
3-yl)-acetic acid (JT-101) 
IR (KBr) cm-1: 3437 (N-H str.), 2973 (C-H str.), 1802 (COOH), 1447 (CH2), 723 (C-Cl). 
C, H, N analysis, Calculated: C, 60.12; H, 3.74; N, 5.19. Found: C, 60.10; H, 3.72; N, 
5.17. 
 
(5-Carboxymethyl-4-(4-hydroxyphenyl)-(2,6-di-(4-chlorophenyl))-1,4-dihydro 
pyridine-3-yl)-acetic acid (JT-102) 
IR (KBr) cm-1: 3593 (free OH str.), 3500 (N-H str.), 2879 (C-H str.), 1815 (COOH), 
1419 (CH2  str.), 744  (C-Cl). 
C, H, N analysis, Calculated: C, 63.54; H, 4.15; N, 2.74. Found: C, 63.46; H, 4.13; N, 
2.73. 
 
(5-Carboxymethyl-4-(4-cyanophenyl)-(2,6-di-(4-chlorophenyl))-1,4-dihydropyridine-
3-yl)-acetic acid (JT-103) 
IR (KBr) cm-1: 3457 (N-H str.), 2863 (C-H str.), 2235 (CN), 1826 (COOH), 1436 
(CH2), 722 (C-Cl). 
Mass: [m/e (%)], M. Wt.: 518, 484, 463, 426, 415, 397, 379, 351, 324, 310, 289, 258, 
224, 184, 175, 142, 130, 122, 107, 95, 63, 44. 
C, H, N analysis, Calculated: C, 64.75; H, 3.88; N, 5.39. Found: C, 64.72; H, 3.87; N, 
5.32. 
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(5-Carboxymethyl-4-(4-methoxy-phenyl)-(2,6-di-(4-chlorophenyl))-1,4-dihydro 
pyridine-3-yl)-acetic acid (JT-104) 
IR (KBr) cm-1: 3453 (N-H str.), 2894 (C-H str.), 1821 (COOH), 1447 (CH2), 1350 
(OCH3), 715 (C-Cl). 
1H NMR 400 MHz (DMSO-d6,  ppm): 1.71 (s, 3H, OCH3), 3.25 (s, 4H, 2 × –CH2), 
4.30 (s, 1H, -CH), 5.57 (s, 1H, -NH), 7.37-8.15 (m, 12H, Ar-H), 9.25 (s, 2H, 2 × -
COOH). 
C, H, N analysis, Calculated: C, 64.13; H, 4.42; N, 2.67. Found: C, 64.10; H, 4.39; N, 
2.64. 
 
(5-Carboxymethyl-4-(2,5-dimethoxyphenyl)-(2,6-di-(4-chlorophenyl))-1,4-dihydro 
pyridine-3-yl)-acetic acid (JT-105) 
IR (KBr) cm-1: 3478 (N-H str.), 2959 (C-H str.), 1825 (COOH), 1447 (CH2), 1350, 1369 
(OCH3), 723 (C-Cl). 
C, H, N analysis, Calculated: C, 62.82; H, 4.55; N, 2.53. Found: C, 62.77; H, 4.54; N, 
2.51. 
 
(5-Carboxymethyl-4-(3,4-dimethoxyphenyl)-(2,6-di-(4-chlorophenyl))-1,4-dihydro 
pyridine-3-yl)-acetic acid (JT-106) 
IR (KBr) cm-1: 3447 (N-H str.), 2937 (C-H str.), 1822 (COOH), 1426 (CH2), 1342, 1348 
(OCH3), 743 (C-Cl). 
C, H, N analysis, Calculated: C, 62.82; H, 4.55; N, 2.53. Found: C, 62.74; H, 4.54; N, 
2.50. 
 
 (5-Carboxymethyl-4-(3,4,5-tri-methoxyphenyl)-(2,6-di-(4-chlorophenyl))-1,4-
dihydropyridine-3-yl)-acetic acid (JT-107) 
IR (KBr) cm-1: 3494 (N-H str.), 2892 (C-H str.), 1814 (COOH), 1425 (CH2), 1326, 
1348, 1363 (OCH3), 726 (C-Cl). 
1H NMR  400 MHz (DMSO-d6,  ppm): 1.71 (s, 3H, OCH3), 3.25 (s, 4H, 2 × –CH2), 
4.30 (s, 1H, -CH), 5.57 (s, 1H, -NH), 7.37-8.15 (m, 12H, Ar-H), 9.25 (s, 2H, 2 × -
COOH). 
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C, H, N analysis, Calculated: C, 61.65; H, 4.66; N, 2.40. Found: C, 61.62; H, 4.61; N, 
2.35. 
 
(5-Carboxymethyl-4-(3,4,5-tri-methoxy-phenyl)-(2,6-di-(4-chlorophenyl))-1,4-
dihydropyridine-3-yl)-acetic acid (JT-108) 
IR (KBr) cm-1: 3483(N-H str.), 2869 (C-H str.), 1823 (COOH), 1603, 1585, 1516, 1486 
(ring skeleton), 1426 (CH2), 936 (R-CH=CH-R), 742 (C-Cl). 
C,H,N analysis, Calculated: C, 66.93; H, 4.45; N, 2.69. Found: C, 66.84; H, 4.42; N, 
2.66. 
 
(5-Carboxymethyl-4-(cinnamyl)-(2,6-di-(4-chlorophenyl))-1,4-dihydropyridine-3-yl)-
acetic acid (JT-109) 
IR (KBr) cm-1: 3483 (N-H str.), 2892 (C-H str.), 1802 (COOH), 1456 (CH2), 1346, 1378 
(CH3), 767 (C-Cl). 
C, H, N analysis, Calculated: C, 64.81; H, 4.88; N, 5.21. Found: C, 64.78; H, 4.83; N, 
5.19. 
 
(5-Carboxymethyl-4-(2-pyridinyl)-(2,6-di-(4-chlorophenyl))-1,4-dihydropyridine-3-
yl)-acetic acid (JT-110) 
IR (KBr) cm-1: 3456 (N-H str.), 2937 (C-H str.), 1812 (COOH), 1467 (CH2), 735 (C-Cl). 
C, H, N analysis, Calculated: C, 63.04; H, 4.07; N, 5.66. Found: C, 63.02; H, 4.01; N, 
5.63. 
 
(5-Carboxymethyl-4-(3-indolyl)-(2,6-di-(4-chlorophenyl))-1,4-dihydropyridine-3-yl)-
acetic acid (JT-111) 
IR (KBr) cm-1: 3445, 3482 (N-H str.), 2956 (C-H str.), 1814 (COOH), 1576, 1513, 1502, 
1458 (ring skeleton), 1436 (CH2), 742 (C-Cl). 
C, H, N analysis, Calculated: C, 65.30; H, 4.16; N, 5.25. Found: C, 65.24; H, 4.13; N, 
5.22. 
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(5-Carboxymethyl-4-(1-naphthyl)-(2,6-(di-4-chlorophenyl))-1,4-dihydropyridine-3-
yl)-acetic acid (JT-112) 
IR (KBr) cm-1: 3467 (N-H str.), 2972 (C-H str.), 1814 (COOH), 1577, 1523, 1546, 1486 
(ring skeleton), 1423 (CH2), 756 (C-Cl). 
C, H, N analysis, Calculated: C, 68.39; H, 4.26; N, 2.57. Found: C, 68.33; H, 4.25; N, 
2.52. 
 
(5-Carboxymethyl-4-(4-nitrophenyl)-(2,6-di-(4-methylphenyl))-1,4-dihydropyridine-
3-yl)-acetic acid (JT-113) 
IR (KBr) cm-1: 3496 (N-H str.), 2924 (C-H str.), 1836 (COOH), 1414 (CH2 str.), 1335, 
1352, 1345 (-CH3 str.). 
1H NMR 400 MHz (DMSO-d6,  ppm): 3.29 (s, 6H, 2 × CH3), 3.65 (s, 4H, 2 × –CH2), 
4.39 (s, 1H, -CH), 5.63 (s, 1H, -NH), 6.82-7.57 (m, 12H, Ar-H), 9.00 (s, 2H, 2 × -
COOH). 
C, H, N analysis, Calculated: C, 69.87; H, 5.26; N, 5.626. Found: C, 69.82; H, 5.24; N, 
5.58. 
 
(5-Carboxymethyl-4-(4-hydroxyphenyl)-(2,6-di-(4-methylphenyl))-1,4-dihydro 
pyridine-3-yl)-acetic acid (JT-114) 
IR (KBr) cm-1: 3601 (free OH str.), 3500 (N-H str.), 2935 (C-H str.), 1907 (COOH), 
1452 (CH2  str.), 1332, 1346 (-CH3 str.). 
C, H, N analysis, Calculated: C, 74.18; H, 5.80; N, 2.98. Found: C, 74.17; H, 5.77; N, 
2.95. 
 
(5-Carboxymethyl-4-(4-cyanophenyl)-(2,6-di-(4-methylphenyl))-1,4-dihydro 
pyridine-3-yl)-acetic acid (JT-115) 
IR (KBr) cm-1: 3467 (N-H str.), 2911 (C-H str.), 2224 (CN), 1923, 1934 (COOH), 
1413 (CH2  str.), 1378, 1383 (-CH3 str.). 
Mass: [m/e (%)], M. Wt.: 478, 475, 440, 425, 383, 341, 315, 301, 263, 238, 203, 175, 
163, 139, 125, 111, 84, 75, 64, 44. 
Synthesis and Characterization of Some (5-Carboxymethyl……. 228 
C, H, N analysis, Calculated: C, 75.30; H, 5.48; N, 5.85. Found: C, 75.24; H, 5.44; N, 
5.82. 
 
(5-Carboxymethyl-4-(4-methoxyphenyl)-(2,6-di-(4-methylphenyl))-1,4-dihydro 
pyridine-3-yl)-acetic acid (JT-116) 
IR (KBr) cm-1: 3479 (N-H str.), 2923 (C-H str.), 1836 (COOH), 1423 (CH2  str.), 1378 
(OCH3), 1378 (-CH3 str.). 
C, H, N analysis, Calculated: C, 74.52; H, 6.04; N, 2.90. Found: C, 74.50; H, 6.01; N, 
2.86. 
 
(5-Carboxymethyl-4-(2,5-dimethoxyphenyl)-(2,6-di-(4-methylphenyl))-1,4-dihydro 
pyridine-3-yl)-acetic acid (JT-117) 
IR (KBr) cm-1: 3489 (N-H str.), 2913 (C-H str.), 1867 (COOH), 1425 (CH2  str.), 1365 
(OCH3), 1378, 1383 (-CH3 str.). 
C, H, N analysis, Calculated: C, 72.50; H, 6.08; N, 2.73. Found: C, 72.48; H, 6.04; N, 
2.71. 
 
(5-Carboxymethyl-4-(3,4-dimethoxyphenyl)-(2,6-di-(4-methylphenyl))-1,4-dihydro 
pyridine-3-yl)-acetic acid (JT-118) 
IR (KBr) cm-1: 3497 (N-H str.), 2912 (C-H str.), 1836 (COOH), 1445 (CH2  str.), 1334, 
1352  (-CH3 str.). 
Mass: [m/e (%)], M. Wt. : 515, 403, 351, 293, 217, 207, 184, 174, 159, 145, 131, 115, 
103, 91, 77, 65, 44. 
C, H, N analysis, Calculated: C, 72.50; H, 6.08; N, 2.73. Found: C, 72.48; H, 6.02; N, 
2.67. 
 
(5-Carboxymethyl-4-(3,4,5-tri-methoxyphenyl)-(2,6-di-(4-methylphenyl))-1,4-
dihydropyridine-3-yl)-acetic acid (JT-119) 
IR (KBr) cm-1: 3487 (N-H str.), 2912 (C-H str.), 1812 (COOH), 1421 (CH2  str.), 1323 
(OCH3), 1367, 1373 (-CH3 str.). 
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C, H, N analysis, Calculated: C, 70.70; H, 6.12; N, 2.58. Found: C, 70.68; H, 6.03; N, 
2.55. 
 
(5-Carboxymethyl-4-(3,4,5-tri-methoxy phenyl)-(2,6-di-(4- methyl phenyl))-1,4-
dihydropyridine-3-yl)-acetic acid (JT-120) 
IR (KBr) cm-1: 3496 (N-H str.), 2863 (C-H str.), 1830 (COOH), 1602, 1586, 1526, 1484 
(ring skeleton), 1449 (CH2  str.), 1359, 1364 (-CH3 str.). 
C, H, N analysis, Calculated: C, 77.64; H, 6.10; N, 2.92. Found: C, 77.61; H, 6.07; N, 
2.89. 
 
(5-Carboxymethyl-4-(cinnamyl)-(2,6-di-(4-methylphenyl))-1,4-dihydropyridine-3-
yl)-acetic acid (JT-121) 
IR (KBr) cm-1: 3497 (N-H str.), 2913 (C-H str.), 1836 (COOH), 1447 (CH2  str.), 1397, 
1399  (-CH3 str.). 
Mass: [m/e (%)], M. Wt.: 496, 481, 466, 451, 322, 256, 224, 197, 180, 165, 152, 137, 
120, 105, 93, 78, 64, 52, 44. 
C, H, N analysis, Calculated: C, 74.98; H, 6.50; N, 5.64. Found: C, 74.94; H, 6.48; N, 
5.62. 
 
(5-Carboxymethyl-4-(2-pyridinyl)-(2,6-di-(4-methylphenyl))-1,4-dihydropyridine-3-
yl)-acetic acid (JT-122) 
IR (KBr) cm-1: 3435 (N-H str.), 2924 (C-H str.), 1846 (COOH), 1423 (CH2  str.), 1332, 
1342 (-CH3 str.). 
C, H, N analysis, Calculated: C, 73.99; H, 5.77; N, 6.16. Found: C, 73.94; H, 5.75; N, 
6.12. 
 
(5-Carboxymethyl-4-(3-indolyl)-(2,6-di-(4-methylphenyl))-1,4-dihydropyridine-3-
yl)-acetic acid (JT-123) 
IR (KBr) cm-1: 3487, 3546 (N-H str.), 2926 (C-H str.), 1893 (COOH), 1434 (CH2  str.), 
1332, 1342 (-CH3 str.). 
Synthesis and Characterization of Some (5-Carboxymethyl……. 230 
C, H, N analysis, Calculated: C, 75.59; H, 5.73; N, 5.699. Found: C, 75.54; H, 5.71; N, 
5.66. 
 
(5-Carboxymethyl-4-(1-naphthyl)-(2,6-di-(4-methylphenyl))-1,4-dihydropyridine-3-
yl)-acetic acid (JT-124) 
IR (KBr) cm-1: 3468 (N-H str.), 2912 (C-H str.), 1848 (COOH), 1623, 1579, 1514, 1476 
(ring skeleton), 1423 (CH2  str.), 1336, 1342 (-CH3 str.). 
C, H, N analysis, Calculated: C, 78.71; H, 5.80; N, 2.78. Found: C, 78.68; H, 5.78; N, 
2.73. 
 
(5-Carboxymethyl-2,6-diphenyl-4-(4-nitrophenyl)-1,4-dihydropyridine-3-yl)-acetic 
acid (JT-125) 
IR (KBr) cm-1: 3473 (N-H str.), 2868 (C-H str.), 1823 (COOH), 1616, 1578, 1524, 1496 
(ring skeleton), 1428 (CH2  str.). 
C, H, N analysis, Calculated: C, 68.93; H, 4.71; N, 5.95. Found: C, 68.91; H, 4.67; N, 
5.93. 
 
(5-Carboxymethyl-2,6-diphenyl-4-(4-methoxyphenyl)-1,4-dihydropyridine-3-yl)-
acetic acid (JT-126) 
IR (KBr) cm-1: 3483 (N-H str.), 2857 (C-H str.), 1827 (COOH), 1623, 1594, 1559, 1469 
(ring skeleton), 1456 (CH2  str.). 
C, H, N analysis, Calculated: C, 73.83; H, 5.53; N, 3.08. Found: C, 73.81; H, 5.48; N, 
3.04. 
 
4.10. Conclusion 
 
Total 26 (5-carboxymethyl-2, 4, 6-triphenyl-1, 4-dihydropyridine-3-yl)-acetic acids were 
synthesized in this chapter. The compounds are characterized by IR, NMR, Mass spectral 
data and elemental analysis. All spectral data are in well agreement with the assigned 
structures. All the newly synthesized compounds have been sent for anti-tubercular 
activity and the results are awaited. 
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4.11. Spectra of some (5-carboxymethyl-2, 4, 6-triphenyl-1, 4-dihydropyridine-3-yl)-
acetic acids 
Infra Red spectrum of (5-carboxymethyl-4-(4-hydroxy phenyl)-(2, 6-di-4-chloro 
phenyl)-1,4-dihydropyridine-3-yl)-acetic acid (JT-102) 
 
 
Infra Red Spectrum of (5-Carboxymethyl-4-(4-hydroxy phenyl)-(2, 6-di-4-methyl 
phenyl)-1,4-dihydropyridine-3-yl)-acetic acid (JT-114) 
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Mass spectrum of 4-(4-chlorophenyl)-4-oxobutanoic acid 
 
 
Mass spectrum of 4-oxo-4-p-tolylbutanoic acid 
COOH
H3C
O
Mol. For.: C11H12O3
Mol. Wt.: 192.21
COOH
Cl
O
Mol. For.: C10H9ClO3
Mol. Wt.: 212.63
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Mass spectrum of (5-carboxymethyl-4-(4-cyanophenyl)-(2,6-di-4-chlorophenyl)-1,4-
dihydropyridine-3-yl)-acetic acid (JT-103) 
 
 
 
Mass spectrum of (5-carboxymethyl-4-(4-cyano phenyl)-(2,6-di-4-methylphenyl)-1,4-
dihydropyridine-3-yl)-acetic acid (JT-115) 
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Mol. For.: C30H26N2O4
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Mass spectrum of (5-carboxymethyl-4-(3,4-dimethoxyphenyl)-(2,6-di-4-methyl 
phenyl)-1,4-dihydropyridine-3-yl)-acetic acid (JT-118) 
 
 
 
Mass spectrum of (5-carboxymethyl-4-(cinnamyl)-(2, 6-di-4-methylphenyl)-1,4-
dihydropyridine-3-yl)-acetic acid (JT-121) 
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1H NMR of 4-(4-chlorophenyl)-4-oxobutanoic acid 
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1H NMR spectrum of (5-carboxymethyl-4-(4-methoxyphenyl)-(2,6-di-4-
chlorophenyl)-1,4-dihydropyridine-3-yl)-acetic acid (JT-104) 
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1H NMR spectrum of (5-carboxymethyl-4-(3, 4, 5-tri-methoxy phenyl)-(2,6-di-4-
chlorophenyl)-1,4-dihydropyridine-3-yl)-acetic acid (JT-107) 
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1H NMR spectrum of (5-carboxymethyl-4-(4-nitrophenyl)-(2,6-di-4-methyl phenyl)-
1,4-dihydropyridine-3-yl)-acetic acid (JT-113) 
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5.2. Introduction 
 
In 1893, Pietro Biginelli1 reported the synthesis of functionalized 3,4-dihydropyrimidin-
2(1H)-ones (DHPMs) via three-component condensation reaction of an aromatic 
aldehyde, urea, and ethyl acetoacetate.  Since then, the “Biginelli reaction” has been 
known as an efficient one-pot reaction protocol to prepare 3, 4-dihydropyrimidine-2(1H)-
one (DHPM) derivatives. 
 
Biginelli formulated structure I, which is used to represent these tetrahydropyrimidines, 
in which R is the grouping joined to aldehyde of the particular aryl, alkyl or arylalkyl 
aldehyde employed in conjunction with urea and ethyl acetoacetate. Accordingly, when 
benzaldehyde was used, Biginelli obtained a pyrimidine which he considered to be 
represented by structure II, namely, 2-keto-4-phenyl-5-carbethoxy-6-methyl-1, 2, 3, 4-
tetrahydropyrimidine. Biginelli’s structure II was apparently accepted by Hinkel and 
Hey2. 
 
HN
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The original Biginelli protocol for the preparation of the DHMPs consisted of heating a 
mixture of the three components (aldehyde 1, -keto-ester 2, and urea 3) in ethanol 
containing a catalytic amount of HCl.3 This procedure leads in one step-one pot to the 
desired DHPM4 (Scheme-1). 
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Scheme-1: Biginell Dihydropyrimidine synthesis
 
 
Multi-componant reactions (MCRs) & dihydropyrimidine synthesis: 
Definition 
Multicomponent Reactions (MCRs) are those reactions in which three or more reactants 
come together in a single reaction vessel to form a new product which contains portions 
of all the components.5  
“MCRs convert more than two adducts directly into their product by one-pot 
reaction.” 
 
Importance 
MCRs occupy an outstanding position in organic and medicinal chemistry for their high 
degree of atom economy, applications in combinatorial chemistry and diversity-oriented 
synthesis.6 MCR strategies offer significant advantages over conventional linear-type 
syntheses. In such reactions, three or more reactants come together in a single reaction 
vessel to form new products that contain portions of all the components. In an ideal case, 
the individual building blocks are commercially available or are easily synthesized and 
cover a broad range of structural variations.  
 
MCRs are providing products with the diversity needed for the discovery of new lead 
compounds or lead optimization employing combinatorial chemistry techniques. MCRs 
leading to interesting heterocyclic scaffolds that are particularly useful for the creation of 
diverse chemical libraries of “drug-like” molecules for biological screening, since the 
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combination of three or more small-molecular-weight building blocks in a single 
operation leads to high combinatorial efficacy.  
 
Over the last decade, industrial and academic researchers have made such powerful MCR 
strategies into one of the most efficient and cost-effective tools for combinatorial and 
parallel synthesis.7(a-i) One prominent MCR that produces an interesting class of nitrogen 
heterocycles is the Biginelli dihydropyrimidine synthesis. 
 
The Biginelli reaction, one-pot cyclocondensation of aldehyde, 1,3-ketoester, and urea or 
thiourea, is inarguably one of the most useful MCRs.1,8(a,b)  The reaction was carried out 
by simply heating a mixture of the three components dissolved in ethanol with a catalytic 
amount of HCl at reflux temperature. The product of this novel one-pot, three-component 
synthesis that precipitated on cooling of the reaction mixture was identified as 3,4-
dihydropyrimidin-2(1H)-one (Scheme-2), and this reaction is referred to as “Biginelli 
reaction”, “Biginelli condensation”, or as “Biginelli dihydropyrimidine synthesis.”9-11 
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Scheme-2: Biginelli three component condensation
 
 
5.2. Synthetic aspects of dihydropyrimidines 
To make diversed DHPM derivatives available for drug discovery, appropriate synthetic 
protocols are needed. 
 
Biginelli dihydropyrimidine synthesis: The standard procedure for the Biginelli 
condensation1 involves one-pot condensation of the three building blocks in a solvent 
such as ethanol using a strongly acidic catalyst, i.e. hydrochloric acid12 (Scheme-3). 
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Atwal’s Modification: Atwal13 modified the synthesis of dihydropyrimidine for better 
yield. He took o-substituted aryl aldehydes as well as aliphatic aldehydes for the 
synthesis of dihydropyrimidines and observed that R1 can be significantly varied with 
little effect on the yield (Scheme-4). 
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The first one makes use of immobilized urea or thiourea moieties. The second uses an 
immobilized β-ketoester, and the third one uses an S-linked isothiouronium 
isothiouranium salt (Scheme-5). 
 
Synthesis and Characterization of 5-Benzoyl-6-methyl……. 255 
O
O
R3
O
R4
O
HR2
N
NH
XHR3
O
O
R3
+
N
NH
S-PolymerR2
O
O
R3
O
O
R3
O
R4
HR2
NH
S-PolymerH2N
1
2 5
6
R4
A= H+, H2O, Reflus
(X=O)
B) TFA, EtSH
(X=S)
C) aminolysis
(X=NR)
R4
7 8
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Rafiee and co-workers14 described an efficient synthesis of 3,4-dihydropyrimidinones or 
thiones (DHPMs), using silica-supported heteropoly acid H3PW12O40/SiO2 (PW/SiO2) for 
the first time as the catalyst from an aldehyde, β-keto ester and urea or thiourea in 
acetonitrile. Compared to the classical Biginelli reaction conditions, this method 
consistently has the advantage of excellent yields, mild reaction conditions, easy workup, 
survival of different functional groups, and short reaction times (Scheme-6). 
 
CHO H3C O CH3
O O
+
H2N NH2
O
N
H
NHO
O
H3C O
H3C
Catalyst
Solvent, 1h
Scheme-6
 
 
It has been reported that Lewis acids (such as BF3OEt2)15 in combination with transition 
metals and a proper proton source were effective catalyst for this reaction. 
Dihydropyrimidinones were also synthesized by using various protic acids such as HCl,16 
and acetic acid17 under microwave irradiation. More recently, ionic liquids,25 
montmorillonite KSF, polyphosphate ester (PPE),18-19 and lanthanide triflate,20 as 
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catalysts for the one-pot solvent-free synthesis of dihydropyrmidinones have also been 
reported. 
 
Bigi21 and co-workers synthesized various dihydropyridinesin the presence of the acidic 
clay montmorillonite KSF 7 taking the mixture of benzaldehyde, ethyl acetoacetate and 
urea with or without water or toluene as solvent, at 100°C (Scheme-7). 
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Phosphotungstic acid (0.05 mol%) catalyzed one-pot condensation22 of aryl aldehydes, 
urea derivatives and -diketones under microwave irradiation rapidly affords substituted 
3,4-dihydropyrimidin-2(1H)-ones in excellent yields and high purity. The low cost 
catalyst has exhibited remarkable reactivity and reusability (Scheme-8). 
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Salehi and co-workers23 reported a facile and efficient method for the one-pot synthesis 
of dihydropyrimidinones using magnesium bromide as catalyst under solvent free 
conditions. Magnesium bromide efficiently catalyzes the three-component condensation 
reaction of aldehyde, β-di-ketone and urea/thiourea under solvent free conditions to 
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afford the corresponding dihydropyrimidinones in high yields and short reaction time 
(Scheme-9). 
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Scheme-9
 
 
One-pot synthesis of a library of 3,4-dihydropyrimidine-2(1H)-thiones and quinazolin-
4(3H)-ones were described by Zhidong124 and co-workers. Ytterium reagent supported 
on ion exchange resin is applied to the multicomponent condensation reactions under 
solvent-free conditions. The advantages of easy separation and recyclability of the 
catalysts were demonstrated (Scheme-10). 
 
R1
O O
+ + H2N NH2
S
N
H
NH
R3
R1
O
R2 S
R2
R3 CHO
SO3]3 Ln3+
Scheme-10
 
 
A simple, efficient, green and cost-effective procedure has been developed for the 
synthesis of dihydropyrimidinones by a solvent-free and catalyst-free Biginelli’s 
condensation of 1,3-dicarbonyl compound, aldehyde and urea. This approach25 of direct 
reaction in neat without solvent and catalyst shows a new direction in green synthesis 
(Scheme-11). 
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Peyman Salehi26 and co-workers also observed that Silica sulfuric acid efficiently 
catalyzes the three-component Biginelli reaction between an aldehyde, and a dicarbonyl 
compound and urea or thiourea in refluxing ethanol to afford the corresponding 
dihydropyrimidinones in high yields. The catalyst is reusable and can be applied several 
times without any decrease in the yields of the reactions (Scheme-12). 
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Stadler et. al.27 have recently described a high yielding and rapid microwave-assisted 
protocol that allows the synthesis of gram quantities of DHPMs utilizing controlled 
single-mode microwave irradiation28 (Scheme-13). 
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Yun Ma and co-workers,29 have tested a variety of reaction conditions with the model 
reaction using lanthanide trifluoromethanesulfonates as a catalyst and obtained the 
dihydropyrimidines in higher yields (Scheme-14). 
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Brindaban Ranu et. al.30 synthesized Indium (III) chloride mediated Biginelli reactions 
(Scheme-15). 
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Ma and co-workers31 synthesized dihydropyrimidines using heavy metal catalysis 
(Scheme-16). 
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An efficient synthesis of 3,4-dihydropyrimidin-2-ones from the aldehydes, -ketoesters 
and urea in ethanol using methanesulfonic acid (CH3SO3H) as the catalyst is described by 
Jin and co-workers.32 Compared with the classical Biginelli reaction conditions, this 
method has the advantage of excellent yields and short reaction time (Scheme-17). 
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A simple, efficient and cost-effective method33 has been developed for the synthesis of 
3,4-dihydropyrimidin-2(1H)-ones by a one-pot three component cyclocondensation 
reaction of 1,3 dicarbonyl compound, aldehyde and urea using benzyltriethylammonium 
chloride as the catalyst, under solvent-free conditions. The scope of this protocol is 
utilized for the synthesis of mitotic Kinesin EG5 inhibitor monastrol (Scheme-18). 
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Wipf et. al.34 reported the solid phase synthesis for combinatorial scaffolds of Biginelli 
compounds (Scheme-19). 
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Studer et. al.35 reported the florous phase modifications for the dihydropyrimidine 
synthesis (Scheme-20). 
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Srinivasan and co-workers36 synthesized dihydropyrimidinones by refluxing 
benzaldehyde, ethyl acetoacetate and urea with 5 wt.% of PANI–HBF4–DHS salt in 
ethanol for 6 h and obtained the products in more than 97% yields (Scheme-21). 
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A closely related approach has been reported by Robinett et. al.37 Here, the supported 
acetoacetate was first subjected to a Knoevenagel condensation on the resin38 with a 
variety of aldehydes, followed by reaction with S-alkylisothioureas to produce 1,4-
dihydropyrimidines on solid support. Rather than hydrolyzing the protected urea/thiourea 
functionality, these intermediates were directly cleaved with TFA/DCM 1:1 to furnish a 
648 member combinatorial library 2637 (Scheme-22). 
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Scheme-22: Solid phase synthesis of 1, 4-dihydropyrimidine-5-carboxilic acids 
employing the Atwal modification of the Biginelli condensation.25
 
 
Recently, cerium (III) chloride and indium (III) chloride have emerged as powerful 
catalysts imparting high regio and chemoselectivity in various chemical 
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transformations.39(a-c) Munoz-Muniz and co-workers40(a-c)  performed enantioselective 
Biginelli condensation reactions catalyzed with InCl3 or CeCl3 in the presence of chiral 
ligands (Scheme-23). 
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5.3. Pharmacology 
Biologically active dihydropyrimidines 
The biological activity makes these pyrimdines such attractive targets especially because 
of the following activities: 
• Calcium channel blockers41a 
• Antiviral activity42a 
• Antibacterial activity42c 
• Antitumor12 
• Anti-inflammatory42b 
• Analgesic43 
• Blood platelet aggregation inhibitor41b 
• Cardiovascular effects44 
 
N
H
NHRO
O
H3C X
HAr
Figure-1
 
 
3,4-Dihydropyrimidin-2(1H)-ones and their synthetic analogues are of considerable 
importance because of their promising biological activities such as antibacterial, antiviral, 
anti-inflammatory and antitumor. 
 
For example, aryl derivatives of dihydropyrimidones, SQ32926 and SQ32547 has been 
found to possess similar biological properties as that of dihydropyridines, a class of 
compounds showing remarkable pharmacological properties.45 Other biological activities 
of DHPMs include 1A adrenergic receptor antagonists as drug candidates for the 
treatment of benign prostatic hyperplasia.  Recently, monastrol has been identified as a 
lead compound of a new class of anticancer agents acting as cell division (mitosis) 
blockers.46       
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Dihydropyrimidine derivatives are known as interesting heterocyclic scaffolds for drug 
research. Polyfunctionalized dihydropyrimidines represent a heterocyclic system of 
remarkable pharmacological efficiency and many exhibit antiviral,12a antitumor,12b 
antibacterial and anti-inflammatory properties.12c  The DHPM core structure was found to 
possess Channel modulating, adrenergic agonistic, mitotic kinesin inhibiting, 
antibacterial, fungicidal and other pharmacological properties. In addition, the 
dihydropyrimidine-5-carboxylate core has been found in several marine natural products.  
 
Monastrol, the only cell-permeable molecule is currently known to specifically inhibit 
mitotic kinase Eg5 and is considered a lead for the development of new anticancer 
drugs.13 (Scheme-24). 
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(R)-SQ 32,926, a potent orally active antihypertensive agent. Several marine natural 
products containing the dihydropyrimidine-5-carboxylate core were found to be potent 
HIVgp-120-CD4 inhibitors.48(a-c) Pharmacological studies concerning the absolute 
configuration at the C4 stereogenic center were well documented and in some cases, 
individual enantiomers perform opposing biological activities.49(a,b) Nevertheless, only a 
few examples of asymmetric synthesis of this heterocyclic target have been reported.50(a,b) 
Chemical resolution and enzymatic strategies have thus far been the methods of choice to 
obtain optically active DHPMs.51(a-d) Access to highly enantiomerically pure DHPMs by 
catalytic asymmetric synthesis is therefore of considerable current interest and a 
formidable task, too (Scheme-25). 
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Scheme-25: Synthesis of R-SQ 32,926
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Table-1: Biologically active dihydropyrimidines under clinical trial at various  
stages 52: 
 
N
H
Ni-PrO
O
H3C O
NO2
NH2
O
 
 
SQ32926 (Anti-viral) 
N
H
NO
O
H3C S
NH2
O
OH
H3C
 
 
Monastrol (Anticancer) 
 
N
H
Ni-PrO
O
H3C O
O
O N
ArCF3
 
SQ32547 (Antitumor) 
 
HN
N
O
O
CH3
CH3
O
H3C
 
MKC-442 (NNRTI) 
 
HN
N
O
O
CH3
S
O
H3C
 
HETP (NNRTI) 
HN
N
O
O
R
X
 
 
DABOs (NNRTI) 
HN
N
O
O
CH3
CH3
O
 
 
TNK—651 (NNRTI) 
N
H
Ni-PrO
O
H3C O
F
N
H
O
F
R
 
Merk-Synaptic product 
(-1A-adrenergic receptor antagonist) 
 
N
H
NH3CO
O
O
F
N
H
O
F
H3CO
N
N
 
L-771,668 
(β1A-selective adrenoceptor antagonist) 
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The preparation of enantiomerically enriched 4-phenyl-dihydropyrimidinone derivative53 
was achieved in moderate enantioselectivity (8-40%) by a modified one-pot Biginelli 
condensation procedure in the presence of the chiral ligands (R,R)-A or (S,S)-B (Figure-
2). 
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Figure-2
 
 
It was recently proposed that calcium channel modulation (antagonist vs. agonist activity) 
is dependent on the absolute configuration at C4, whereby the orientation of the 4-aryl 
group (R- versus S-enantiomer) acts as a "molecular switch" between antagonist and 
agonist activity.54 In the receptor-bound conformation the substituted aryl ring should be 
positioned axially, perpendicular to, and bisecting the boat-like dihydropyridine ring, 
with the 4-aryl substituent (X) prefering the synperiplanar (sp) orientation relative to C4-
H (Figure-3). 
 
N H
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Figure-3: Proposed receptor-bound conformation of DHPM calcium 
channel modulator.
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Over the years, research interest in multifunctionalized 3,4-dihydropyrimidin-2(1H)-ones 
viz. the Biginelli scaffold, has surged rapidly, owing to the pharmacological properties 
associated with many derivatives of this privileged heterocyclic core.55-58 Reports 
describe several DHPMs that have been identified, for example, Ca2+ channel 
modulators,56(a-c) or small molecules targeting the mitotic machinery.57(a-c) Notably, 4-
aryldihydropyrimidinone heterocycles attached to an aminopropyl-4-piperidine moiety 
via a C5 amide linkage have proven to be excellent templates for selective -1A-receptor 
subtype antagonists to warrant further consideration for the treatment of Benign Prostatic 
Hyperplasia (BPH).58(a,b) In the synthesis of these DHPM-5-carboxamides. 
 
Zhang and co-workers59 reported a solid-phase organic synthesis protocol to introduce 
carboxamido acid functionality on the C5  position of the DHPMs using amino acids.   
 
Oliver Kappe and co-workers,60 synthesized the amide bond formation between the 
requisite amines and the corresponding DHPM acids was performed using standard 
solution phase amide coupling chemistry involving carbodiimide coupling reagents 
(Figure-4). 
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A few compounds synthesized in our laboratory having 1,4-dihydropyrimidine as a 
core structure 
The following work deals with the multi-component reactions of aldehydes, thiourea and 
pyrazolone by classical heating using conc. HCl as the acid catalyst and by microwave 
assisted synthesis employing HClO4-Fuller’s earth as the novel heterogeneous acid 
catalyst. To our best knowledge, this is the first report of HClO4-Fuller’s earth as the 
heterogeneous catalyst. The synthesis of the catalyst is shown in the experimental section. 
The introduction of phenyl ring at position-4 of the core structure is itself novel by 
employing one pot reaction condition i.e. Biginelli type reaction. In fact, current protocol 
is the novel protocol for the solution-phase synthesis of pyrazolo[3,4-d]pyrimidine by 
classical heating as well as Microwave Assisted Organic Synthesis (MAOS). In MAOS, 
the overall yields of the products are higher than the conventional counterparts (Scheme-
26). 
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Another series of tetrahydropyrimidine was synthesized by two step synthesis. 
Substituted aniline and ethyl acetoacetate were heated at reflux in presence of toluene as 
a solvent to obtain substituted acetoacetanilides. Acetoacetanilide, substituted aldehydes 
and urea were taken in a round bottom flask and was heated at reflux in presence of 
methanol as a solvent. Few drops of conc. HCl was added to obtain substituted 6-methyl-
2-oxo-N,4-diphenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamides (Scheme-27). 
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5.4. Present work 
Multi-component condensation strategies are capable of providing in a single step 
durable core structures and highly variable side chains from simple starting materials. In 
the Biginelli dihydropyrimidine synthesis, the one-pot cyclocondensation of β-keto 
esters, aldehydes, and ureas provides DHPMs (Biginelli compounds) of well-established 
pharmacological potential.  
 
In a typical general experimental procedure, equivalent amounts of aldehyde, benzoyl 
acetone and urea/thiourea were taken in a round bottom flask, adding 2-3 drops of conc. 
HCl and methanol was taken as solvent. The mixture was refluxed for 7-8 h to obtain 
dihydropyrimidinones. 
 
A wide range of substituted aldehydes and several -diketones and urea/thiourea were 
subjected to this procedure to produce the corresponding DHPMs. The procedure gave 
the products in good to excellent yields. Urea and thiourea have been used with success 
to provide the corresponding dihydropyrimidinones, which are also of much interest with 
regard to the biological activity. Another important aspect of this procedure is survival of 
a variety of functional groups, such as CH3, OCH3, OH, and CN under the experimental 
conditions. Furthermore, aromatic aldehydes bearing either electron-donating or electron-
withdrawing substituents all worked well, giving good to excellent yields. In addition, 
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acid sensitive aldehydes, such as furfural reacted well without any side products. The 
adopted procedure is convenient, involves simple experimental procedure and product 
isolation; hence, it is a useful addition to the existing methods (Scheme-28). 
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5.5. REACTION  SCHEME-I
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REACTION  SCHEME-II
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R
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R
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Synthesis of Dihydropyrimidine
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5.6. Experimental 
 
Method for preparation of benzoylacetone61 
A suspension of 0.5 mol of granulated sodium metal in dry xylene was prepared and was 
transferred to a 1-litre three neck flask and the xylene was decanted. The flask was kept 
in water bath with a stirrer and 100 ml of ethanol was added to the flask. The mixture was 
continued to reflux till all the sodium was reacted. The residual sodium ethoxide 
containing flask was then surrounded with ice and 2.0 mol of pure, dry ethyl acetate was 
added. The stirring was started and 0.5 mol of acetophenones was added dropwise. The 
reaction commences with the precipitation of sodium salt of benzoylacetone. The stirring 
was continued for 2 h and was kept in ice box overnight, the precipates were filtered and 
dried. The dried solid was dissolved in cold water and finally acidified with glacial acetic 
acid. Crude benzoylacetone was finally purified by distillation under reduced pressure 
and obtained as colourless crystalline needles. m.p. 61oC, (reported m.p.62oC), yield 
62%.  
 
General method of preparation of 5-benzoyl-6-methyl-4-(substituted)phenyl-3,4-
dihydropyrimidin-2(1H)-one 
A neat mixture of benzoylacetone (10 mmol), benzaldehyde (10 mmol), urea/thiourea (15 
mmol), were taken in a round bottom flask. Ethanol (10 ml) was added to the flask and 
the contents were dissolved by gently heating the flask. Conc. HCl (1-2 drops)was added 
to the flask and was then refluxed for 6-8 hours. After cooling at room temperature, the 
product was filtered and washed with methanol and then recrystallized from ethanol to 
afford to yield 5-benzoyl-6-methyl-4-(substituted)phenyl-3,4-dihydropyrimidin-2(1H)-
ones.  
All the products were characterized by m.p., spectral and analytical data. 
The same procedure was followed for the preparation of all the dihydropyrimidinones 
listed in Table 2. 
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5.7. Table 2.:  Physical data of 5-benzoyl-6-methyl-4-(substituted)phenyl-3,4-dihydropyrimidin-2(1H)-ones 
 
N
H
NH
H3C X
O
R
 
   
Substitution 
Codes 
R X 
Molecular formula Molecular weight Melting point (oC) Rf  value 
% of 
Yield 
JT-151 2-OCH3 S C19H18N2O2S 338.42 218-220 0.57 63 
JT-152 2-NO2 S C18H15N3O3S 353.39 120-122 0.49 71 
JT-153 4-NO2 S C18H15N3O3S 353.39 152-154 0.51 74 
JT-154 4-F S C18H15FN2OS 326.39 198-200 0.43 86 
JT-155 3-OH S C18H16N2O2S 324.4 158-160 0.62 56 
 
TLC solvent system: Ethyl acetate: Hexane :: 6:4 
Ref.: (a) Kappe, C. O. Tetrahedron 1993, 49, 6937-6963. (b) Kappe, C. O. Acc. Chem. Res. 2000, 33, 879-888. (c) Kappe, C. O. Eur. 
J. Med. Chem. 2000, 35, 1043-1052 
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5.7. Table 2 (contd.):  5-Benzoyl-6-methyl-4-(substituted)phenyl-3,4-dihydropyrimidin-2(1H)-ones 
 
 
 
  
Substitution 
Codes 
R X 
Molecular formula Molecular weight Melting point (oC) Rf  value 
% of 
Yield 
JT-156 4-OH S C18H16N2O2S 
 
324.4 224-226 0.47 52 
JT-157 4-CH3 S C19H18N2OS 
 
322.42 232-234 0.64 53 
JT-158 4-OCH3 S C19H18N2O2S 
 
338.42 200-202 0.53 69 
JT-159 4-CN S C19H15N3OS 
 
333.41 204-206 0.56 51 
JT-160 2,5-Di OCH3 S C20H20N2O3S 
 
368.45 210-212 0.59 64 
JT-161 C4-Furfural S 
C16H14N2O2S 
 
298.36 240-242 0.44 42 
JT-162 C4-N-Indolyl S 
C20H17N3OS 
 
347.43 120-122 0.41 49 
JT-163 4-N,N-Di CH3 S 
C20H21N3OS 
 
351.47 200-204 0.68 76 
JT-164 3-OCH3, 4-OH S 
C19H18N2O3S 
 
354.42 188-190 0.64 79 
JT-165 3,5-Di Br, 4-OH S C18H14Br2N2O2S 
 
482.19 208-210 0.58 82 
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5.7. Table 2 (contd.):  5-Benzoyl-6-methyl-4-(substituted)phenyl-3,4-dihydropyrimidin-2(1H)-ones 
 
 
 
 
Substitution 
 
Codes 
R X 
Molecular formula Molecular weight Melting point (oC) Rf  value 
% of 
Yield 
JT-166 2-OCH3 O 
C19H18N2O3 
 
322.36 216-218 0.55 83 
JT-167 4-F O C18H15FN2O2 
 
310.32 202-20 0.63 78 
JT-168 4-NO2 O 
C18H15N3O4 
 
337.33 238-240 0.66 74 
JT-169 4-OH O C18H16N2O3 
 
308.33 186-188 0.68 58 
JT-170 4-CH3 O 
C19H18N2O2 
 
306.36 232-234 0.48 54 
JT-171 4-N,N-Di CH3 O 
C20H21N3O2 
 
335.4 238-240 0.61 73 
JT-172 Vanillin O C19H18N2O4 
 
338.36 228-230 0.53 84 
JT-173 3-OCH3, 4-OH O 
C19H18N2O4 
 
338.36 234-236 0.50 75 
JT-174 3,5-Di Br, 4-OH O C18H14Br2N2O3 
 
466.12 190-200 0.52 71 
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5.8. Spectral study 
Infra Red spectra 
IR Spectra were recorded on SHIMADZU IR-435 Spectrometer using KBr Pellet 
method.  The N-H stretch in dihydropyrimidines was onserved at 3400-3520 cm-1. In 
some cases, free hydroxyl group (OH) was observed at 3550-3640 cm-1. The 
characteristic carbonyl group (C=O) was observed between 1660-1720 cm-1. The 
dihydropyrimidines showed the ring skeleton vibrations at 1600-1630, 1550-1590, 1550-
1520, 1470-1495 cm-1. The methyl groups were observed between 1356-1395 cm-1. 
 
1H NMR spectra 
1H NMR Spectra were recorded on a Bruker AC 400 MHz FT-NMR Spectrometer using 
TMS (Tetramethyl silane) as an internal standard and DMSO-d6 as a solvent. In the NMR 
spectra of 5-benzoyl-6-methyl-4-(substituted)phenyl-3,4-dihydropyrimidin-2(1H)-ones, 
various proton values of methyl (-CH3), aromatic protons (Ar-H), N-H protons and were 
recorded and in few synthesized compounds, hydroxyl (-OH) were also observed. 
 
The values for methyl (-CH3) proton is observed between 1.71-1.79  ppm .The aromatic 
protons (Ar-H) shows doublets or multiplets between 6.02-8.24  ppm. N-H protons were 
observed between value 7.8-9.8  ppm. The value for hydroxyl proton (-OH) was 
observed between 8.6-10.3  ppm. 
 
13C NMR spectra 
13C NMR spectra were recorded on Bruker AC 400 MHz instrument using DMSO as the 
solvent with TMS (Tetramethyl silane) as respective internal standard.   
 
Mass spectra 
The mass spectrum of compounds was recorded by GCMS-QP2010 spectromeyter (EI 
method). The mass spectrums of compounds were obtained by positive chemical 
ionization mass spectrometry. The molecular ion peak and the base peak in all 
compounds were clearly obtained in mass spectral study. The molecular ion peak (M+) 
values are in good agreement with molecular formula of all the synthesized compounds.  
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C, H, N analysis 
Elemental analysis of the compounds was carried out on Elemental Vario EL III Carlo 
Erba 1108 model at CDRI, Lucknow and the results are in agreement with the structures 
assigned. 
 
5.9. Spectral characterization 
 
4-(2-Methoxyphenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidin-5-yl](phenyl) 
methanone (JT-151) 
IR (KBr) cm-1: 3437 (N-H str.), 2968 (C-H str.), 1680 (>C=O), 1577, 1518, 1506, 1456 
(ring skeleton), 1357 (CH3), 1210 (C=S). 
1H NMR 400 MHz (DMSO-d6,  ppm): 1.19 (s, 3H, CH3), 3.73 (s, 3H, OCH3), 4.79 (s, 
1H, CH), 6.8-8.02 (m, 9H, Ar-H), 8.43 (s, 1H, NH), 8.60 (s, 1H, NH). 
13C NMR 400 MHz (DMSO-d6,  ppm): 21.40, 47.26, 48.04, 50.81, 54.44, 82.48, 
109.54, 119.40, 127.07, 132.95, 136.99, 154.67, 176.84, 198.10. 
C, H, N analysis, Calculated: C, 67.43; H, 5.36; N, 8.28. Found: C, 67.37; H, 5.23; N, 
8.17.  
 
[6-Methyl-4-(2-nitrophenyl)-2-thioxo-1,2,3,4-tetrahydropyrimidin-5-yl](phenyl) 
methanone (JT-152) 
IR (KBr) cm-1: 3447 (N-H str.), 2973 (C-H str.), 1689 (>C=O), 1589, 1519, 1512, 1464 
(ring skeleton), 1379 (CH3), 1168 (C=S). 
Mass: [m/e (%)], M. Wt.: 220, 202, 192, 176, 148, 131, 120, 91, 74, 65, 44. 
C,H,O analysis, Calculated: C, 60.00; H, 3.66; O, 36.33. Found: C, 60.23; H, 3.54; O, 
36.24.  
 
[6-Methyl-4-(4-nitrophenyl)-2-thioxo-1,2,3,4-tetrahydropyrimidin-5-yl](phenyl) 
methanone (JT-153) 
IR (KBr) cm-1: 3468 (N-H str.), 2979 (C-H str.), 1696 (>C=O), 1593, 1552, 1515, 1473 
(ring skeleton), 1384 (CH3), 1206 (C=S). 
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1H NMR 400 MHz (DMSO-d6,  ppm): 1.27 (s, 3H, CH3), 4.76 (s, 1H, CH), 6.6-7.89 
(m, 9H, Ar-H), 8.46 (2s, 2H, 2NH). 
C, H, N analysis, Calculated: C, 61.18; H, 4.28; N, 11.89. Found: C, 61.12; H, 4.24; N, 
11.82. 
 
4-(4-Fluorophenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidin-5-yl](phenyl) 
methanone (JT-154) 
IR (KBr) cm-1: 3414 (N-H str.), 2986 (C-H str.), 1675 (>C=O), 1579, 1536, 1516, 1487 
(ring skeleton), 1377 (CH3), 1186 (C=S), 780 (C-F). 
C, H, N analysis, Calculated: C, 66.24; H, 4.63; F, 5.82; N, 8.58. Found: C, 66.18; H, 
4.62; F, 5.78. 
 
 [4-(3-Hydroxyphenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidin-5-yl](phenyl) 
methanone (JT-155) 
IR (KBr) cm-1: 3606 (free OH), 3457 (N-H str.), 2957 (C-H str.), 1678 (>C=O), 1602, 
1580, 1503, 1484 (ring skeleton), 1379 (CH3), 1176 (C=S). 
C, H, N analysis, Calculated: C, 66.64; H, 4.97; N, 8.64. Found: C, 66.56; H, 4.92; N, 
8.61. 
 
 [4-(4-Hydroxyphenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidin-5-yl](phenyl) 
methanone (JT-156) 
IR (KBr) cm-1: 3586 (free OH), 3465 (N-H str.), 2984 (C-H str.), 1676 (>C=O), 1592, 
1523, 1499, 1456 (ring skeleton), 1364 (CH3), 1194 (C=S). 
C, H, N analysis, Calculated: C, 66.64; H, 4.97; N, 8.64. Found: C, 66.54; H, 4.91; N, 
8.58. 
 
 [6-Methyl-4-(4-methylphenyl)-2-thioxo-1,2,3,4-tetrahydropyrimidin-5-yl](phenyl) 
methanone (JT-157) 
IR (KBr) cm-1: 3496 (N-H str.), 2983 (C-H str.), 1669 (>C=O), 1565, 1520, 1524, 1468 
(ring skeleton), 1379, 1380 (CH3), 1063 (C=S). 
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C, H, N analysis, Calculated: C, 70.78; H, 5.63; N, 8.69. Found: C, 70.75; H, 5.61; N, 
8.66. 
 
 [4-(4-Methoxyphenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidin-5-yl](phenyl) 
methanone (JT-158) 
IR (KBr) cm-1: 3489 (N-H str.), 2944 (C-H str.), 1678 (>C=O), 1613, 1580, 1503, 1456 
(ring skeleton), 1423 (OCH3), 1379 (CH3), 1123 (C=S). 
C, H, N analysis, Calculated: C, 67.43; H, 5.36; N, 8.28. Found: C, 67.43; H, 5.36; N, 
8.28. 
 
4-(5-Benzoyl-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidin-4-yl)benzonitrile (JT-
159) 
IR (KBr) cm-1: 3437 (N-H str.), 2943 (C-H str.), 1714 (>C=O), 2229 (C=N), 1593, 1562, 
1500, 1460 (ring skeleton), 1383 (CH3), 900 (mono substd.), 1204 (C=S). 
1H NMR 400 MHz (DMSO-d6,  ppm): 1.74 (s, 3H, CH3), 5.48 (s, 1H, CH), 7.3-7.9 (m, 
9H, Ar-H), 9.76 (s, 1H, NH), 10.35 (s, 1H, NH). 
13C NMR 400 MHz (DMSO-d6,  ppm): 18.09, 39.9, 77.88, 110.60, 118.05, 126.95, 
131.41, 139.92, 142.61, 147.69, 174.76, 194.24. 
Mass: [m/e (%)], M. Wt.: 333, 318, 300, 273, 231, 201, 169, 144, 105, 77, 67, 42. 
C, H, N analysis, Calculated: C, 68.45; H, 4.53; N, 12.60. Found: C, 68.36; H, 4.7; N, 
12.57. 
 
[4-(2,5-Dimethoxyphenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidin-5-
yl](phenyl)methanone (JT-160) 
IR (KBr) cm-1: 3459 (N-H str.), 2935 (C-H str.), 1689 (>C=O), 1602, 1585, 1506, 1466 
(ring skeleton), 1423, 1457 (OCH3), 1374 (CH3), 1208 (C=S). 
C, H, N analysis, Calculated: C, 65.20; H, 5.47; N, 7.60. Found: C, 65.16; H, 5.43; N, 
7.47. 
 
 [4-(2-Furyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidin-5-yl](phenyl) 
methanone (JT-161) 
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IR (KBr) cm-1: 3509 (N-H str.), 2923 (C-H str.), 1689 (>C=O), 1601, 1581, 1553, 1486 
(ring skeleton), 1392 (CH3), 1256 (C-O-C, ether linkage), 1192 (C=S). 
C, H, N analysis, Calculated: C, 64.41; H, 4.73; N, 9.39. Found: C, 64.34; H, 4.70; N, 
9.33. 
 
 [4-(1H-Indol-3-yl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidin-5-yl](phenyl) 
methanone (JT-162) 
IR (KBr) cm-1: 3513, 3478 (N-H str.), 2936 (C-H str.), 1698 (>C=O), 1600, 1584, 1521, 
1476 (ring skeleton), 1397 (CH3), 1123 (C=S). 
C, H, N analysis, Calculated: C, 69.14; H, 4.93; N, 12.09. Found: C, 69.12; H, 4.87; N, 
12.03. 
 
{4-[4-(Dimethylamino)phenyl]-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidin-5-
yl}(phenyl) methanone (JT-163) 
IR (KBr) cm-1: 3560 (N-H str.), 3049 (C-H str.), 1651 (>C=O), 1593, 1568, 1554, 1429 
(ring skeleton), 1398, 1386, 1379 (CH3), 1212 (C=S). 
1H NMR 400 MHz (DMSO-d6,  ppm): 1.73 (s, 3H, CH3), 3.07 (s, 6H, CH3), 4.40 (d, 
1H, CH, J= 3.48), 7.2-7.8 (m, 9H, Ar-H), 9.52 (s, 1H, NH), 10.18 (s, 1H, NH). 
13C NMR 400 MHz (DMSO-d6,  ppm): 17.93, 43.59, 54.69, 110.05, 117.46, 127.59, 
131.39, 139.91, 141.73, 174.34, 194.44. 
Mass: [m/e (%)], M. Wt.: 351, 334, 291, 246, 187, 120, 105, 77, 44. 
C, H, N analysis, Calculated: C, 68.35; H, 6.02; N, 11.96. Found: C, 68.32; H, 5,99; N, 
11.92. 
 
 [4-(4-Hydroxy-3-methoxyphenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidin-5-
yl](phenyl)methanone (JT-164) 
IR (KBr) cm-1: 3603 (OH str), 3491 (N-H str.), 2976 (C-H str.), 1723 (>C=O), 1606, 
1578, 1514, 1489 (ring skeleton), 1428 (OCH3), 1399 (CH3), 1162 (C=S). 
C, H, N analysis, Calculated: C, 64.39; H, 5.12; N, 7.90. Found: C, 64.34; H, 5.07; N, 
7.68. 
 
Synthesis and Characterization of 5-Benzoyl-6-methyl……. 284 
 [4-(3,5-Dibromo-4-hydroxyphenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidin-
5-yl](phenyl)methanone (JT-165) 
IR (KBr) cm-1: 3598 (OH str), 3503 (N-H str.), 2986 (C-H str.), 1711 (>C=O), 1592, 
1576, 1512, 1489 (ring skeleton), 1409 (CH3), 1153 (C=S). 
C, H, N analysis, Calculated: C, 44.84; H, 2.93; N, 5.81. Found: C, 44.77; H, 2.89; N, 
5.79. 
 
5-Benzoyl-4-(2-methoxyphenyl)-6-methyl-3,4-dihydropyrimidin-2(1H)-one (JT-166) 
IR (KBr) cm-1: 3519 (N-H str.), 2946 (C-H str.), 1763, 1672 (>C=O), 1605, 1582, 1515, 
1459 (ring skeleton), 1432 (OCH3), 1383 (CH3). 
1H NMR 400 MHz (DMSO-d6,  ppm): 1.80 (s, 3H, CH3), 3.65 (s, 3H, OCH3), 5.63 (d, 
1H, CH, J = 3.0), 6.82-7.57 (m, 9H, Ar-H), 6.91 (s, 1H, NH), 9.00 (s, 1H, NH). 
13C NMR 400 MHz (DMSO-d6,  ppm): 17.81, 50.53, 54.53, 108.06, 110.16, 119.92, 
127.92, 131.06, 140.03, 144.24, 153.32, 155.79, 194.07. 
C, H, N analysis, Calculated: C, 70.79; H, 5.63; N, 8.69. Found: C, 70.73; H, 5.61; N, 
8.64. 
 
5-Benzoyl-4-(4-fluorophenyl)-6-methyl-3,4-dihydropyrimidin-2(1H)-one (JT-167) 
IR (KBr) cm-1: 3508 (N-H str.), 2931 (C-H str.), 1685 (>C=O), 1591, 1556, 1508, 1487 
(ring skeleton), 1344 (CH3), 732 (C-F). 
1H NMR 400 MHz (DMSO-d6,  ppm): 1.71 (s, 3H, CH3), 5.43 (d, 1H, CH, J = 2.96), 
6.9-7.49 (m, 9H, Ar-H), 7.63 (s, 1H, NH), 9.10 (s, 1H, NH). 
13C NMR 400 MHz (DMSO-d6,  ppm): 18.42, 54.76, 109.50, 114.78, 127.90, 131.03, 
139.94, 140.75, 144.81, 152.37, 160.07, 162.48, 194.40. 
Mass: [m/e (%)], M. Wt.: 310, 295, 266, 248, 233, 215, 205, 185, 172, 162, 146, 133, 
122, 105, 95, 95, 77, 67, 42 
C, H, N analysis, Calculated: C, 69.67; H, 4.87; N, 9.03. Found: C, 69.63; H, 4.82; N, 
9.00. 
 
5-Benzoyl-6-methyl-4-(4-nitrophenyl)-3,4-dihydropyrimidin-2(1H)-one (JT-168) 
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IR (KBr) cm-1: 3487 (N-H str.), 2982 (C-H str.), 1723, 1691 (>C=O), 1608, 1562, 1512, 
1482 (ring skeleton), 1386 (CH3). 
1H NMR 400 MHz (DMSO-d6,  ppm): 1.71 (s, 3H, CH3), 5.57 (d, 1H, CH, J = 3.24), 
7.37-8.15 (m, 9H, Ar-H), 7.80 (d, 1H, NH, J = 3.76), 9.26 (s, 1H, NH). 
13C NMR 400 MHz (DMSO-d6,  ppm): 18.69, 54.76, 108.64, 123.19, 127.35, 131.10, 
140.63, 146.37, 150.98, 152.31, 194.19. 
C, H, N analysis, Calculated: C, 64.09; H, 4.48; N, 12.46. Found: C, 64.03; H, 4.43; N, 
12.42. 
 
5-Benzoyl-4-(4-hydroxyphenyl)-6-methyl-3,4-dihydropyrimidin-2(1H)-one (JT-169) 
IR (KBr) cm-1: 3601 (OH str.), 3497 (N-H str.), 2944 (C-H str.), 1721, 1689 (>C=O), 
1602, 1580, 1523, 1469 (ring skeleton), 1367 (CH3). 
C, H, N analysis, Calculated: C, 68.35; H, 6.02; N, 11.96. Found: C, 68.31; H, 5.89; N, 
11.93. 
 
5-Benzoyl-6-methyl-4-(4-methylphenyl)-3,4-dihydropyrimidin-2(1H)-one (JT-170) 
IR (KBr) cm-1: 3500 (N-H str.), 2935 (C-H str.), 1701, 1695 (>C=O), 1624, 1537, 1477, 
1452 (ring skeleton), 1379, 1332 (CH3). 
1H NMR 400 MHz (DMSO-d6,  ppm): 1.71 (s, 3H, CH3), 2.27, (s, 3H, CH3), 5.41 (d, 
1H, CH, J = 2.8), 7.05-7.48 (m, 9H, Ar-H), 7.48 (s, 1H, NH), 9.02 (d, 1H, NH, J = 1). 
13C NMR 400 MHz (DMSO-d6,  ppm): 18.31, 20.56, 55.29, 109.84, 128.62, 131.01, 
136.33, 140.88, 144.00, 152.60, 194.57. 
C, H, N analysis, Calculated: C, 74.49; H, 5.92; N, 9.14. Found: C, 74.45; H, 5.88; N, 
9.12. 
 
5-Benzoyl-4-[4-(dimethylamino)phenyl]-6-methyl-3,4-dihydropyrimidin-2(1H)-one 
(JT-171) 
IR (KBr) cm-1: 3566 (N-H str.), 2032 (C-H str.), 1765, 1687 (>C=O), 1602, 1596, 1545, 
1479 (ring skeleton), 1383, 1334, 1313 (CH3). 
C, H, N analysis, Calculated: C, 71.62; H, 6.31; N, 12.53. Found: C, 71.57; H, 6.27; N, 
12.48. 
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5-Benzoyl-4-(4-hydroxy-3-methoxyphenyl)-6-methyl-3,4-dihydropyrimidin-2(1H)-
one (JT-172) 
IR (KBr) cm-1: 3609 (OH str.), 3486 (N-H str.), 2965 (C-H str.), 1766, 1689 (>C=O), 
1597, 1586, 1523, 1467 (ring skeleton), 1443 (OCH3), 1390 (CH3). 
C, H, N analysis, Calculated: C, 67.44; H, 5.36; N, 8.28. Found: C, 67.38; H, 5.32; N, 
8.25. 
 
5-Benzoyl-4-(4-hydroxy-3-methoxyphenyl)-6-methyl-3,4-dihydropyrimidin-2(1H)-
one (JT-173) 
IR (KBr) cm-1: 3600, 1583 (OH str.), 3453 (N-H str.), 2977 (C-H str.), 1763, 1659 
(>C=O), 1599, 1546, 1490, 1430 (ring skeleton), 1436 (OCH3), 1380 (CH3). 
C, H, N analysis, Calculated: C, 66.66; H, 4.97; N, 8.64.Found: C, 66.62; H, 4.93; N, 
8.62. 
 
5-Benzoyl-4-(3,5-dibromo-4-hydroxyphenyl)-6-methyl-3,4-dihydropyrimidin-2(1H)-
one (JT-174) 
IR (KBr) cm-1: 3593 (OH str.), 3454 (N-H str.), 2881 (C-H str.), 1699 (>C=O), 1618, 
1564, 1462 (ring skeleton), 1386 (CH3). 
C, H, N analysis, Calculated: C, 46.38; H, 3.03; N, 6.01. Found: C, 46.32; H, 3.00; N, 
5.97. 
 
5.10. Conclusion 
 
Total 24 5-benzoyl-6-methyl-4-(substituted)phenyl -3,4-dihydropyrimidin-2(1H)-ones 
were synthesized in this chapter. The compounds are characterized by IR, 1H NMR, Mass 
spectral data and elemental analysis. All the compounds have been sent for anti-cancer 
activity and the results are awaited.  
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5.11. Spectra of some 5-benzoyl-6-methyl-4-(substituted)phenyl -3,4-
dihydropyrimidin-2(1H)-ones 
 
Infra Red spectrum of 4-(2-methoxyphenyl)-6-methyl-2-thioxo-1,2,3,4-
tetrahydropyrimidin-5-yl](phenyl)methanone (JT-151) 
 
 
 
IR spectrum of 4-(5-benzoyl-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidin-4-
yl)benzonitrile (JT-159) 
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IR spectrum of 5-benzoyl-4-(4-fluorophenyl)-6-methyl-3,4-dihydropyrimidin-2(1H)-
one (JT-167) 
 
 
 
IR spectrum of 5-benzoyl-6-methyl-4-(4-methylphenyl)-3,4-dihydropyrimidin-
2(1H)-one (JT-170) 
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IR spectrum of 5-benzoyl-4-(3,5-dibromo-4-hydroxyphenyl)-6-methyl-3,4-
dihydropyrimidin-2(1H)-one (JT-174) 
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Mass spectrum of 4-(5-benzoyl-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidin-4-
yl)benzonitrile (JT-159) 
 
 
 
Mass spectrum of {4-[4-(dimethylamino)phenyl]-6-methyl-2-thioxo-1,2,3,4-
tetrahydropyrimidin-5-yl}(phenyl)methanone (JT-163) 
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Mol. Formula C19H15N3OS
Mol. Wt.: 333.41
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CH3H3C
Mol. Formula: C20H21N3OS
Mol. Wt.: 351.47
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Mass spectrum of 5-benzoyl-4-(4-fluorophenyl)-6-methyl-3,4-dihydropyrimidin-
2(1H)-one (JT-167) 
 
 
 
Mass spectrum of 5-benzoyl-4-(3,5-dibromo-4-hydroxyphenyl)-6-methyl-3,4-
dihydropyrimidin-2(1H)-one (JT-174) 
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Mol. Formula: C18H15FN2O2
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Mol. Formula: C18H14Br2N2O3
Mol. Wt.: 466.12
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1H NMR spectrum of 4-(2-methoxyphenyl)-6-methyl-2-thioxo-1,2,3,4-
tetrahydropyrimidin-5-yl](phenyl)methanone (JT-151) 
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1H NMR spectrum of {4-[4-(dimethylamino)phenyl]-6-methyl-2-thioxo-1,2,3,4-
tetrahydropyrimidin-5-yl}(phenyl)methanone (JT-163) 
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1H NMR spectrum of 5-benzoyl-4-(2-methoxyphenyl)-6-methyl-3,4-
dihydropyrimidin-2(1H)-one (JT-166) 
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1H NMR spectrum of 5-benzoyl-4-(4-fluorophenyl)-6-methyl-3,4-dihydropyrimidin-
2(1H)-one (JT-167) 
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1H NMR spectrum of 5-benzoyl-6-methyl-4-(4-nitrophenyl)-3,4-dihydropyrimidin-
2(1H)-one (JT-168) 
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1H NMR spectrum of 5-benzoyl-6-methyl-4-(4-methylphenyl)-3,4-dihydropyrimidin-
2(1H)-one (JT-170) 
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13C NMR spectrum of 4-(2-methoxyphenyl)-6-methyl-2-thioxo-1,2,3,4-
tetrahydropyrimidin-5-yl](phenyl)methanone (JT-151) 
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13C NMR spectrum of 4-(5-benzoyl-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidin-
4-yl)benzonitrile (JT-159) 
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13C NMR spectrum of 5-benzoyl-4-(2-methoxyphenyl)-6-methyl-3,4-
dihydropyrimidin-2(1H)-one (JT-166) 
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13C NMR spectrum of 5-benzoyl-4-(4-fluorophenyl)-6-methyl-3,4-dihydropyrimidin-
2(1H)-one (JT-167) 
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13C NMR spectrum of 5-benzoyl-6-methyl-4-(4-nitrophenyl)-3,4-dihydropyrimidin-
2(1H)-one (JT-168) 
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13C NMR spectrum of 5-benzoyl-4-(4-hydroxyphenyl)-6-methyl-3,4-
dihydropyrimidin-2(1H)-one (JT-169) 
 
 
 
 
N
H
NH
O
CH3 O
OH
Synthesis and Characterization of 5-Benzoyl-6-methyl……. 304 
13C NMR spectrum of 5-benzoyl-6-methyl-4-(4-methylphenyl)-3,4-
dihydropyrimidin-2(1H)-one (JT-170) 
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Summary of the present work 
 
The work presented in this thesis, entitled “Studies on Some Important Heterocyclic 
Moieties.” is divided into five chapters.  
 
In Chapter-1, synthesis and characterization of some (2-oxo-2H-chromen-4-yl) acetic 
acid derivatives is reported. This chapter deals with the synthesis of coumarin-4-acetic 
acid derivatives. The coumarin skeleton has been associated with different types of 
pharmacological activities. The brief review about coumarins, especially derivatives of 
coumarin-4-acetic acid is given which covers synthesis & pharmacological activities of 
different types of coumarin derivatives. The series of 15 compounds have been 
synthesized by the reaction of citric acid and various substituted phenols in presence of 
conc. H2SO4. The structure of the synthesized compounds has been confirmed by IR, 
NMR and Mass spectroscopy. All the synthesized compounds have been sent for anti-
cancer activity and the results are awaited. 
 
Chapter-2, deals with the synthesis of N-1, 3-benzo[d]thiazol-2-yl-2-(2-oxo-2H-
chromen-4-yl) acetamide derivatives. Total 26 title compounds are prepared by forming 
an amide linkage between various substituted coumarin-4-acetic acids and 2-amino 
benzothiazoles. The coumarin ring linked with amide group is a moiety of biological 
interest. The structures of the newly synthesized compounds have been confirmed by IR, 
NMR and Mass spectroscopy. All the newly synthesized compounds have been sent for 
anti-viral activity and the results are awaited. 
 
Chapter-3 covers a detailed study of imidazoles, 2-imidazolones, 2-amino pyrimidines 
and synthesis of amide linkage between 2-imidazolone-4-carboxylic acid and 2-amino-
4,6-disubstituted pyrimidines. Total 24 compounds have been synthesized and screened 
for anti-inflammatory as well as anti-cancer activities. The structures of the newly 
synthesized compounds have been confirmed by IR, NMR and Mass spectroscopy.  
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Chapter-4, synthesis and characterization of some (5-carboxymethyl-2, 4, 6-triphenyl-1, 
4-dihydropyridine-3-yl)-acetic acids. A series of 26 compounds have been synthesized by 
reacting different aromatic aldehydes with β–aroylpropanoic acid and ammonia in 
ethanol. The synthesized compounds belong to heteroaryl alkanoic acids, which are well 
known as NSAIDs.  The structures of the newly synthesized compounds have been 
confirmed by IR, NMR and Mass spectroscopy. All the newly synthesized compounds 
have been sent for anti-tubercular activity and the results are awaited. 
 
Chapter-5 encompasses synthesis and characterization of 5-benzoyl-6-methyl-4-
(substituted) phenyl -3,4-dihydropyrimidin-2(1H)-ones. Total 24 dihydropyrimidines are 
prepared. Urea and thiourea have been used successfully to provide the corresponding 
dihydropyrimidinones, which are also of much interest with regard to the biological 
activity. This protocol gave the products in good to excellent yields. Another important 
aspect of this procedure is survival of a variety of functional groups, such as CH3, OCH3, 
OH, and CN under the experimental conditions. The structures of the newly synthesized 
compounds have been confirmed by IR, NMR and Mass spectroscopy. All the newly 
synthesized compounds have been sent for anti-cancer activity and the results are 
awaited. 
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